Citation Report
List of articles citing

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes

DOI: 10.1056/nejmoa1504720
New England Journal of Medicine, 2015, 373, 2117-28.

#	Paper	IF	Citations
2203	Comparison of Adipose Distribution Indices with Gold Standard Body Composition Assessments in the EMPA-REG H2H SU Trial: A Body Composition Sub-Study. **2015**, 6, 635-642		15
2202	Safety, tolerability and effects on cardiometabolic risk factors of empagliflozin monotherapy in drug-naïve patients with type 2 diabetes: a double-blind extension of a Phase III randomized controlled trial. **2015**, 14, 154		74
2201	[Diabetes mellitus. SGLT2 inhibitor reduces cardiovascular mortality]. **2015**, 157, 16		
2200	Wie kriegt man das Geﬂisiko in den Griff?. **2015**, 9, 34-45		
2199	Die â□diabetischeâ□Herzinsuffizienz hat viele Ursachen. **2015**, 9, 48-48		
2198	Sterblichkeit signifikant reduziert. **2015**, 17, 19-19		1
2197	[Empagliflozin reduces heart failure risk by a third]. **2015**, 157, 22		
2196	Empagliflozin raises the stakes in diabetes CV outcomes trials. **2015**, 1573, 6-7		0
2195	Empagliflozin in diabetes: A therapeutic light at the end of the cardiovascular tunnel?. **2015**, 12, 394-5		1
2194	Recent cardiovascular safety trials with antidiabetic drugs: time to change the guidelines!. **2015**, 32, 319-320		4
2193	NICE guidelines for Type 2 diabetes: revised but still not fit for purpose. **2015**, 32, 1398-403		7
2192	NICE guidelines must reflect consensus and be up-to-date. **2015**, 32, 1397		
2191	Nephroprotection by Hypoglycemic Agents: Do We Have Supporting Data?. **2015**, 4, 1866-89		13
2190	SGLT-2 INHIBITION ADDED TO GLP-1 AGONIST THERAPY FOR TYPE 2 DIABETES: WHAT IS THE BENEFIT?. **2015**, 21, 1442-4		
2189	Cardiovascular Implications of Hypoglycemia in Diabetes Mellitus. **2015**, 132, 2345-50		35
2188	Efficacy and safety of dapagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in diabetes mellitus. **2015**, 14, 142		55
2187	Sotagliflozin as a potential treatment for type 2 diabetes mellitus. **2015**, 24, 1647-56		23

2186 Understanding EMPA-REG OUTCOME. **2015**, 3, 928-9 57

2185 The Role of the Kidney and SGLT2 Inhibitors in Type 2 Diabetes. **2015**, 39 Suppl 5, S167-75 17

2184 Challenging Issues in Clinical Trial Design: Part 4 of a 4-Part Series on Statistics for Clinical Trials. **2015**, 66, 2886-2898 33

2183 EMPA-REG OUTCOME : enfin de bonnes nouvelles ! Mais comment lâ□xpliquer ?. **2015**, 9, 725-727

2182 Insulinosensibilisateurs (metformine/glitazones) : niveau de preuve et controverse. **2015**, 9, 759-767

2181 S□curit□cardiovasculaire des incr□tines et des inhibiteurs des co-transporteurs sodium-glucose de type 2 (SGLT2). Revue. **2015**, 9, 768-775 3

2180 Current and Emerging Pharmacotherapies for Type 2 Diabetes. **2015**, 39 Suppl 5, S127-8 1

2179 Comment expliquer la controverse ˆ propos de lâ□fficacit□/s□curit□cardiovasculaire dans les essais cliniques concernant le diab□e de type 2 ?. **2015**, 9, 752-758

2178 Pleiotropic effects of insulin and GLP-1 receptor agonists: Potential benefits of the association. **2015**, 41, 6S28-6S35 12

2177 Exenatide exerts a PKA-dependent positive inotropic effect in human atrial myocardium: GLP-1R mediated effects in human myocardium. **2015**, 89, 365-75 34

2176 SGLT2 inhibition: efficacy and safety in type 2 diabetes treatment. **2015**, 14, 1879-904 49

2175 Sodium-Glucose Cotransporter 2 Inhibitors in the Treatment of Type 2 Diabetes Mellitus. **2015**, 41, 5S-18S 4

2174 One Small Step for Empagliflozin, One Giant Leap for Diabetology. **2015**, 6, 405-409 5

2173 Understanding EMPA-REG OUTCOME. **2015**, 3, 930-1 8

2172 Understanding EMPA-REG OUTCOME. **2015**, 3, 929-30 27

2171 Preventing cardiovascular events with empagliflozin: at what cost?. **2015**, 3, 931 3

2170 Cardiovascular Risk and Sodium-Glucose Cotransporter 2 Inhibition in Type 2 Diabetes. *New England Journal of Medicine*, **2015**, 373, 2178-9 59.2 11

2169 Effects of Baseline Blood Pressure and Low-Density Lipoprotein Cholesterol on Safety and Efficacy of Canagliflozin in Japanese Patients with Type 2 Diabetes Mellitus. **2015**, 32, 1085-103 14

2168	Empagliflozin and linagliptin combination therapy for treatment of patients with type 2 diabetes mellitus. **2015**, 16, 2819-33	15
2167	Clinical practice guideline for the prevention, early detection, diagnosis, management and follow up of type 2 diabetes mellitus in adults.. **2016**, 109-130	27
2166	Fighting with obesity: the "gold standard" and new horizons. **2016**, 12, 450-458	3
2165	Cardiology update: First scientific statement on acute MI in women, antidiabetic drugs with CV benefits. **2016**, 22, 26-27	
2164	SGLT-2 INHIBITORS AS ADJUNCT THERAPY IN TYPE 1 DIABETES: REASON FOR HOPE AND CAUTION. **2016**, 22, 371-3	1
2163	Cardiovascular pharmacotherapy-2015 was a good year. **2016**, 2, 209-11	
2162	Hyperglycemia, hypoglycemia and glycemic variability in the elderly: a fatal triad?. **2016**, 84, 726	
2161	Review of Cardiovascular Effects of Antidiabetic Drugs and Recent Cardiovascular Outcome Trials. **2016**, 17, 1	
2160	THE INTERIM EXPERTSâ€COUNCIL RESOLUTION ON THE EMPA-REG OUTCOME TRIAL ISSUES. **2016**, 12, 186-190	3
2159	Practical combination therapy based on pathophysiology of type 2 diabetes. **2016**, 9, 355-369	14
2158	Recent advances in managing and understanding diabetic nephropathy. **2016**, 5,	24
2157	Editorial: The New Trial EMPAREG-OUTCOMES in Type 2 Diabetes: "and Death Shall Have no Dominion"?. **2016**, 14, 316-8	1
2156	The Gut Impacts Diabetic Management Tomorrow: The Recent Messages from Intestine and Microbiota. **2016**, 02,	4
2155	The Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients (EMPA-REG OUTCOME) Trial and Its Clinical Impact on Patterns of Prescription for Anti-Diabetes Medication. **2016**, 17, 225	
2154	Differential pharmacology and clinical utility of empagliflozin in type 2 diabetes. **2016**, 8, 19-34	3
2153	Sodium-glucose cotransporter-2 inhibitor combination therapy to optimize glycemic control and tolerability in patients with type 2 diabetes: focus on dapagliflozin-metformin. **2016**, 9, 71-82	3
2152	The role of lipids in the pathogenesis and treatment of type 2 diabetes and associated co-morbidities. **2016**, 49, 139-48	44
2151	Spotlight on empagliflozin/metformin fixed-dose combination for the treatment of type 2 diabetes: a systematic review. **2016**, 10, 1999-2006	5

2150 Diabetes Drugs and Cardiovascular Safety. **2016**, 31, 239-44 10

2149 Dapagliflozin-Induced Acute-on-Chronic Liver Injury. **2016**, 3, e169 4

2148 Cardiovascular safety of type 2 diabetes medications: Review of existing literature and clinical implications. **2016**, 15, 170-185 7

2147 Type 2 Diabetes and Heart Failure: Challenges and Solutions. **2016**, 12, 249-55 42

2146 AMCP Partnership Forum: Navigating Innovations in Diabetes Care. **2016**, 22, 1369-1375

2145 Bringing patient centricity to diabetes medication access in Canada. **2016**, 8, 599-611 1

2144 New Pathogenic Concepts and Therapeutic Approaches to Oxidative Stress in Chronic Kidney Disease. **2016**, 2016, 6043601 37

2143 Mesenchymal Stem Cells as Therapeutic Candidates for Halting the Progression of Diabetic Nephropathy. **2016**, 2016, 9521629 22

2142 Editorial: Can Glucagon Like Peptide 1 (GLP1) Agonists or Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitors Ameliorate Non-Alcoholic Steatohepatitis in People with or without Diabetes?. **2016**, 14, 494-497 11

2141 Impact of sodium-glucose cotransporter 2 inhibitors on blood pressure. **2016**, 12, 393-405 38

2140 Advances in the treatment of type 2 diabetes: impact of dulaglutide. **2016**, 9, 125-36 8

2139 Sodium-Glucose Cotransporter 2 Inhibitors: Possible Anti-Atherosclerotic Effects Beyond Glucose Lowering. **2016**, 8, 10-4 22

2138 Editorial: Do Some Glucagon-Like-Peptide-1 Receptor Agonists (GLP-1 RA) Reduce Macrovascular Complications of Type 2 Diabetes Mellitus A Commentary on the Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results (LEADER) Trial. **2016**, 14, 469-473 9

2137 Options for empagliflozin in combination therapy in type 2 diabetes mellitus. **2016**, 9, 155-72 12

2136 Glycemic Control with Ipragliflozin, a Novel Selective SGLT2 Inhibitor, Ameliorated Endothelial Dysfunction in Streptozotocin-Induced Diabetic Mouse. **2016**, 3, 43 71

2135 The Association between Sulfonylurea Use and All-Cause and Cardiovascular Mortality: A Meta-Analysis with Trial Sequential Analysis of Randomized Clinical Trials. **2016**, 13, e1001992 69

2134 Benefits and Harms of Sodium-Glucose Co-Transporter 2 Inhibitors in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis. **2016**, 11, e0166125 126

2133 Hyperglycemia-Induced Hypovolemia Is Involved in Early Cardiac Magnetic Resonance Alterations in Streptozotocin-Induced Diabetic Mice: A Comparison with Furosemide-Induced Hypovolemia. **2016**, 11, e0149808 2

2132	SGLT2 inhibitors or GLP-1 receptor agonists as second-line therapy in type 2 diabetes: patient selection and perspectives. **2016**, 12, 239-49	24
2131	An update on sodium-glucose co-transporter-2 inhibitors for the treatment of diabetes mellitus. **2017**, 24, 73-79	117
2130	High blood pressure in US diabetic veterans with normal renal function: a plea for the design of a more powerful and conclusive outcome trial. **2016**, 34, 836-7	
2129	Effects of Dipeptidyl Peptidase 4 Inhibitors and Sodium-Glucose Linked coTransporter-2 Inhibitors on cardiovascular events in patients with type 2 diabetes mellitus: A meta-analysis. **2016**, 220, 595-601	50
2128	Low-glycaemic index diet to improve glycaemic control and cardiovascular disease in type 2 diabetes: design and methods for a randomised, controlled, clinical trial. **2016**, 6, e012220	3
2127	Combining sodium-dependent glucose co-transporter 2 inhibition with conventional diuretics: Dr Jekyll and Mr Hyde?. **2016**, 34, 833-5	
2126	The changing therapeutic armamentarium for patients with type 1 diabetes. **2016**, 23, 106-10	4
2125	Addition of SGLT2 inhibitor to GLP-1 agonist therapy in people with type 2 diabetes and suboptimal glycaemic control. **2016**, 33, 129-132	8
2124	Long-term maintenance of efficacy of dapagliflozin in patients with type 2 diabetes mellitus and cardiovascular disease. **2016**, 18, 766-74	19
2123	Current Therapies for the Medical Management of Diabetes. **2016**, 127, 780-794	15
2122	Kidney tubules: intertubular, vascular, and glomerular cross-talk. **2016**, 25, 194-202	20
2121	Long-Term Safety of Dapagliflozin in Older Patients with Type 2 Diabetes Mellitus: A Pooled Analysis of Phase IIb/III Studies. **2016**, 33, 511-22	21
2120	Drug development and licensing in diabetes. **2016**, 33, 60-64	1
2119	Increasing Patient Acceptance and Adherence Toward Insulin. **2016**, 128 Suppl 1, 11-20	0
2118	Cardiovascular risk assessment in oncological clinical trials: is there a role for centralized events adjudication?. **2016**, 18, 128-32	6
2117	Vascular Complications of Diabetes. **2016**, 118, 1771-85	157
2116	Sodium-glucose cotransporter (SGLT) 2 inhibitors for prevention or delay of type 2 diabetes mellitus and its associated complications in people at risk for development of type 2 diabetes mellitus. **2016**,	
2115	Does Elevated Glucose Promote Atherosclerosis? Pros and Cons. **2016**, 119, 190-3	14

2114	The EMPA-REG outcome study: critical appraisal and potential clinical implications. **2016**, 15, 85	13
2113	Using systems biology to evaluate targets and mechanism of action of drugs for diabetes comorbidities. **2016**, 59, 2503-2506	6
2112	Contemporary clinical trial updates in heart failure. **2016**, 31, 349-55	1
2111	Sodium glucose cotransporter 2 inhibition in the diabetic kidney: an update. **2016**, 25, 50-8	62
2110	A critical review on the translational journey of cardioprotective therapies!. **2016**, 220, 176-84	25
2109	Current cardiovascular outcomes trials in type 2 diabetes: Perspectives and insight. **2016**, 26, 767-72	9
2108	Effects of diuretics on sodium-dependent glucose cotransporter 2 inhibitor-induced changes in blood pressure in obese rats suffering from the metabolic syndrome. **2016**, 34, 893-906	36
2107	Sodium-glucose cotransporter (SGLT) 2 inhibitors for prevention or delay of type 2 diabetes mellitus and its associated complications in people at risk for the development of type 2 diabetes mellitus. **2016**, 4, CD012106	10
2106	? Empagliflozin, diabetes and outcomes. **2016**, 54, 78-81	1
2105	The SGLT2 inhibitor empagliflozin: results of EMPA-REG OUTCOMER trial. **2016**, 148, 282	
2104	Rationale and design of the randomised controlled trial to assess the impact of liraglutide on cardiac function and structure in young adults with type 2 diabetes (the LYDIA study). **2016**, 15, 102	11
2103	Comments on the 2016 ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure. **2016**, 69, 1119-1125	5
2102	Pharmacologic Management of Type 2 Diabetes: 2016 Interim Update. **2016**, 40, 484-486	44
2101	More Than 7 Years of Hindsight: Revisiting the FDA's 2008 Guidance on Cardiovascular Outcomes Trials for Type 2 Diabetes Medications. **2016**, 34, 173-180	24
2100	Existing evidence is insufficient to justify metformin or other agents as first-line therapy for type 2 diabetes. **2016**, 21, 224	1
2099	SUSTAIN-6: cardiovascular safety of a once-weekly GLP-1 receptor agonist. **2016**, 33, 266-268a	2
2098	London buses: A cardiovascular outcome trial equivalent?. **2016**, 13, 382-383	
2097	The reliability of clinical trials. The risky way towards drug deregulation. **2016**, 147, 554-557	

2096	AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY POSITION STATEMENT ON THE ASSOCIATION OF SGLT-2 INHIBITORS AND DIABETIC KETOACIDOSIS. **2016**, 22, 753-62	186
2095	Diabetes und Herz. **2016**, 12, 328-334	
2094	Kardiovaskuläres Outcome unter Semaglutid. **2016**, 12, 582-583	0
2093	LEADER-Studie: 22 %ige Senkung der kardiovaskulären Mortalität. **2016**, 10, 339-340	
2092	Kardiale Effekte aktueller Antidiabetika. **2016**, 16, 38-42	
2091	Neue Antidiabetika und kardiovaskuläre Outcome-Studien. **2016**, 12, 203-216	
2090	CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM--2016 EXECUTIVE SUMMARY. **2016**, 22, 84-113	333
2089	Evolving Concepts of Myocardial Energy Metabolism: More Than Just Fats and Carbohydrates. **2016**, 119, 1173-1176	60
2088	Are Diabetes Care Providers Too Glucocentric?. **2016**, 40, 479-481	3
2087	Use of Sodium Glucose Cotransporter 2 Inhibitors in the Hands of Cardiologists: With Great Power Comes Great Responsibility. **2016**, 134, 1915-1917	32
2086	Glycosuria and Renal Outcomes in Patients with Nondiabetic Advanced Chronic Kidney Disease. **2016**, 6, 39372	13
2085	The History of Diabetes Mellitus. **2016**, 1-22	3
2084	How to Use Type 2 Diabetes Treatments in Clinical Practice: Combination Therapies. **2016**, 471-492	
2083	Pathogenesis of Macrovascular Complications in Diabetes. **2016**, 599-628	1
2082	SGLT2 Inhibitor-associated Diabetic Ketoacidosis: Clinical Review and Recommendations for Prevention and Diagnosis. **2016**, 38, 2654-2664.e1	129
2081	Oral Glucose-Lowering Agents. **2016**, 426-454	
2080	Diabetic Dyslipidemia and Risk of Cardiovascular Disease. **2016**, 643-652	
2079	Ischemic Heart Disease in Diabetes. **2016**, 653-658	

2078	The Emerging Role of Metabolomics in the Diagnosis and Prognosis of Cardiovascular Disease. **2016**, 68, 2850-2870	158
2077	The Three-Decade Long Journey in Heart Failure Drug Development. **2017**, 243, 1-14	6
2076	Effects of the glucagon-like peptide-1 receptor agonist liraglutide on systolic function in patients with coronary artery disease and type 2 diabetes: a randomized double-blind placebo-controlled crossover study. **2016**, 15, 105	40
2075	Sodiumâglucose co-transporter 2 inhibitors: a review of their use in older people with type 2 diabetes mellitus. **2016**, 46, 377-383	2
2074	Heart failure - what's new and what's changed?. **2016**, 16, s37-s42	3
2073	Congestive Heart Failure. **2016**, 659-672	
2072	Developing Treatments for Chronic Kidney Disease in the 21st Century. **2016**, 36, 436-447	32
2071	Research into the effect Of SGLT2 inhibition on left ventricular remodelling in patients with heart failure and diabetes mellitus (REFORM) trial rationale and design. **2016**, 15, 97	41
2070	Contribution of Maladaptive Adipose Tissue Expansion to Development of Cardiovascular Disease. **2016**, 7, 253-262	19
2069	Empagliflozin lessened cardiac injury and reduced visceral adipocyte hypertrophy in prediabetic rats with metabolic syndrome. **2016**, 15, 157	86
2068	[Therapy with oral antidiabetic drugs]. **2016**, 158, 48-54	
2067	Quelle place pour les nouveaux antidiabtiques dans la prise en charge du diabte du sujet g?. **2016**, 10, 574-580	
2066	The year in cardiology 2015: prevention. **2016**, 68, 291-300	
2065	[Improvement in cardiovascular prognosis of type 2 diabetes mellitus, is it a reality?]. **2016**, 33, 123-125	
2064	I nuovi farmaci per il diabete: gli inibitori del co-trasportatore sodio-glucosio di tipo 2 (SGLT-2i). **2016**, 17, 259-261	
2063	2016 Meet-The-Professor: Endocrine Case Management. **2016**,	1
2062	The reliability of clinical trials. The risky way towards drug deregulation. **2016**, 147, 554-557	0
2061	Comentarios a la gua ESC 2016 sobre el diagnstico y tratamiento de la insuficiencia cardiaca aguda y crica. **2016**, 69, 1119-1125	15

2060	Guía ESC 2016 sobre el diagnóstico y tratamiento de la insuficiencia cardiaca aguda y crónica. **2016**, 69, 1167.e1-1167.e85	91
2059	Review of systematic reviews and Meta-analyses investigating Traditional Chinese Medicine treatment for type 2 diabetes mellitus. **2016**, 36, 555-63	10
2058	Reflections on changing paradigms. **2016**, 33, 1011-2	1
2057	LEADER and the new âcardiovascularâglucose-lowering agents. **2016**, 33, 187-189	1
2056	Is diabetes still a state of premature cardiovascular death?. **2016**, 33, 285-290	1
2055	Diabetes and cardiovascular disease: pathophysiology of a life-threatening epidemic. **2016**, 41, 184-92	31
2054	No Need to Sugarcoat the Message: Is Cardiovascular Risk Reduction From SGLT2 Inhibition Related to Natriuresis?. **2016**, 68, 349-52	15
2053	Insulin Signaling and Heart Failure. **2016**, 118, 1151-69	197
2052	Pharmacologic Management of Type 2 Diabetes: 2016 Interim Update. **2016**, 40, 193-5	29
2051	The effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, on mineral metabolism and bone in patients with type 2 diabetes mellitus. **2016**, 32, 1375-85	48
2050	Lipid Use and Misuse by the Heart. **2016**, 118, 1736-51	143
2049	Heart Failure Considerations of Antihyperglycemic Medications for Type 2 Diabetes. **2016**, 118, 1830-43	46
2048	Is the risk of cardiovascular disease altered with anti-inflammatory therapies? Insights from rheumatoid arthritis. **2016**, 5, e84	15
2047	The next generation of therapeutics for chronic kidney disease. **2016**, 15, 568-88	140
2046	2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts)Developed with the special contribution of the European Association for Cardiovascular [illegible]	3919
2045	Evidence for Good Cardiovascular Outcomes among Patients with Type 2 Diabetes, and Promising Treatment for Patients with Type 1 Diabetes. **2016**, 38, 1274-1278	0
2044	[Chronic ischaemic heart disease in the elderly]. **2016**, 51, 170-9	2
2043	Precision Obesity Treatments Including Pharmacogenetic and Nutrigenetic Approaches. **2016**, 37, 575-593	28

2042	Update in Hypertension Therapy. **2016**, 100, 665-93	6
2041	Pharmacologic Therapy of Type 2 Diabetes. **2016**, 100, 647-63	16
2040	Novel antidiabetic drugs and cardiovascular risk: Primum non nocere. **2016**, 26, 759-66	16
2039	Mortality risk in admitted patients with diabetes mellitus according to treatment. **2016**, 30, 1025-31	4
2038	Getting to the "Heart" of the Matter on Diabetic Cardiovascular Disease: "Thanks for the Memory". **2016**, 39, 664-7	14
2037	NUEVOS FÁRMACOS EN DIABETES MELLITUS. **2016**, 27, 235-256	2
2036	Integrating medical and surgical therapies to optimize the outcomes of type 2 diabetes. **2016**, 12, 1186-91	4
2035	Pharmacologic Approaches to Weight Management: Recent Gains and Shortfalls in Combating Obesity. **2016**, 18, 36	9
2034	Treating Diabetes in Patients with Heart Failure: Moving from Risk to Benefit. **2016**, 13, 111-8	3
2033	The changing face of diabetes complications. **2016**, 4, 537-47	247
2032	Insulin sensitivity is a Rubik's Cube. **2016**, 103, 1381-2	
2031	[What do they offer new oral antibiotics?]. **2016**, 48, 279-80	1
2030	EMPA-REG and Other Cardiovascular Outcome Trials of Glucose-lowering Agents: Implications for Future Treatment Strategies in Type 2 Diabetes Mellitus. **2016**, 38, 1288-1298	24
2029	Cardiovascular outcome trials for anti-diabetes medication: A holy grail of drug development?. **2016**, 68, 564-71	12
2028	Silent myocardial ischemia in asymptomatic patients with type 2 diabetes mellitus without previous histories of cardiovascular disease. **2016**, 216, 151-5	6
2027	Concerted efforts to combat diabetic complications. **2016**, 89, 269-71	
2026	Obviating much of the need for insulin therapy in type 2 diabetes mellitus: A re-assessment of insulin therapy's safety profile. **2016**, 128, 609-19	13
2025	2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. **2016**, 37, 2129-2200	7751

2024	Rationale and design of a randomized trial to test the safety and non-inferiority of canagliflozin in patients with diabetes with chronic heart failure: the CANDLE trial. **2016**, 15, 57	24
2023	Empagliflozin/Linagliptin: Combination therapy in patients with type 2 diabetes. **2016**, 77, 557-562	10
2022	Selecci de temas de actualidad en riesgo vascular y rehabilitaci cardiaca 2015. **2016**, 69, 294-299	5
2021	Clinical management of the uraemic syndrome in chronic kidney disease. **2016**, 4, 360-73	57
2020	Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME trial. **2016**, 37, 1526-34	629
2019	The metabolic vascular syndrome - guide to an individualized treatment. **2016**, 17, 5-17	25
2018	Diabetes and oral therapies: A review of oral therapies for diabetes mellitus. **2016**, 11, 317-329	20
2017	[Glucose renal excretion as diabetes treatment: From an old diagnostic method to a new way of treatment]. **2016**, 146, 460-4	4
2016	Glucagon-Like Peptide 1 Receptor Activation Attenuates Platelet Aggregation and Thrombosis. **2016**, 65, 1714-23	68
2015	Empagliflozin reduces cardiovascular events and mortality in type 2 diabetes. **2016**, 128, 335-7	2
2014	Diabetes Dyslipidemia. **2016**, 7, 203-19	171
2013	Role of SGLT2 inhibitors in the treatment of type 2 diabetes mellitus. **2016**, 53, 863-870	14
2012	Cardiovascular Risk Factor Targets and Cardiovascular Disease Event Risk in Diabetes: A Pooling Project of the Atherosclerosis Risk in Communities Study, Multi-Ethnic Study of Atherosclerosis, and Jackson Heart Study. **2016**, 39, 668-76	71
2011	[Diabetic kidney disease - Update 2016]. **2016**, 128 Suppl 2, S85-96	1
2010	Selecting the right drug treatment for adults with type 2 diabetes. **2016**, 352, i1663	5
2009	Myocardial dysfunction and cardiovascular disease in type 2 diabetes. **2016**, 76, 271-81	12
2008	Evidence and Perspectives on the 24-hour Management of Hypertension: Hemodynamic Biomarker-Initiated 'Anticipation Medicine' for Zero Cardiovascular Event. **2016**, 59, 262-281	88
2007	[Insulin therapy: as late as possible]. **2016**, 141, 579-80	1

2006	Empagliflozin, via Switching Metabolism Toward Lipid Utilization, Moderately Increases LDL Cholesterol Levels Through Reduced LDL Catabolism. **2016**, 65, 2032-8	72
2005	Novel insight into the dangerous connection between diabetes and heart failure. **2016**, 41, 201-7	9
2004	Glucose-lowering therapy in type 2 diabetes. New hope after the EMPA-REG outcome trial. **2016**, 41, 208-16	3
2003	Secondary Prevention Beyond Hospital Discharge for Acute Coronary Syndrome: Evidence-Based Recommendations. **2016**, 32, S15-34	7
2002	Safety and Tolerability of Empagliflozin in Patients with Type 2 Diabetes. **2016**, 38, 1299-1313	61
2001	[Individualized diabetes therapy in older persons]. **2016**, 57, 502-7	1
2000	SGLT2 Inhibitors and Cardiovascular Risk: Lessons Learned From the EMPA-REG OUTCOME Study. **2016**, 39, 717-25	211
1999	Sodium-Glucose Cotransporter 2 Inhibition and Cardiovascular Risk. **2016**, 10, 1	
1998	[Antihyperglycemic treatment guidelines for diabetes mellitus type 2]. **2016**, 128 Suppl 2, S45-53	4
1997	Combination therapy for the improvement of long-term macrovascular and microvascular outcomes in type 2 diabetes: Rationale and evidence for early initiation. **2016**, 30, 1177-85	13
1996	Clinical Implications of Cardiovascular Outcome Trials in Type 2 Diabetes: From DCCT to EMPA-REG. **2016**, 38, 1279-1287	15
1995	Assessment of cardiovascular risk of new drugs for the treatment of diabetes mellitus: risk assessment vs. risk aversion. **2016**, 2, 200-5	21
1994	Sodium-glucose co-transporter-2 (SGLT-2) inhibitors in patients with type 2 diabetes mellitus: the road ahead. **2016**, 37, 3201-3202	6
1993	The Role of Mitochondria in Diabetic Kidney Disease. **2016**, 16, 61	56
1992	Treatment of Nonalcoholic Fatty Liver Disease (NAFLD) in patients with Type 2 Diabetes Mellitus. **2016**, 2, 9	35
1991	Meta-analysis of dipeptidyl peptidase-4 inhibitors use and cardiovascular risk in patients with type 2 diabetes mellitus. **2016**, 116, 171-82	9
1990	Outcome studies and safety as guide for decision making in treating patients with type 2 diabetes. **2016**, 17, 117-27	3
1989	Evaluating the Cardiovascular Safety of New Medications for Type 2 Diabetes: Time to Reassess?. **2016**, 39, 738-42	43

1988	[Modern antihyperglycaemic agents--what is the patient benefit?]. **2016**, 158, 45-8		
1987	SGLT2 Inhibition and cardiovascular events: why did EMPA-REG Outcomes surprise and what were the likely mechanisms?. **2016**, 59, 1333-1339		207
1986	Precision medicine: The future in diabetes care?. **2016**, 117, 12-21		32
1985	Ipragliflozin as an Initial Therapy in Drug Naïve Subjects with Type 2 Diabetes. **2016**, 66, 345-50		4
1984	Orale Antidiabetika bei herzkranken Patienten. **2016**, 11, R1-R10		
1983	Diabetische Nephropathie â Hintergrñde und Therapiemöglichkeiten. **2016**, 20, 128-133		
1982	New strategies to tackle diabetic kidney disease. **2016**, 25, 348-54		2
1981	The current role of thiazolidinediones in diabetes management. **2016**, 90, 1861-81		45
1980	Cardiac Output and Renal Dysfunction: Definitely More Than Impaired Flow. **2016**, 67, 2209-2212		19
1979	Microbiota and the nitrogen cycle: Implications in the development and progression of CVD and CKD. **2016**, 57, 64-70		16
1978	Sodium-glucose cotransporter-2 inhibition for the reduction of cardiovascular events in high-risk patients with diabetes mellitus. **2016**, 37, 3192-3200		117
1977	9th Hatter Biannual Meeting: position document on ischaemia/reperfusion injury, conditioning and the ten commandments of cardioprotection. **2016**, 111, 41		62
1976	LEADER-4: blood pressure control in patients with type 2 diabetes and high cardiovascular risk: baseline data from the LEADER randomized trial. **2016**, 34, 1140-50		10
1975	A post-hoc analysis of the comparative efficacy of canagliflozin and glimepiride in the attainment of type 2 diabetes-related quality measures. **2016**, 16, 356		5
1974	Finding Efficacy in a Safety Trial: Empagliflozin and Cardiovascular Death. **2016**, 134, 773-5		3
1973	The Primary Outcome Is Positive - Is That Good Enough?. *New England Journal of Medicine*, **2016**, 375, 971-9	59.2	78
1972	SGLT2 inhibitors in the pipeline for the treatment of diabetes mellitus in Japan. **2016**, 17, 2073-84		14
1971	Combined insulin/GLP-1 pens near market. **2016**, 34, 897-9		

1970 Low adoption of weight loss medications: A comparison of prescribing patterns of antiobesity pharmacotherapies and SGLT2s. **2016**, 24, 1955-61 59

1969 Antiglycemic Agents. **2016**, 5, 542-554

1968 Gu□a ESC 2016 sobre prevenci□ de la enfermedad cardiovascular en la pr□tica cl□nica. **2016**, 69, 939.e1-939.e87 10

1967 Canagliflozin: Efficacy and Safety in Combination with Metformin Alone or with Other Antihyperglycemic Agents in Type 2 Diabetes. **2016**, 7, 659-678 3

1966 Pharmacodynamic Effects of Single and Multiple Doses of Empagliflozin in Patients With Type 2 Diabetes. **2016**, 38, 2265-2276 53

1965 Ipragliflozin lowers small, dense low-density lipoprotein cholesterol levels in Japanese patients with type 2 diabetes mellitus. **2016**, 6, 1-7 12

1964 Rationale and design of a multicenter randomized controlled study to evaluate the preventive effect of ipragliflozin on carotid atherosclerosis: the PROTECT study. **2016**, 15, 133 15

1963 Glucose renal excretion as diabetes treatment: From an old diagnostic method to a new way of treatment. **2016**, 146, 460-464

1962 Acute Pharmacodynamic Effects of Empagliflozin With and Without Diuretic Agents in Patients With Type 2 Diabetes Mellitus. **2016**, 38, 2248-2264.e5 33

1961 Empagliflozin Protects against Diet-Induced NLRP-3 Inflammasome Activation and Lipid Accumulation. **2016**, 359, 45-53 39

1960 Effect of Empagliflozin on Left Ventricular Mass and Diastolic Function in Individuals With Diabetes: An Important Clue to the EMPA-REG OUTCOME Trial?. **2016**, 39, e212-e213 141

1959 Effects of reducing blood pressure on cardiovascular outcomes and mortality in patients with type 2 diabetes: Focus on SGLT2 inhibitors and EMPA-REG OUTCOME. **2016**, 121, 204-214 33

1958 □tude EMPA-REG OUTCOME : L□□nalyse du cardiologue. **2016**, 10, 300-302

1957 Cardiovascular pharmacotherapy. **2016**, 224, 412-415

1956 Sodium glucose co-transporter 2 inhibitors in patients with resistant hypertension: a case study. **2016**, 7, 2054270416649285 3

1955 New Oral Hypoglycemic Agents and Cardiovascular Risk. Crossing the Metabolic Border. **2016**, 69, 1088-1097 1

1954 Drug therapies in type 2 diabetes: an era of personalised medicine. **2016**, 16, 441-447 3

1953 Diabetes Update 2016. **2016**, 12, 302-311

1952	Results from Cardiovascular Outcome Trials in Diabetes. **2016**, 63, 317-9	2
1951	Cardiovascular Outcome Trials in Diabetes: Will the EMPA-REG OUTCOME and LEADER Trials Influence Clinical Decisions in Type 2 Diabetes?. **2016**, 40, 379-381	1
1950	Tratamiento de la diabetes mellitus (II). Hipoglucemiantes no insul□hicos. **2016**, 12, 1013-1025	
1949	[Role of SGLT2 inhibitors in elderly diabetic patients; we should avoid ageism]. **2016**, 51, 307-308	2
1948	[Not Available]. **2016**, 48 Suppl 1, 4-26	5
1947	Current perspectives on cardiovascular outcome trials in diabetes. **2016**, 15, 139	51
1946	Heart Failure: a Major Cardiovascular Complication of Diabetes Mellitus. **2016**, 16, 116	33
1945	Albiglutide: a unique GLP-1 receptor agonist. **2016**, 16, 1557-1569	11
1944	Which is the main molecular target responsible for the cardiovascular benefits in the EMPA-REG OUTCOME trial? A journey through the kidney, the heart and other interesting places. **2016**, 26, 1071-1078	12
1943	Effects of Incretin-Based Therapies and SGLT2 Inhibitors on Skeletal Health. **2016**, 14, 345-350	14
1942	Impact of EMPA-REG OUTCOME on the management of type 2 diabetes mellitus: a review for primary care physicians. **2016**, 128, 822-827	
1941	Impact of Empagliflozin on Blood Pressure in Patients With Type 2 Diabetes Mellitus and Hypertension by Background Antihypertensive Medication. **2016**, 68, 1355-1364	68
1940	Fatty Liver and Chronic Kidney Disease: Novel Mechanistic Insights and Therapeutic Opportunities. **2016**, 39, 1830-45	97
1939	New Treatments for Type 2 Diabetes Mellitus and Cardiovascular Disease. The Revolution Has Begun. **2016**, 69, 1005-1007	
1938	Effects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial. **2016**, 316, 500-8	327
1937	Evidence-based practice use of quick-release bromocriptine across the natural history of type 2 diabetes mellitus. **2016**, 128, 828-838	9
1936	Reframing the association and significance of co-morbidities in heart failure. **2016**, 18, 744-58	116
1935	Initial Combination of Empagliflozin and Metformin in Patients With Type 2 Diabetes. **2016**, 39, 1718-28	56

1934	Dapagliflozin as Additional Treatment to Liraglutide and Insulin in Patients With Type 1 Diabetes. **2016**, 101, 3506-15	44
1933	Risk assessment and management of post-transplant diabetes mellitus. **2016**, 65, 1559-69	9
1932	Drugs for hypercholesterolaemia - from statins to pro-protein convertase subtilisin kexin 9 (PCSK9) inhibition. **2016**, 16, 353-7	8
1931	Empagliflozin's Fuel Hypothesis: Not so Soon. **2016**, 24, 200-2	87
1930	Management of type 2 diabetes: the current situation and key opportunities to improve care in the UK. **2016**, 18, 1157-1166	15
1929	Effective Utilization of Oral Hypoglycemic Agents to Achieve Individualized HbA1c Targets in Patients with Type 2 Diabetes Mellitus. **2016**, 7, 387-99	6
1928	Targeting hepatic glucose metabolism in the treatment of type 2 diabetes. **2016**, 15, 786-804	164
1927	Sodium glucose CoTransporter 2 (SGLT2) inhibitors: Current status and future perspective. **2016**, 93, 244-52	58
1926	Why China guidelines for type 2 diabetes represent an opportunity for treating this disease. **2016**, 32, 438-9	2
1925	Chronic ischaemic heart disease in the elderly. **2016**, 146, 372.e1-372.e10	
1924	Established and Emerging Strategies in the Treatment of Chronic Kidney Disease. **2016**, 36, 331-42	14
1923	Baseline characteristics and interim (3-month) efficacy and safety data from STELLA-LONG TERM, a long-term post-marketing surveillance study of ipragliflozin in Japanese patients with type 2 diabetes in real-world clinical practice. **2016**, 17, 1985-94	21
1922	Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus: Cardiovascular and Kidney Effects, Potential Mechanisms, and Clinical Applications. **2016**, 134, 752-72	631
1921	2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. **2016**, 18, 891-975	4036
1920	NICE: type 2 diabetes in adults, 2015. **2016**, 33, 4-5	2
1919	Properties of GLP-1 agonists and their use in type 2 diabetes. **2016**, 27, 43-46	2
1918	Treatment of diabetes: Crossing to the other side. **2016**, 57, 304-310	11
1917	Omarigliptin for the treatment of type 2 diabetes mellitus. **2016**, 17, 1947-52	14

1916	Approaches to treatment 2: Comparison of American Association of Clinical Endocrinologists (AACE) and American Diabetes Association (ADA) type 2 diabetes treatment guidelines. **2016**, 8, 4-6	10
1915	The IRIS (Insulin Resistance Intervention after Stroke) trial: A new perspective on pioglitazone. **2016**, 8, 607-9	3
1914	Increased grip strength with sodium-glucose cotransporter 2. **2016**, 8, 736-7	25
1913	Diabetes News. **2016**, 8, 602-6	
1912	Novel approaches to the treatment of hyperglycaemia in type 2 diabetes mellitus. **2016**, 46, 540-9	2
1911	Diabetic Nephropathy: Perspective on Novel Molecular Mechanisms. **2016**, 27, 820-830	179
1910	Glycemic control and the heart: it matters how you get there. **2016**, 8, 453-4	1
1909	10th International conference on advanced technologies & treatments for diabetes. **2016**, 8, 455-9	
1908	Reductions in Mean 24-Hour Ambulatory Blood Pressure After 6-Week Treatment With Canagliflozin in Patients With Type 2 Diabetes Mellitus and Hypertension. **2016**, 18, 43-52	59
1907	Investigational glucagon-like peptide-1 agonists for the treatment of obesity. **2016**, 25, 1167-79	15
1906	Dapagliflozin Enhances Fat Oxidation and Ketone Production in Patients With Type 2 Diabetes. **2016**, 39, 2036-2041	105
1905	Medical Treatment and Revascularization Options in Patients With Type 2 Diabetes and Coronary Disease. **2016**, 68, 985-95	34
1904	Glucagon and heart in type 2 diabetes: new perspectives. **2016**, 15, 123	42
1903	Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors and Cardiovascular Disease: A Systematic Review. **2016**, 5, 161-168	10
1902	Glycaemic control and cardiovascular disease: is there a light at the end of the tunnel?. **2017**, 110, 421-423	3
1901	Randomized Trials to Evaluate Cardiovascular Safety of Antihyperglycemic Medications: A Worthwhile Effort?. **2016**, 134, 571-3	13
1900	Response to Comment on Rosenstock and Ferrannini. Euglycemic Diabetic Ketoacidosis: A Predictable, Detectable, and Preventable Safety Concern With SGLT2 Inhibitors. Diabetes Care 2015;38:1638-1642. **2016**, 39, e139-40	
1899	What Are We Learning from the FDA-Mandated Cardiovascular Outcome Studies for New Pharmacological Antidiabetic Agents?. **2016**, 16, 94	1

1898	Continued efforts to translate diabetes cardiovascular outcome trials into clinical practice. **2016**, 15, 111		40
1897	Cardiac implications of drugs used to treat type 2 diabetes. **2016**, 11, 168-172		
1896	Gliflozin monotherapy for type 2 diabetes: a review of NICE Technology Appraisal 390. **2016**, 33, 192-193		
1895	[Management of hyperglycemic/diabetic patient during and in the immediate follow-up of an acute coronary syndrome]. **2016**, 45, 865-870		1
1894	SGLT2 Inhibitors: Benefit/Risk Balance. **2016**, 16, 92		64
1893	Management of patients with diabetes and CKD: conclusions from a "Kidney Disease: Improving Global Outcomes" (KDIGO) Controversies Conference. **2016**, 90, 1175-1183		73
1892	Once daily administration of the SGLT2 inhibitor, empagliflozin, attenuates markers of renal fibrosis without improving albuminuria in diabetic db/db mice. **2016**, 6, 26428		86
1891	Nephron Protection in Diabetic Kidney Disease. *New England Journal of Medicine*, **2016**, 375, 2096-2098	59.2	66
1890	Acute kidney injury from SGLT2 inhibitors: potential mechanisms. **2016**, 12, 711-712		64
1889	Diuretic Action of Sodium-Glucose Cotransporter 2 Inhibitors and Its Importance in the Management of Heart Failure. **2016**, 80, 2277-2281		38
1888	Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. *New England Journal of Medicine*, **2016**, 375, 1834-1844	59.2	2547
1887	Effects of glucose-lowering drugs on cardiovascular outcomes in patients with type 2 diabetes. **2016**, 12, 1267-1271		7
1886	GLP-1 receptor agonists and SGLT2 inhibitors: a couple at last?. **2016**, 4, 963-964		15
1885	Exenatide once weekly plus dapagliflozin once daily versus exenatide or dapagliflozin alone in patients with type 2 diabetes inadequately controlled with metformin monotherapy (DURATION-8): a 28 week, multicentre, double-blind, phase 3, randomised controlled trial. **2016**, 4, 1004-1016		249
1884	Meta-Analysis of Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Cardiovascular Outcomes and All-Cause Mortality Among Patients With Type 2 Diabetes Mellitus. **2016**, 118, 1774-1780		48
1883	Elevated serum magnesium associated with SGLT2 inhibitor use in type 2 diabetes patients: a meta-analysis of randomised controlled trials. **2016**, 59, 2546-2551		62
1882	Temporal trends and factors associated with diabetes mellitus among patients hospitalized with heart failure: Findings from Get With The Guidelines-Heart Failure registry. **2016**, 182, 9-20		72
1881	Reply: Trading Lower HbA1c for Increased Adverse Events: A Zero Sum Game?. **2016**, 68, 1373-4		

1880	Luseogliflozin, A Sodium Glucose Co-transporter 2 Inhibitor, Alleviates Hepatic Impairment in Japanese Patients with Type 2 Diabetes. **2016**, 66, 603-606	12
1879	2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts) Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). **2016**, 252, 207-274	341
1878	Diabetes and Heart Failure: Sugared Words Prove Bitter. **2016**, 68, 1417-1419	1
1877	Follow the LEADER-Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results Trial. **2016**, 7, 601-609	9
1876	The potential of SGLT2 inhibitors in phase II clinical development for treating type 2 diabetes. **2016**, 25, 1133-52	6
1875	Update review of the safety of sodium-glucose cotransporter 2 inhibitors for the treatment of patients with type 2 diabetes mellitus. **2016**, 15, 1401-12	25
1874	Common medications used by patients with type 2 diabetes mellitus: what are their effects on the lipid profile?. **2016**, 15, 95	39
1873	Copeptin and the risk of incident stroke, CHD and cardiovascular mortality in older men with and without diabetes: The British Regional Heart Study. **2016**, 59, 1904-12	18
1872	One-year efficacy and safety of saxagliptin add-on in patients receiving dapagliflozin and metformin. **2016**, 18, 1128-1133	25
1871	Diabetic nephropathy: SGLT2 inhibitors might halt progression of diabetic nephropathy. **2016**, 12, 583-4	5
1870	DPP-4 inhibitor plus SGLT-2 inhibitor as combination therapy for type 2 diabetes: from rationale to clinical aspects. **2016**, 12, 1407-1417	57
1869	Personalized Therapy by Phenotype and Genotype. **2016**, 39 Suppl 2, S127-36	11
1868	Treatment of Type 2 Diabetes: From "Guidelines" to "Position Statements" and Back: Recommendations of the Israel National Diabetes Council. **2016**, 39 Suppl 2, S146-53	17
1867	Positioning SGLT2 Inhibitors/Incretin-Based Therapies in the Treatment Algorithm. **2016**, 39 Suppl 2, S154-64	28
1866	SGLT2 Inhibitors and the Diabetic Kidney. **2016**, 39 Suppl 2, S165-71	192
1865	Clinical Considerations for Use of Initial Combination Therapy in Type 2 Diabetes. **2016**, 39 Suppl 2, S137-45	53
1864	Sodium-Glucose Cotransporter-2 Inhibition and the Glomerulus: A Review. **2016**, 33, 1502-18	29
1863	Heart Failure, Diabetes Mellitus, and Chronic Kidney Disease: A Clinical Conundrum. **2016**, 9,	12

1862	Is the Use of DPP-4 Inhibitors Associated With an Increased Risk for Heart Failure? Lessons From EXAMINE, SAVOR-TIMI 53, and TECOS. **2016**, 39 Suppl 2, S210-8	17
1861	Anti-inflammatory Agents in the Treatment of Diabetes and Its Vascular Complications. **2016**, 39 Suppl 2, S244-52	134
1860	Glucose Control and Vascular Outcomes in Type 2 Diabetes: Is the Picture Clear?. **2016**, 39 Suppl 2, S187-95	37
1859	Analyses of Results From Cardiovascular Safety Trials With DPP-4 Inhibitors: Cardiovascular Outcomes, Predefined Safety Outcomes, and Pooled Analysis and Meta-analysis. **2016**, 39 Suppl 2, S196-204	30
1858	Perspectives on Some Controversies in Cardiovascular Disease Risk Assessment in the Pharmaceutical Development of Glucose-Lowering Medications. **2016**, 39 Suppl 2, S219-27	9
1857	Pharmacogenomics in type 2 diabetes: oral antidiabetic drugs. **2016**, 16, 399-410	14
1856	Interventional procedures and future drug therapy for hypertension. **2017**, 38, 1101-1111	26
1855	Is the Mortality Benefit With Empagliflozin in Type 2 Diabetes Mellitus Too Good To Be True?. **2016**, 134, 94-6	16
1854	Genitourinary infections in diabetic patients in the new era of diabetes therapy with sodium-glucose cotransporter-2 inhibitors. **2016**, 26, 963-970	23
1853	Diabetes: Time for reconciliation between cardiologists and diabetologists. **2016**, 13, 509-10	6
1852	Comparison of Clinical Outcomes and Adverse Events Associated With Glucose-Lowering Drugs in Patients With Type 2 Diabetes: A Meta-analysis. **2016**, 316, 313-24	253
1851	Cardiovascular safety of empagliflozin in patients with type 2 diabetes: a meta-analysis of data from randomized placebo-controlled trials. **2016**, 18, 1034-40	29
1850	Antihyperglycemic Medication Use Among Medicare Beneficiaries With Heart Failure, Diabetes Mellitus, and Chronic Kidney Disease. **2016**, 9,	16
1849	Nâest-il pas temps dâactualiser les recommandations 2013 de la HAS pour le traitement du diabète de type 2 ? La Socit francophone de diabtologie (SFD) devrait-elle se charger de cette actualisation ? Analyse de la campagne des visites confraternelles de lâAssurance Maladie. **2016**, 10, 193-195	1
1848	Les acidoctoses diabtiques atypiques. **2016**, 10, 314-319	
1847	Results from Cardiovascular Outcome Trials in Diabetes. **2016**, 63, 317-319	1
1846	Nuevos hipoglucemiantes orales y riesgo cardiovascular. Cruzando la frontera metabica. **2016**, 69, 1088-1097	6
1845	Nuevos tratamientos para la diabetes mellitus tipo 2 y enfermedad cardiovascular. La revoluci ya ha empezado. **2016**, 69, 1005-1007	1

1844	The impact of insulin resistance on the kidney and vasculature. **2016**, 12, 721-737	151
1843	Prevention: some important steps forward, but many unmet needs in a world with cardiovascular disease as the leading cause of death. **2016**, 37, 3179-3181	11
1842	[The new ESC Guidelines for acute and chronic heart failure 2016]. **2016**, 41, 655-663	16
1841	Insuffisance cardiaque´: du NT-Pro-BNP ˆ lâ□hsuffisance cardiaque non systoliqueâ□**2016**, 37, A2-A6	
1840	The renal effects of SGLT2 inhibitors and a mini-review of the literature. **2016**, 7, 212-228	32
1839	Second-Line Agents for the Treatment of Type 2 Diabetes and Prevention of CKD. **2016**, 11, 2104-2106	1
1838	Cardiovascular Outcomes of New Medications for Type 2 Diabetes. **2016**, 18, 749-758	6
1837	Clinical Effectiveness and Impact on Insulin Therapy Cost After Addition of Dapagliflozin to Patients with Uncontrolled Type 2 Diabetes. **2016**, 7, 765-776	9
1836	Strategies for Diabetes Management: Using Newer Oral Combination Therapies Early in the Disease. **2016**, 7, 621-639	18
1835	Metabolic support for the heart: complementary therapy for heart failure?. **2016**, 18, 1420-1429	52
1834	Novel Anti-glycemic Drugs and Reduction of Cardiovascular Risk in Diabetes: Expectations Realized, Promises Unmet. **2016**, 18, 79	5
1833	Implications of the EMPA-REG Trial for Clinical Care and Research. **2016**, 16, 131	4
1832	Empagliflozin/metformin fixed-dose combination: a review in patients with type 2 diabetes. **2016**, 17, 2471-2477	8
1831	An update on DPP-4 inhibitors in the management of type 2 diabetes. **2016**, 21, 409-419	36
1830	Distinct Glucose-Lowering Mechanisms of Ipragliflozin Depending on Body Weight Changes. **2016**, 16, 369-376	5
1829	SGLT2 inhibitors: anti-diabetic drug discovery based on transporter inhibition. **2016**, 31, 450-461	
1828	Real-world evidence studies into treatment adherence, thresholds for intervention and disparities in treatment in people with type 2 diabetes in the UK. **2016**, 6, e012801	35
1827	Typ-2-Diabetes: Nierenschutz ist Herzschutz. **2016**, 10, 55-55	

1826	Antidiabetikum mit betr□chtlichem Zusatznutzen. **2016**, 10, 55-55	
1825	Letter by Koh Regarding Article, "Randomized Trials to Evaluate Cardiovascular Safety of Antihyperglycemic Medications: A Worthwhile Effort?". **2016**, 134, e650-e651	1
1824	Complementary Efforts Make for Efficient Research. **2016**, 164, 771-2	0
1823	Epidemiology and clinical management of type 2 diabetes mellitus and associated comorbidities in Spain (e-Management study). **2016**, 147 Suppl 1, 1-7	8
1822	Reabsorption von Glukose in der Niere. **2016**, 11, 443-446	
1821	Relevance of weight in the management of patients with type 2 diabetes mellitus: towards an adipocentric approach to diabetes. **2016**, 147 Suppl 1, 8-16	2
1820	Positioning of sodium-glucose cotransporter-2 inhibitors in national and international guidelines. **2016**, 147 Suppl 1, 49-53	2
1819	Design of and rationale for the Japan Diabetes Optimal Integrated Treatment study for 3 major risk factors of cardiovascular diseases (J-DOIT3): a multicenter, open-label, randomized, parallel-group trial. **2016**, 4, e000123	19
1818	Use of an electronic health record to identify prevalent and incident cardiovascular disease in type 2 diabetes according to treatment strategy. **2016**, 4, e000206	5
1817	Characteristics and outcomes of diabetic patients with an implantable cardioverter defibrillator in a real world setting: results from the Israeli ICD registry. **2016**, 15, 160	3
1816	Kardiovaskul□e Effekte von Antidiabetika. **2016**, 12, 150-153	
1815	Verminderung der Progression einer chronischen Niereninsuffizienz. **2016**, 11, 260-267	1
1814	(Empa-)Gliflozin. **2016**, 11, 357-360	
1813	ESC Heart Failure 2016: Was gibt es Neues?. **2016**, 10, 347-350	
1812	Zwei Studien, die die Diabeteswelt ver□dern. **2016**, 10, 46-47	
1811	Hemodynamic and renal implications of sodium-glucose cotransporter- 2 inhibitors in type 2 diabetes mellitus. **2016**, 147 Suppl 1, 35-43	3
1810	The future of n-3 polyunsaturated fatty acid therapy. **2016**, 27, 570-578	13
1809	Diabetes medications improve cardiovascular outcomes: the paradigm shifts. **2016**, 27, 633-635	

1808	Revitalization of pioglitazone: the optimum agent to be combined with a sodium-glucose co-transporter-2 inhibitor. **2016**, 18, 454-62	34
1807	Efficacy and safety of sodium-glucose co-transporter-2 inhibitors in type 2 diabetes mellitus: systematic review and network meta-analysis. **2016**, 18, 783-94	256
1806	Pharmacological management of nonalcoholic fatty liver disease. **2016**, 65, 1183-95	70
1805	Cardiovascular safety assessment of pramlintide in type 2 diabetes: results from a pooled analysis of five clinical trials. **2016**, 2, 12	10
1804	Cardiovascular effects of anti-diabetes drugs. **2016**, 15, 1239-57	11
1803	Metformin: nicht nur zur Therapie sondern auch zur Prvention?. **2016**, 49, 252-257	
1802	[Diabetes mellitus, coronary artery disease and heart disease]. **2016**, 128 Suppl 2, S212-5	4
1801	Aktuelle kardiovaskulre Outcome-Studien bei Diabetes. **2016**, 12, 88-95	1
1800	Herz und Diabetes. **2016**, 12, 78-79	
1799	Structured therapeutic education in diabetes: is it time to re-write the chapter on the prevention of diabetic complications?. **2016**, 53, 347-9	13
1798	EMPA-REG-OUTCOME-Studie. **2016**, 10, 78-80	
1797	SGLT2-remmers en diabetische ketoacidoses. **2016**, 14, 10-13	1
1796	Herzinsuffizienz bei Diabetes vorbeugen und entgegenwirken. **2016**, 10, 37-47	
1795	The Contribution of Diabetes Education in the Treatment of People with Type 2 Diabetes and Risk of Cardiovascular Disease. **2016**, 18, 44	3
1794	Cardiovascular safety for once-weekly dulaglutide in type 2 diabetes: a pre-specified meta-analysis of prospectively adjudicated cardiovascular events. **2016**, 15, 38	54
1793	Reappraisal of the diuretic effect of empagliflozin in the EMPA-REG OUTCOME trial: Comparison with classic diuretics. **2016**, 42, 224-33	55
1792	Diabetes remission off medications is not a suitable endpoint for comparing bariatric/metabolic surgery with pharmacotherapy. **2016**, 59, 2040-1	4
1791	Mechanisms of blood pressure reduction with sodium-glucose co-transporter 2 (SGLT2) inhibitors. **2016**, 17, 1581-3	23

1790	Effect of Sodium-Glucose Cotransporter 2 Inhibitors on Diabetic Ketoacidosis Among Patients With Type 2 Diabetes: A Meta-analysis of Randomized Controlled Trials. **2016**, 39, e123-4	42
1789	Adherence to antihyperglycemic treatment: a work in progress. **2016**, 17, 1579-80	1
1788	The Cardiovascular Biology of Glucagon-like Peptide-1. **2016**, 24, 15-30	311
1787	The evolving frontier of diabetes therapy: The renaissance of glycemology. **2016**, 118, 168-71	3
1786	Osteoporose und Typ-2-Diabetes. **2016**, 12, 254-260	
1785	Efficacy and safety of canagliflozin in combination with insulin: a double-blind, randomized, placebo-controlled study in Japanese patients with type 2 diabetes mellitus. **2016**, 15, 89	49
1784	Skeletal Metabolism, Fracture Risk, and Fracture Outcomes in Type 1 and Type 2 Diabetes. **2016**, 65, 1757-66	93
1783	Pharmacology and therapeutic implications of current drugs for type 2 diabetes mellitus. **2016**, 12, 566-92	205
1782	Sodium glucose transport modulation in type 2 diabetes and gastric bypass surgery. **2016**, 12, 1206-12	18
1781	[Geriatric aspects for the management of diabetes mellitus]. **2016**, 128 Suppl 2, S124-30	1
1780	Der besondere Fokus auf der Herzinsuffizienz. **2016**, 10, 20-21	
1779	Targeting adipose tissue in the treatment of obesity-associated diabetes. **2016**, 15, 639-660	369
1778	GLP-1 receptor agonist as treatment for cancer as well as diabetes: beyond blood glucose control. **2016**, 11, 357-364	5
1777	Glucose, cholesterol, and blood pressure: is lower always better for type 2 diabetes?. **2016**, 54, 32-37	1
1776	Predicted consequences of diabetes and SGLT inhibition on transport and oxygen consumption along a rat nephron. **2016**, 310, F1269-83	80
1775	Treating patients with diabetes and cardiovascular disease--Does the glucose matter?. **2016**, 26, 180-1	
1774	Need for streamlined use of DPP-4 inhibitors in the treatment of type 2 diabetes. **2016**, 15, 55	3
1773	Clinical and metabolic characteristics of treated hyperlipidemic patients additionally affected by subclinical hyperglycemia. **2016**, 15, 10	3

1772	Cardiovascular Outcomes Trials in Type 2 Diabetes Mellitus. **2016**, 135, 108-26		4
1771	CV Protection in the EMPA-REG OUTCOME Trial: A "Thrifty Substrate" Hypothesis. **2016**, 39, 1108-14		573
1770	NK cell count and glucotransporter 4 (GLUT4) expression in subjects with type 2 diabetes and colon cancer. **2016**, 8, 38		9
1769	Cardiovascular Mortality in Patients With Type 2 Diabetes and Recent Acute Coronary Syndromes From the EXAMINE Trial. **2016**, 39, 1267-73		38
1768	Can a Shift in Fuel Energetics Explain the Beneficial Cardiorenal Outcomes in the EMPA-REG OUTCOME Study? A Unifying Hypothesis. **2016**, 39, 1115-22		377
1767	Optimizing management of glycaemia. **2016**, 30, 397-411		5
1766	Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. *New England Journal of Medicine*, **2016**, 375, 311-22	59.2	3606
1765	Clinical Update: Cardiovascular Disease in Diabetes Mellitus: Atherosclerotic Cardiovascular Disease and Heart Failure in Type 2 Diabetes Mellitus - Mechanisms, Management, and Clinical Considerations. **2016**, 133, 2459-502		520
1764	Cardiac and Renovascular Complications in Type 2 Diabetes--Is There Hope?. *New England Journal of Medicine*, **2016**, 375, 380-2	59.2	26
1763	Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes. *New England Journal of Medicine*, **2016**, 375, 323-34	59.2	1956
1762	Sodium-glucose cotransporter 2 inhibition: cardioprotection by treating diabetes-a translational viewpoint explaining its potential salutary effects. **2016**, 2, 244-55		29
1761	Kardiovaskuläre Effekte von SGLT-2-Hemmern. **2016**, 12, 195-200		
1760	SGLT2 inhibitors in the management of type 2 diabetes. **2016**, 53, 364-72		47
1759	Managing hypertension in type 2 diabetes mellitus. **2016**, 30, 445-54		29
1758	Targeting inflammation in diabetic kidney disease: early clinical trials. **2016**, 25, 1045-58		52
1757	Cardiovascular effects of dapagliflozin in patients with type 2 diabetes and different risk categories: a meta-analysis. **2016**, 15, 37		129
1756	Diabetes and the heart--the battle is not lost yet!. **2016**, 41, 173-4		
1755	Diabetes en cardiovasculaire sterfte. **2016**, 59, 182-182		

1754	A Review of the Key Clinical Trials of 2015: Results and Implications. **2016**, 5, 109-132	5
1753	2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts): Developed with the special contribution of the European Association for Cardiovascular	445
1752	Safety of ipragliflozin in elderly Japanese patients with type 2 diabetes mellitus (STELLA-ELDER): Interim results of a post-marketing surveillance study. **2016**, 17, 463-71	22
1751	Importance of inhibiting sodium-glucose cotransporter and its compelling indication in type 2 diabetes: pathophysiological hypothesis. **2016**, 10, 271-8	41
1750	Circadian blood pressure rhythm as a possible key target of SGLT2 inhibitors used for the treatment of Type 2 diabetes. **2016**, 39, 396-8	7
1749	A sodium-glucose co-transporter 2 inhibitor empagliflozin prevents abnormality of circadian rhythm of blood pressure in salt-treated obese rats. **2016**, 39, 415-22	35
1748	The year in cardiology 2015: heart failure. **2016**, 37, 437-41	1
1747	A Safety Evaluation of Empagliflozin for the Treatment of Type 2 Diabetes. **2016**, 15, 393-402	9
1746	The Impact of Hypoglycemia on the Cardiovascular System: Physiology and Pathophysiology. **2016**, 67, 802-9	17
1745	A Multifactorial Approach to Reduce Cardiovascular Disease in Type 2 Diabetes Mellitus: Now More Than Ever. **2016**, 44, 9-20	1
1744	The Time Is Right for a New Classification System for Diabetes: Rationale and Implications of the β-Cell-Centric Classification Schema. **2016**, 39, 179-86	173
1743	Dipeptidyl peptidase-4 inhibition in chronic kidney disease and potential for protection against diabetes-related renal injury. **2016**, 26, 361-73	30
1742	Cardiometabolic Effects of Glucagon-Like Peptide-1 Agonists. **2016**, 18, 7	2
1741	Future glucose-lowering drugs for type 2 diabetes. **2016**, 4, 350-9	67
1740	[Treatment of type 2 diabetes]. **2016**, 57, 153-65	3
1739	Vascular Risk and Cardiac Rehabilitation 2015: A Selection of Topical Issues. **2016**, 69, 294-9	1
1738	Treatment of hypertension in diabetes: a contemporary approach with a focus on improving cardiovascular outcomes. **2016**, 11, 41-50	2
1737	Insulin resistance and hyperinsulinaemia in diabetic cardiomyopathy. **2016**, 12, 144-53	383

1736	EMPA-REG - the "diuretic hypothesis". **2016**, 30, 3-4		57
1735	SGLT2 Inhibitors and Ketoacidosis: Cause for Concern?. **2016**, 14, 1-2		1
1734	Post-transplantation diabetes-state of the art. **2016**, 4, 337-49		54
1733	The EMPA-REG study: What has it told us? A diabetologist's perspective. **2016**, 30, 1-2		33
1732	Heart Failure Prevention: Special Considerations for Women. **2016**, 10, 1		
1731	Prevalence and co-prevalence of comorbidities among patients with type 2 diabetes mellitus. **2016**, 32, 1243-52		167
1730	Simultaneous Reduction in Both HbA1c and Body Weight with Canagliflozin Versus Glimepiride in Patients with Type 2 Diabetes on Metformin. **2016**, 7, 269-78		12
1729	Near normal HbA1c with stable glucose homeostasis: the ultimate target/aim of diabetes therapy. **2016**, 17, 91-101		17
1728	Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular events, death, and major safety outcomes in adults with type 2 diabetes: a systematic review and meta-analysis. **2016**, 4, 411-9		308
1727	SGLT2 inhibitors: providing cardiovascular protection in type 2 diabetes?. **2016**, 4, 379-81		6
1726	DPP-4 inhibitors and cardiovascular disease in type 2 diabetes mellitus. Expectations, observations and perspectives. **2016**, 26, 273-84		16
1725	Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. *New England Journal of Medicine*, **2016**, 374, 1094	59.2	125
1724	Le choix du traitement lorsque la metformine ne suffit plus : quelles particularitŝ au Maroc ?. **2016**, 10, 114-120		
1723	Cardiovascular outcomes of sodium-glucose cotransporter 2 inhibitors: A comprehensive review of clinical and preclinical studies. **2016**, 212, 29-36		38
1722	Innovative metabolic operations. **2016**, 12, 1247-55		10
1721	Sodium-glucose cotransporter 2 inhibitors and cardiovascular outcomes. **2016**, 128, 398-408		2
1720	[Chronic ischaemic heart disease in the elderly]. **2016**, 146, 372.e1-372.e10		4
1719	Sodium glucose cotransporter SGLT1 as a therapeutic target in diabetes mellitus. **2016**, 20, 1109-25		89

1718	Reduction in cardiovascular and all-cause mortality in the EMPA-REG OUTCOME trial: A critical analysis. **2016**, 42, 71-6	42
1717	Osmotic diuresis with SGLT2 inhibition: analysis of events related to volume reduction in dapagliflozin clinical trials. **2016**, 128, 346-55	31
1716	Sodium-glucose cotransporter 2 inhibition and cardiovascular risk reduction in patients with type 2 diabetes: the emerging role of natriuresis. **2016**, 89, 524-6	85
1715	Disordered haematopoiesis and athero-thrombosis. **2016**, 37, 1113-21	71
1714	Type 2 Diabetes Medication Review. **2016**, 351, 342-55	18
1713	The year in cardiology 2015: prevention. **2016**, 37, 510-9	10
1712	[Type 2 diabetes--criteria for the selection of the antidiabetic drug]. **2016**, 141, 285-8	0
1711	Efficacy and safety of empagliflozin as add-on to metformin for type 2 diabetes: a systematic review and meta-analysis. **2016**, 72, 655-63	20
1710	Blood pressure effects of SGLT2 inhibitors make them an attractive option in diabetic patients with hypertension. **2016**, 10, 186-7	1
1709	[Important endpoint trials in diabetes mellitus - impact on clinical care]. **2016**, 158, 45-49	
1708	Lipid-lowering efficacy of the PCSK9 inhibitor evolocumab (AMG 145) in patients with type 2 diabetes: a meta-analysis of individual patient data. **2016**, 4, 403-10	110
1707	Sodium-glucose cotransporter 2 inhibitors: an evidence-based practice approach to their use in the natural history of type 2 diabetes. **2016**, 32, 907-19	10
1706	Shift to Fatty Substrate Utilization in Response to Sodium-Glucose Cotransporter 2 Inhibition in Subjects Without Diabetes and Patients With Type 2 Diabetes. **2016**, 65, 1190-5	327
1705	[New aspects in prevention and therapy of diabetic nephropathy]. **2016**, 141, 186-9	4
1704	Superiority trials: statistical trickery or mass blindness?. **2016**, 92, 118-9	2
1703	New Management Strategies in Heart Failure. **2016**, 118, 480-95	23
1702	To overcome two diseases with one pill. **2016**, 39, 399-400	1
1701	Hypertension: Benefits of strict blood-pressure lowering in hypertension. **2016**, 13, 125-6	8

1700	The kidney and type 2 diabetes mellitus: therapeutic implications of SGLT2 inhibitors. **2016**, 128, 290-8	18
1699	Comparative effectiveness of sodium-glucose co-transporter 2 inhibitors for controlling hyperglycaemia in patients with type 2 diabetes: protocol for a systematic review and network meta-analysis. **2016**, 6, e010252	6
1698	Sitagliptin and other 'gliptins'--why prescribe them?. **2016**, 17, 757-60	3
1697	Treatment of diabetes and heart failure: joint forces. **2016**, 37, 1535-7	10
1696	EMPA-REG: Glucose excretion and lipid mobilization - not storage - saves lives. **2016**, 30, 753	7
1695	Endothelial progenitor cells (EPCs) in ageing and age-related diseases: How currently available treatment modalities affect EPC biology, atherosclerosis, and cardiovascular outcomes. **2016**, 159, 49-62	31
1694	Empagliflozin reduces body weight and indices of adipose distribution in patients with type 2 diabetes mellitus. **2016**, 13, 119-26	94
1693	Unraveling the association of heart failure from drug and disease: Insights from recent cardiovascular trials in type 2 diabetes mellitus. **2016**, 30, 189-91	
1692	Medical management of obesity in Scandinavia 2016. **2016**, 1, 38-44	11
1691	Ranolazine and Its Effects on Hemoglobin A1C. **2016**, 50, 410-5	9
1690	Practical considerations for the use of sodium-glucose co-transporter type 2 inhibitors in treating hyperglycemia in type 2 diabetes. **2016**, 32, 1097-108	12
1689	Risks of cardiovascular diseases associated with dipeptidyl peptidase-4 inhibitors and other antidiabetic drugs in patients with type 2 diabetes: a nation-wide longitudinal study. **2016**, 15, 41	48
1688	Polypharmacy in the Aging Patient: A Review of Glycemic Control in Older Adults With Type 2 Diabetes. **2016**, 315, 1034-45	126
1687	Non-insulin drugs to treat hyperglycaemia in type 1 diabetes mellitus. **2016**, 4, 766-780	61
1686	Aspects of Hyperglycemia Contribution to Arterial Stiffness and Cardiovascular Complications in Patients With Type 1 Diabetes. **2016**, 10, 1059-64	18
1685	Heart failure: SGLT2 inhibitors and heart failure -- clinical implications. **2016**, 13, 185-6	14
1684	Cardiometabolic crosstalk in obesity-associated arterial hypertension. **2016**, 17, 19-28	11
1683	Glycemic Control and Heart Failure: Separating the Contributors to Left Ventricular Dysfunction. **2016**, 9, e004613	1

1682	Cardiovascular risk with DPP-4 inhibitors: latest evidence and clinical implications. **2016**, 7, 36-8	12
1681	The evolution of diabetic ketoacidosis: An update of its etiology, pathogenesis and management. **2016**, 65, 507-21	119
1680	Dipeptidyl peptidase-4 inhibitors as add-on therapy to insulin: rationale and evidences. **2016**, 9, 605-616	3
1679	8. Cardiovascular Disease and Risk Management. **2016**, 39 Suppl 1, S60-71	196
1678	Potential Drug Combinations to Reduce Cardiovascular Disease Burden in Diabetes. **2016**, 37, 207-219	10
1677	Heart failure in 2015: Better results from prevention than from additional treatment. **2016**, 13, 75-7	2
1676	Obesity in 2015: Advances in managing obesity. **2016**, 12, 65-6	13
1675	7. Approaches to Glycemic Treatment. **2016**, 39 Suppl 1, S52-9	204
1674	Hypertension: SGLT2 inhibitors: not just another glucose-lowering agent. **2016**, 12, 128-9	2
1673	Diabetes Management and Cardiovascular Risk: Are SGLT-2 Inhibitors the Safest?. **2016**, 14, 3-6	2
1672	Sodium-glucose co-transporter-2 inhibitors as add-on therapy to insulin: rationale and evidences. **2016**, 9, 409-18	9
1671	Blood pressure and glycaemic effects of dapagliflozin versus placebo in patients with type 2 diabetes on combination antihypertensive therapy: a randomised, double-blind, placebo-controlled, phase 3 study. **2016**, 4, 211-220	143
1670	Combination therapy of sodium-glucose co-transporter-2 inhibitors and dipeptidyl peptidase-4 inhibitors in type 2 diabetes: rationale and evidences. **2016**, 9, 229-40	6
1669	[Chronic ischaemic heart disease in the elderly]. **2017**, 43, 109-122	5
1668	[Acidosis without marked hyperglycemia : Euglycemic diabetic ketoacidosis associated with SGLT2-Inhibitors]. **2017**, 112, 145-148	1
1667	Pharmacological aspects of the safety of gliflozins. **2017**, 118, 71-81	37
1666	Managing Diabetic Nephropathies in Clinical Practice. **2017**,	
1665	Examining factors associated with excess mortality in older people (age â‰¥70 years) with diabetes - a 10-year cohort study of older people with and without diabetes. **2017**, 34, 387-395	7

1664	Blood pressure control in type 2 diabetic patients. **2017**, 16, 3	44
1663	Ketosis and diabetic ketoacidosis in response to SGLT2 inhibitors: Basic mechanisms and therapeutic perspectives. **2017**, 33, e2886	101
1662	Medical Management of Diabesity: Do We Have Realistic Targets?. **2017**, 17, 4	26
1661	Back to glycemic control: An alternative look at the results of cardiovascular outcome trials in type 2 diabetes. **2017**, 27, 375-377	4
1660	Antidiabetic agents and cardiovascular outcomes in patients with heart diseases. **2017**, 33, 985-992	7
1659	Mechanisms of metabolic memory and renal hypoxia as a therapeutic target in diabetic kidney disease. **2017**, 8, 261-271	27
1658	Impact of Sodium-Glucose Cotransporter 2 Inhibitors on Nonglycemic Outcomes in Patients with Type 2 Diabetes. **2017**, 37, 481-491	29
1657	Cardioprotective effects of SGLT2 inhibitors are possibly associated with normalization of the circadian rhythm of blood pressure. **2017**, 40, 535-540	24
1656	Blood pressure reduction in diabetes: lessons from ACCORD, SPRINT and EMPA-REG OUTCOME. **2017**, 13, 365-374	24
1655	Cardiovascular safety and benefits of GLP-1 receptor agonists. **2017**, 16, 351-363	25
1654	The Sodium-Glucose Cotransporter 2 Inhibitor Dapagliflozin Prevents Cardiomyopathy in a Diabetic Lipodystrophic Mouse Model. **2017**, 66, 1030-1040	84
1653	Comparison of the diabetes guidelines from the ADA/EASD and the AACE/ACE. **2017**, 57, 261-265	23
1652	The year in cardiology 2016: prevention. **2017**, 38, 542-549	1
1651	The Diabetic Heart Failure With Preserved Ejection Fraction Phenotype: Is it Real and Is It Worth Targeting Therapeutically?. **2017**, 135, 736-740	20
1650	Antihyperglycemic Medications. **2017**, 2, 25-38	
1649	[Spanish adaptation of the 2016 European Guidelines on cardiovascular disease prevention in clinical practice]. **2017**, 34, 24-40	2
1648	Effect of a selective SGLT2 inhibitor, luseogliflozin, on circadian rhythm of sympathetic nervous function and locomotor activities in metabolic syndrome rats. **2017**, 44, 522-525	29
1647	An Evidence-Based Medicine Approach to Antihyperglycemic Therapy in Diabetes Mellitus to Overcome Overtreatment. **2017**, 135, 180-195	23

1646	New guidelines, new recommendations! But what is really new? A pragmatic interpretation of the 2016 European guidelines for the management of chronic heart failure. **2017**, 110, 1-6	2
1645	Treatment of Dyslipidemias to Prevent Cardiovascular Disease in Patients with Type 2 Diabetes. **2017**, 19, 7	36
1644	[Cardiovascular safety concerns of glucose-lowering drugs]. **2017**, 159, 62-66	
1643	Sodium-Glucose Co-Transporter-2 (SGLT2) Inhibitors: Comparing Trial and Real World Use (Study Protocol). **2017**, 8, 355-363	4
1642	Early Combination Therapy with Oral Glucose-Lowering Agents in Type 2 Diabetes. **2017**, 77, 247-264	22
1641	Effects of reducing blood pressure on renal outcomes in patients with type 2 diabetes: Focus on SGLT2 inhibitors and EMPA-REG OUTCOME. **2017**, 43, 99-109	27
1640	Differential effects of metformin on age related comorbidities in older men with type 2 diabetes. **2017**, 31, 679-686	62
1639	Clinical parameters affecting dapagliflozin response in patients with type 2 diabetes. **2017**, 43, 191-194	9
1638	American Diabetes Association Standards of Medical Care in Diabetes 2017. **2017**, 9, 320-324	255
1637	Postprandial macrophage-derived IL-1β stimulates insulin, and both synergistically promote glucose disposal and inflammation. **2017**, 18, 283-292	194
1636	Is Hemoglobin A1c the Right Outcome for Studies of Diabetes?. **2017**, 317, 1017-1018	65
1635	[Cardiovascular aspects of diabetes treatment : Finally a reason for cardiologists to be pleased]. **2017**, 58, 293-302	
1634	Integration of recent evidence into management of patients with atherosclerotic cardiovascular disease and type 2 diabetes. **2017**, 5, 391-402	42
1633	SAVOR-TIMI to SUSTAIN-6: a critical comparison of cardiovascular outcome trials of antidiabetic drugs. **2017**, 10, 429-442	13
1632	Rationale, design and baseline characteristics of the CANagliflozin cardioVascular Assessment Study-Renal (CANVAS-R): A randomized, placebo-controlled trial. **2017**, 19, 387-393	101
1631	Novel oral glucose-lowering drugs are associated with lower risk of all-cause mortality, cardiovascular events and severe hypoglycaemia compared with insulin in patients with type 2 diabetes. **2017**, 19, 831-841	60
1630	Comparisons of weight changes between sodium-glucose cotransporter 2 inhibitors treatment and glucagon-like peptide-1 analogs treatment in type 2 diabetes patients: A meta-analysis. **2017**, 8, 510-517	38
1629	Advances in the pharmacotherapy of chronic heart failure with preserved ejection fraction: an ideal opportunity for precision medicine. **2017**, 18, 399-409	11

1628	The cardiovascular benefits of empagliflozin: SGLT2-dependent and -independent effects. **2017**, 60, 395-398	26
1627	Evaluation of large-scale clinical trials on cardiovascular disease risk in patients with type 2 diabetes mellitus treated with dipeptidyl peptidase 4 inhibitors and a new class of drugs. **2017**, 8, 633-634	2
1626	Diabète de type 2 : concilier Médecine de Précision et Primauté des Soins de Premier recours. Pas simple !: Quid du rôle des diabétologues et de l'hôpital ?. **2017**, 11, 5-7	1
1625	Pharmacotherapy of 'treatment resistant' type 2 diabetes. **2017**, 18, 503-515	17
1624	Looking Back at Look AHEAD Through the Lens of Recent Diabetes Outcome Trials. **2017**, 135, 720-723	6
1623	Cardiac Effects of Sulfonylurea-Related Hypoglycemia. **2017**, 40, 663-670	21
1622	Recommendations on the effect of antidiabetic drugs in bone. **2017**, 64 Suppl 1, 1-6	1
1621	Hypoglycaemia in patients with diabetes mellitus and renal impairment. **2017**, 14, 166-168	3
1620	Updates in heart failure: Highlights from the Iranian Joint Cardiovascular Congress Tehran, Iran, 1-4 March 2016. **2017**, 235, 179-182	1
1619	Primary prevention of cardiovascular disease: A review of contemporary guidance and literature. **2017**, 6, 2048004016687211	152
1618	Endocrine System and Cardiovascular Disease. **2017**, 99-107	
1617	Arterial pressure lability is improved by sodium-glucose cotransporter 2 inhibitor in streptozotocin-induced diabetic rats. **2017**, 40, 646-651	26
1616	[Cardiovascular effects of liraglutide therapy in patients with type 2 diabetes : Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results (LEADER)]. **2017**, 58, 303-306	
1615	Tendencias de la mortalidad por diabetes en España: por el buen camino. **2017**, 70, 421-422	1
1614	The long and unfinished journey of hyperglycaemia and heart failure research. **2017**, 103, 331-332	
1613	Delays in treatment intensification with oral antidiabetic drugs and risk of microvascular and macrovascular events in patients with poor glycaemic control: An individual patient simulation study. **2017**, 19, 1006-1013	10
1612	Spanish adaptation of the 2016 European Guidelines on cardiovascular disease prevention in clinical practice. **2017**, 29, 69-85	4
1611	Dapagliflozin in patients with type II diabetes mellitus, with and without elevated triglyceride and reduced high-density lipoprotein cholesterol levels. **2017**, 11, 450-458.e1	21

1610	The cardiovascular safety trials of DPP-4 inhibitors, GLP-1 agonists, and SGLT2 inhibitors. **2017**, 27, 194-202	28
1609	Are diabetes guidelines truly evidence based?. **2017**, 127, 70-79	3
1608	The efficacy and safety of SGLT2 inhibitors for adjunctive treatment of type 1 diabetes: a systematic review and meta-analysis. **2017**, 7, 44128	51
1607	Association between high-sensitivity troponin T and cardiovascular risk in individuals with and without metabolic syndrome: The ARIC study. **2017**, 24, 628-638	13
1606	Selection of the Best of 2016 in Diabetes and Heart. **2017**, 70, 124-125	
1605	A randomised study of the impact of the SGLT2 inhibitor dapagliflozin on microvascular and macrovascular circulation. **2017**, 16, 26	89
1604	Challenges with Evidence-Based Management of Stable Ischemic Heart Disease. **2017**, 19, 11	5
1603	Intestinal gluconeogenesis: another weight loss-independent antidiabetic effect of metabolic surgery. **2017**, 13, 630-631	
1602	Novel avenues for treating diabetic nephropathy: new investigational drugs. **2017**, 26, 445-462	17
1601	Sodium-glucose co-transporter-2 inhibitors and risk of adverse renal outcomes among patients with type 2 diabetes: A network and cumulative meta-analysis of randomized controlled trials. **2017** , 19, 1106-1115	49
1600	Development of Type 2 Diabetes Mellitus Phenotyping Framework Using Expert Knowledge and Machine Learning Approach. **2017**, 11, 791-799	14
1599	Diagnostic approaches for diabetic cardiomyopathy. **2017**, 16, 28	111
1598	Aggressive clinical approach to obesity improves metabolic and clinical outcomes and can prevent bariatric surgery: a single center experience. **2017**, 4, 9	7
1597	Management of Type 2 Diabetes in 2017: Getting to Goal. **2017**, 317, 1015-1016	87
1596	Optimizing the analysis strategy for the CANVAS Program: A prespecified plan for the integrated analyses of the CANVAS and CANVAS-R trials. **2017**, 19, 926-935	78
1595	Statistical Considerations for Cardiovascular Outcome Trials in Patients with Type 2 Diabetes Mellitus. **2017**, 9, 347-360	5
1594	SGLT2 inhibitor empagliflozin reduces renal outcomes and dampens the progressive reduction in glomerular filtration rate in patients with type 2 diabetes and antecedents of cardiovascular disease. **2017**, 22, 69-70	
1593	Multi-dimensional Roles of Ketone Bodies in Fuel Metabolism, Signaling, and Therapeutics. **2017**, 25, 262-284	552

1592	Sodium-myoinositol cotransporter-1, SMIT1, mediates the production of reactive oxygen species induced by hyperglycemia in the heart. **2017**, 7, 41166	43
1591	Metabolic and hemodynamic effects of sodium-dependent glucose cotransporter 2 inhibitors on cardio-renal protection in the treatment of patients with type 2 diabetes mellitus. **2017**, 8, 416-427	31
1590	Stroke paradox with SGLT-2 inhibitors: a play of chance or a viscosity-mediated reality?. **2017**, 88, 249-253	30
1589	Dapagliflozin decreases small dense low-density lipoprotein-cholesterol and increases high-density lipoprotein 2-cholesterol in patients with type 2 diabetes: comparison with sitagliptin. **2017**, 16, 8	76
1588	New pharmacological approaches in heart failure therapy: developments and possibilities. **2017**, 13, 173-188	
1587	Effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, on blood pressure and markers of arterial stiffness in patients with type 2 diabetes mellitus: a post hoc analysis. **2017**, 16, 29	63
1586	SGLT2 Inhibition in the Diabetic Kidney-From Mechanisms to Clinical Outcome. **2017**, 12, 700-710	118
1585	[Diabetology as an interdisciplinary challenge]. **2017**, 58, 329-335	2
1584	Intensifying Treatment Beyond Monotherapy in Type 2 Diabetes Mellitus: Where Do Newer Therapies Fit?. **2017**, 19, 25	1
1583	Contemporary risk estimates of three HbA variables in relation to heart failure following diagnosis of type 2 diabetes. **2017**, 103, 353-358	7
1582	Ketone Body Infusion With 3-Hydroxybutyrate Reduces Myocardial Glucose Uptake and Increases Blood Flow in Humans: A Positron Emission Tomography Study. **2017**, 6,	84
1581	Luseogliflozin reduces epicardial fat accumulation in patients with type 2 diabetes: a pilot study. **2017**, 16, 32	85
1580	WITHDRAWN: The Role of Sodium-Glucose Cotransporter 2 Inhibitors in the Management of Type 2 Diabetes. **2017**,	
1579	Editorial commentary: New drugs for diabetes: Finally safety and cardiovascular efficacy. **2017**, 27, 376-377	
1578	Dulaglutide for the treatment of type 2 diabetes. **2017**, 17, 485-496	20
1577	Heart failure and diabetes - underestimated, underdiagnosed and poorly understood: A call for action. **2017**, 14, 67-68	5
1576	Dapagliflozin: potential beneficial effects in the prevention and treatment of renal and cardiovascular complications in patients with type 2 diabetes. **2017**, 18, 517-527	4
1575	Pharmacological management of nonalcoholic fatty liver disease in type 2 diabetes. **2017**, 10, 535-547	13

1574	Acute changes in glomerular filtration rate with renin-angiotensin system (RAS) inhibition: clinical implications. **2017**, 91, 529-531	13
1573	35th Annual J. P. Morgan healthcare conference. **2017**, 9, 431-433	
1572	Efficacy and safety of dapagliflozin in patients with type 2 diabetes and concomitant heart failure. **2017**, 31, 1215-1221	25
1571	Interpreting Cardiovascular Endpoints in Trials of Antihyperglycemic Drugs. **2017**, 17, 203-215	4
1570	Response by Lee and Ovbiagele to Letter Regarding Article, "Pioglitazone for Secondary Stroke Prevention: A Systematic Review and Meta-Analysis". **2017**, 48, e136	
1569	Impact of empagliflozin on blood pressure in dipper and non-dipper patients with type 2 diabetes mellitus and hypertension. **2017**, 19, 1620-1624	27
1568	Integrating New Pharmacologic Agents into Heart Failure Care: Role of Heart Failure Practice Guidelines in Meeting This Challenge. **2017**, 37, 645-656	6
1567	Effect of empagliflozin on cardiac biomarkers in a zebrafish model of heart failure: clues to the EMPA-REG OUTCOME trial?. **2017**, 433, 97-102	43
1566	Kardiovaskulär wirksame Therapie bei Patienten mit Diabetes mellitus. **2017**, 13, 100-107	1
1565	Strategien zur Gewichtsreduktion bei Typ-2-Diabetes. **2017**, 13, 123-136	
1564	The effect of PPARγ agonist on SGLT2 and glucagon expressions in alpha cells under hyperglycemia. **2017**, 40, 1069-1076	3
1563	This patient is not breathing properly: is this COPD, heart failure, or neither?. **2017**, 15, 389-396	4
1562	[Diabetes and heart failure : Update 2017]. **2017**, 42, 329-340	0
1561	Mechanism of the blood pressure-lowering effect of sodium-glucose cotransporter 2 inhibitors in obese patients with type 2 diabetes. **2017**, 18, 23	49
1560	Diabetes Medications and Cardiovascular Outcomes in Type 2 Diabetes. **2017**, 26, 1133-1141	8
1559	Herzinsuffizienz-Guidelines der ESC â Was ist neu und klinisch relevant?. **2017**, 6, 122-128	
1558	Heart, lipids and hormones. **2017**, 6, R59-R69	7
1557	Surgery: Metabolic surgery: the cutting edge of diabetes care. **2017**, 14, 389-390	4

1556	Sulfonylureas and the Risks of Cardiovascular Events and Death: A Methodological Meta-Regression Analysis of the Observational Studies. **2017**, 40, 706-714	115
1555	Global kidney health 2017 and beyond: a roadmap for closing gaps in care, research, and policy. **2017**, 390, 1888-1917	419
1554	Assessment of Saxagliptin Efficacy: Meta-Analysis of 14 Phase 2 and 3 Clinical Trials. **2017**, 8, 587-599	9
1553	Future challenges and therapeutic opportunities in type 2 diabetes: Changing the paradigm of current therapy. **2017**, 19, 1339-1352	28
1552	Combination therapy with GLP-1 receptor agonist and SGLT2 inhibitor. **2017**, 19, 1353-1362	88
1551	Primary care diabetes prescribing rates: latest analysis shows continued rise in volume and cost. **2017**, 34, 30-33	1
1550	GLP-1 receptor agonists and heart failure in diabetes. **2017**, 43 Suppl 1, 2S13-2S19	37
1549	Absolute benefits of empagliflozin in type 2 diabetes: a game changer?. **2017**, 93, 373-375	3
1548	[Diabetes and the central nervous system]. **2017**, 88, 675-690	1
1547	Sodium-Glucose Cotransporter 2 Inhibitors with Renoprotective Effects. **2017**, 3, 24-32	25
1546	Letter by Castilla-Guerra et al Regarding Article, "Pioglitazone for Secondary Stroke Prevention: A Systematic Review and Meta-Analysis". **2017**, 48, e135	
1545	Dyslipidaemia in type 2 diabetes mellitus: bad for the heart. **2017**, 32, 422-429	18
1544	Use of Canagliflozin in Kidney Transplant Recipients for the Treatment of Type 2 Diabetes: A Case Series. **2017**, 40, e75-e76	37
1543	Recommendations on the effect of antidiabetic drugs in bone. **2017**, 64, 1-6	
1542	Guideline: In type 2 diabetes, ACP recommends metformin monotherapy if drugs are needed for glycemic control. **2017**, 166, JC39	4
1541	Review: Sulfonylureas are associated with overall mortality and CV events vs other antihyperglycemics in T2DM. **2017**, 166, JC40	
1540	Effects of dapagliflozin on insulin-requirement, glucose excretion and Ehydroxybutyrate levels are not related to baseline HbA1c in youth with type 1 diabetes. **2017**, 19, 1635-1639	24
1539	Efficacy and safety of ipragliflozin and metformin for visceral fat reduction in patients with type 2 diabetes receiving treatment with dipeptidyl peptidase-4 inhibitors in Japan: a study protocol for a prospective, multicentre, blinded-endpoint phase IV randomised controlled trial (PRIME-V study). **2017**, 7, e015766	4

1538	SGLT2 inhibitors and diabetic ketoacidosis: data from the FDA Adverse Event Reporting System. **2017**, 60, 1385-1389	134
1537	Drug-disease modeling in the pharmaceutical industry - where mechanistic systems pharmacology and statistical pharmacometrics meet. **2017**, 109S, S39-S46	17
1536	The effect of empagliflozin on oxidative nucleic acid modifications in patients with type 2 diabetes: protocol for a randomised, double-blinded, placebo-controlled trial. **2017**, 7, e014728	9
1535	The Sodium-Glucose Co-Transporter 2 Inhibitor, Empagliflozin, Protects against Diabetic Cardiomyopathy by Inhibition of the Endoplasmic Reticulum Stress Pathway. **2017**, 41, 2503-2512	32
1534	Sodium glucose transporter 2 (SGLT2) inhibition with empagliflozin improves cardiac diastolic function in a female rodent model of diabetes. **2017**, 16, 9	134
1533	A review of chemical therapies for treating diabetic hypertension. **2017**, 18, 909-923	5
1532	A Review of the Efficacy and Safety of Sodium-Glucose Cotransporter 2 Inhibitors: A Focus on Diabetic Ketoacidosis. **2017**, 30, 137-142	11
1531	Renal Effects of SGLT-2 Inhibitors and Other Anti-diabetic Drugs: Clinical Relevance and Potential Risks. **2017**, 102, 470-480	2
1530	A Practical Guide to the Use of Glucose-Lowering Agents With Cardiovascular Benefit or Proven Safety. **2017**, 33, 940-942	4
1529	ACE and SGLT2 inhibitors: the future for non-diabetic and diabetic proteinuric renal disease. **2017**, 33, 34-40	20
1528	Sodium-Glucose Co-transporters and Their Inhibition: Clinical Physiology. **2017**, 26, 27-38	152
1527	Has the SPRINT trial introduced a new blood-pressure goal in hypertension?. **2017**, 14, 560-566	11
1526	Activation of Skeletal Muscle AMPK Promotes Glucose Disposal and Glucose Lowering in Non-human Primates and Mice. **2017**, 25, 1147-1159.e10	139
1525	Metabolic Surgery in a Pill. **2017**, 25, 985-987	7
1524	Therapeutic Considerations for Antihyperglycemic Agents in Diabetic Kidney Disease. **2017**, 28, 2263-2274	45
1523	Dipeptidyl peptidase-4 inhibitors and the risk of heart failure: a systematic review and meta-analysis. **2017**, 5, E152-E177	47
1522	Sodium-glucose co-transporter type 2 inhibitors reduce evening home blood pressure in type 2 diabetes with nephropathy. **2017**, 14, 258-261	1
1521	Are targeted therapies for diabetic cardiomyopathy on the horizon?. **2017**, 131, 897-915	48

1520	A review of glucagon-like peptide-1 receptor agonists and their effects on lowering postprandial plasma glucose and cardiovascular outcomes in the treatment of type 2 diabetes mellitus. **2017**, 19, 1645-1654	21
1519	Towards an improved global understanding of treatment and outcomes in people with type 2 diabetes: Rationale and methods of the DISCOVER observational study program. **2017**, 31, 1188-1196	37
1518	Blood pressure management in patients with type 2 diabetes mellitus. **2017**, 40, 721-729	7
1517	American College of Cardiology 2017. **2017**, 9, 724-727	
1516	Sodium-glucose co-transporter 2 inhibitors for type 2 diabetes mellitus: An overview for the primary care physician. **2017**, 71, e12937	18
1515	All-Cause Mortality in Patients With Diabetes Under Treatment With Dapagliflozin: A Population-Based, Open-Cohort Study in The Health Improvement Network Database. **2017**, 102, 1719-1725	52
1514	The Effect of Sodium-Glucose Co-transporter-2 (SGLT-2) Inhibitors on Cardiometabolic Profile; Beyond the Hypoglycaemic Action. **2017**, 31, 215-225	7
1513	The potential and pitfalls of GLP-1 receptor agonists for renal protection in type 2 diabetes. **2017**, 43 Suppl 1, 2S20-2S27	41
1512	Discovery of a Potent, Selective Renal Sodium-Dependent Glucose Cotransporter 2 (SGLT2) Inhibitor (HSK0935) for the Treatment of Type 2 Diabetes. **2017**, 60, 4173-4184	20
1511	Heart failure. **2017**, 390, 1981-1995	306
1510	Once-weekly dipeptidyl peptidase-4 inhibitors for type 2 diabetes: a systematic review and meta-analysis. **2017**, 18, 843-851	14
1509	Diabetes, bone and glucose-lowering agents: clinical outcomes. **2017**, 60, 1170-1179	39
1508	SGLT-2 Inhibition with Dapagliflozin Reduces the Activation of the Nlrp3/ASC Inflammasome and Attenuates the Development of Diabetic Cardiomyopathy in Mice with Type 2 Diabetes. Further Augmentation of the Effects with Saxagliptin, a DPP4 Inhibitor. **2017**, 31, 119-132	165
1507	Neurological outcomes of antidiabetic therapy: What the neurologist should know. **2017**, 158, 60-66	3
1506	Safety and efficacy of liraglutide treatment in Japanese type 2 diabetes patients after acute myocardial infarction: A non-randomized interventional pilot trial. **2017**, 69, 511-517	6
1505	Bone effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in patients with type 2 diabetes mellitus. **2017**, 129, 159-168	27
1504	Does Gender Influence the Cardiovascular Benefits Observed with Sodium Glucose Co-Transporter-2 (SGLT-2) Inhibitors? A Meta-Regression Analysis. **2017**, 6, 129-132	5
1503	Empagliflozin as Add-on Therapy in Patients With Type 2 Diabetes Inadequately Controlled With Linagliptin and Metformin: A 24-Week Randomized, Double-Blind, Parallel-Group Trial. **2017**, 40, 201-209	77

1502	Recent advances in CKD and ESRD: A literature update. **2017**, 21, 11-18	0
1501	EMPA-REG OUTCOME: The Cardiologist's Point of View. **2017**, 120, S53-S58	15
1500	EMPA-REG OUTCOME: The Nephrologist's Point of View. **2017**, 120, S59-S67	38
1499	Diabetes: SGLT2 inhibitors and diabetic ketoacidosis - a growing concern. **2017**, 13, 441-442	17
1498	Ipragliflozin Reduces Epicardial Fat Accumulation in Non-Obese Type 2 Diabetic Patients with Visceral Obesity: A Pilot Study. **2017**, 8, 851-861	61
1497	A Unified Pathophysiological Construct of Diabetes and its Complications. **2017**, 28, 645-655	47
1496	Clinical characteristics and mortality in patients treated in a Multidisciplinary Diabetic Foot Unit. **2017**, 64, 241-249	2
1495	EMPA-REG OUTCOME: The Endocrinologist's Point of View. **2017**, 120, S48-S52	2
1494	Post-Discharge Worsening Renal Function in Patients with Type 2 Diabetes and Recent Acute Coronary Syndrome. **2017**, 130, 1068-1075	1
1493	[Cardiovascular Effects of Antidiabetic Therapies]. **2017**, 142, 737-745	1
1492	SGLT2 inhibitors: a novel choice for the combination therapy in diabetic kidney disease. **2017**, 16, 65	50
1491	Diabetic Kidney Disease: Challenges, Progress, and Possibilities. **2017**, 12, 2032-2045	739
1490	Impact of glucose-lowering therapies on risk of stroke in type 2 diabetes. **2017**, 43, 299-313	16
1489	Neue Therapieansätze bei Typ-2-Diabetes und hohem kardiovaskulärem Risiko. **2017**, 15, 77-80	
1488	Effects of Sodium-Glucose Cotransporter 2 Inhibitors on 24-Hour Ambulatory Blood Pressure: A Systematic Review and Meta-Analysis. **2017**, 6,	89
1487	Effects of canagliflozin on cardiovascular risk factors in patients with type 2 diabetes mellitus. **2017**, 71, e12948	14
1486	Lower Risk of Heart Failure and Death in Patients Initiated on Sodium-Glucose Cotransporter-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL Study (Comparative Effectiveness of Cardiovascular Outcomes in New Users of Sodium-Glucose Cotransporter-2 Inhibitors). **2017**, 136, 249-259	519
1485	Progress in the Presence of Failure: Updates in Chronic Systolic Heart Failure Management. **2017**, 19, 50	3

1484	2017 Position Paper of the Italian Society for Cardiovascular Prevention (SIPREC) for an Updated Clinical Management of Hypercholesterolemia and Cardiovascular Risk: Executive Document. **2017**, 24, 313-329	7
1483	Pharmacologic Treatment of Dyslipidemia in Diabetes: A Case for Therapies in Addition to Statins. **2017**, 19, 62	3
1482	Kommentar zu den neuen Leitlinien (2016) der Europ□ischen Gesellschaft f□r Kardiologie (ESC) zur kardiovaskul□ren Pr□vention. **2017**, 11, 21-26	4
1481	EMPA-REG OUTCOME: The Nephrologist's Point of View. **2017**, 130, S63-S72	25
1480	The Metabolodiuretic Promise of Sodium-Dependent Glucose Cotransporter 2 Inhibition: The Search for the Sweet Spot in Heart Failure. **2017**, 2, 939-940	104
1479	Novel SGLT2 inhibitor: first-in-man studies of antisense compound is associated with unexpected renal effects. **2017**, 5, e00292	10
1478	Safety and Tolerability of Empagliflozin in Patients with Type 2 Diabetes: Pooled Analysis of Phase I-III Clinical Trials. **2017**, 34, 1707-1726	119
1477	Cardiovascular safety of noninsulin antidiabetic drugs: Facts and promises. **2017**, 217, 473-477	
1476	Long-term follow-up of a hospital-based, multi-intervention programme in type 2 diabetes mellitus: impact on cardiovascular events and death. **2017**, 45, 1535-1552	2
1475	Planning secondary prevention: Room for improvement. **2017**, 24, 22-28	12
1474	We Know More Than We Can Tell About Diabetes and Vascular Disease: The 2016 Edwin Bierman Award Lecture. **2017**, 66, 1735-1741	12
1473	Cardiovascular Disease and Type 2 Diabetes: Has the Dawn of a New Era Arrived?. **2017**, 40, 813-820	78
1472	Mitigating Cardiovascular Risk in Type 2 Diabetes With Antidiabetes Drugs: A Review of Principal Cardiovascular Outcome Results of EMPA-REG OUTCOME, LEADER, and SUSTAIN-6 Trials. **2017**, 40, 821-831	48
1471	Commentary on R&D Trends Away from General Medicine/Cardiovascular Drugs: Can the FDA Help Reverse the Trend?. **2017**, 102, 186-188	1
1470	Network meta-analysis of liraglutide versus dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes in Japanese patients. **2017**, 33, 1653-1661	7
1469	The Prognostic Value of Fasting Plasma Glucose, Two-Hour Postload Glucose, and HbA in Patients With Coronary Artery Disease: A Report From EUROASPIRE IV: A Survey From the European Society of Cardiology. **2017**, 40, 1233-1240	57
1468	The use of lipid-lowering therapy and effects of antihyperglycaemic therapy on lipids in subjects with type 2 diabetes with or without cardiovascular disease: a pooled analysis of data from eleven randomized trials with insulin glargine 100 U/mL. **2017**, 16, 66	9
1467	The Role of SGLT-2 Inhibitors as Part of Optimal Medical Therapy in Improving Cardiovascular Outcomes in Patients with Diabetes and Coronary Artery Disease. **2017**, 31, 311-318	7

1466	Shifting Paradigms in the Medical Management of Type 2 Diabetes: Reflections on Recent Cardiovascular Outcome Trials. **2017**, 32, 1044-1051		17
1465	A single dose of dapagliflozin, an SGLT-2 inhibitor, induces higher glycosuria in GCK- and HNF1A-MODY than in type 2 diabetes mellitus. **2017**, 57, 272-279		16
1464	Salt and hypertension in diabetes. **2017**, 8, 154-159		5
1463	Risk of Diabetic Ketoacidosis after Initiation of an SGLT2 Inhibitor. *New England Journal of Medicine*, **2017**, 376, 2300-2302	59.2	191
1462	Bolstering your armamentarium with SGLT2 inhibitors. **2017**,		
1461	Do effects of sodium-glucose cotransporter-2 inhibitors in patients with diabetes give insight into potential use in non-diabetic kidney disease?. **2017**, 26, 358-367		18
1460	Protocol for a randomised controlled trial of the effect of dapagliflozin, metformin and exercise on glycaemic variability, body composition and cardiovascular risk in prediabetes (the PRE-D Trial). **2017**, 7, e013802		11
1459	SGLT2-I in the Hospital Setting: Diabetic Ketoacidosis and Other Benefits and Concerns. **2017**, 17, 54		11
1458	Cardiovascular Protection by Sodium Glucose Cotransporter 2 Inhibitors: Potential Mechanisms. **2017**, 120, S28-S36		30
1457	Diabetic Peripheral Neuropathy and Associated Pain: Emerging and Updated Research. **2017**, 39, 1082-1084		0
1456	Effects of SGLT-2 inhibitors on diabetic ketoacidosis: A meta-analysis of randomised controlled trials. **2017**, 130, 53-60		67
1455	Novel Diabetes Drugs and the Cardiovascular Specialist. **2017**, 69, 2646-2656		64
1454	GLP-1R as a Target for the Treatment of Diabetic Retinopathy: Friend or Foe?. **2017**, 66, 1453-1460		36
1453	Sodium glucose cotransporter 2 in mesangial cells and retinal pericytes and its implications for diabetic nephropathy and retinopathy. **2017**, 27, 691-695		21
1452	Cardiovascular Protection in the Treatment of Type 2 Diabetes: A Review of Clinical Trial Results Across Drug Classes. **2017**, 130, S18-S29		37
1451	Diabetes Mellitus and Heart Failure. **2017**, 130, S40-S50		77
1450	A review on cardiovascular effects of newer hypoglycaemic medications. **2017**, 49, 603-612		9
1449	Revascularization for patients with diabetes mellitus and stable ischemic heart disease: an update. **2017**, 32, 608-616		1

1448	American Association of Clinical Endocrinologists 2017. **2017**, 9, 817-820		2
1447	EMPA-REG OUTCOME: The Endocrinologist's Point of View. **2017**, 130, S51-S56		3
1446	EMPA-REG OUTCOME: The Cardiologist's Point of View. **2017**, 130, S57-S62		8
1445	Cardiovascular Protection by Sodium Glucose Cotransporter 2 Inhibitors: Potential Mechanisms. **2017**, 130, S30-S39		42
1444	Interventions in type 2 diabetes mellitus and cardiovascular mortality-An overview of clinical trials. **2017**, 42, 1-15		6
1443	Cardiovascular Protection in the Treatment of Type 2 Diabetes: A Review of Clinical Trial Results Across Drug Classes. **2017**, 120, S17-S27		54
1442	Rationale and design of a multicenter placebo-controlled double-blind randomized trial to evaluate the effect of empagliflozin on endothelial function: the EMBLEM trial. **2017**, 16, 48		26
1441	Prevention of heart failure mortality and hospitalizations in SPRINT, EMPA-REG, ALLHAT and HYVET: are diuretics the clue?. **2017**, 26, 193-194		2
1440	Role of the sympathetic nervous system in regulation of the sodium glucose cotransporter 2. **2017**, 35, 2059-2068		97
1439	Effects of sodium-glucose cotransporter 2 inhibitors on urinary excretion of intact and total angiotensinogen in patients with type 2 diabetes. **2017**, 65, 1057-1061		31
1438	So Many Antihyperglycemics: How to Choose? A Practical Approach. **2017**, 41, 469-473		3
1437	Metabolic Recovery of the Failing Heart: Emerging Therapeutic Options. **2017**, 13, 25-28		2
1436	Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. *New England Journal of Medicine*, **2017**, 377, 644-657	59.2	3789
1435	Effects of Canagliflozin on Cardiovascular Biomarkers in Older Adults With Type 2 Diabetes. **2017**, 70, 704-712		106
1434	Metabolic Remodeling in Diabetic Cardiomyopathy. **2017**, 113, 422-430		69
1433	Rapid Onset of Diabetic Ketoacidosis After SGLT2 Inhibition in a Patient With Unrecognized Acromegaly. **2017**, 102, 1451-1453		10
1432	Diabetes Mellitus and Heart Failure. **2017**, 120, S37-S47		98
1431	Hematocrit and Stroke: A Forgotten and Neglected Link?. **2017**, 43, 591-598		8

1430	Genetic analysis and literature review of Chinese patients with familial renal glucosuria: Identification of a novel SLC5A2 mutation. **2017**, 469, 105-110		8
1429	Renal sodium avidity in heart failure: from pathophysiology to treatment strategies. **2017**, 38, 1872-1882		73
1428	Use of lorcaserin for glycemic control in patients with type 2 diabetes mellitus. **2017**, 25, 816		1
1427	Trends in Mortality From Diabetes in Spain: On the Right Way. **2017**, 70, 421-422		
1426	Diabetes medication pharmacology. **2017**, 17, 198-207		2
1425	Considerations on glycaemic control in older and/or frail individuals with diabetes and advanced kidney disease. **2017**, 32, 591-597		6
1424	Endothelial and Perivascular Adipose Tissue Abnormalities in Obesity-Related Vascular Dysfunction: Novel Targets for Treatment. **2017**, 69, 360-368		29
1423	Efficacy and safety of tofogliflozin in Japanese patients with type 2 diabetes mellitus with inadequate glycaemic control on insulin therapy (J-STEP/INS): Results of a 16-week randomized, double-blind, placebo-controlled multicentre trial. **2017**, 19, 1397-1407		29
1422	Comorbidities in Heart Failure. **2017**, 243, 35-66		21
1421	Renal glucosuria is not associated with atherosclerotic cardiovascular disease outcome in a general Japanese community. **2017**, 261, 111-116		6
1420	SGLT2-inhibitors in type-2 diabetes: The remaining questions!. **2017**, 11 Suppl 1, S433-S438		2
1419	Cardiovascular safety of noninsulin antidiabetic drugs: facts and promises. **2017**, 217, 473-477		1
1418	Selection of the Best of 2016 in Clinical Cardiology: Therapeutic Novelties. **2017**, 70, 123-124		
1417	Selecci□n de lo mejor del a□o 2016 en diabetes y coraz□n. **2017**, 70, 124-125		2
1416	Selecci□n de lo mejor del a□o 2016 en cardiolog□a cl□nica. Novedades terap□uticas. **2017**, 70, 123-124		
1415	[Cardiogeriatrics: What do the current guidelines say about the elderly patient?]. **2017**, 52, 115-118		0
1414	SGLT2 inhibitor/DPP-4 inhibitor combination therapy - complementary mechanisms of action for management of type 2 diabetes mellitus. **2017**, 129, 409-420		25
1413	Geographic Variations in Controlled Trials. *New England Journal of Medicine*, **2017**, 376, 1198	59.2	3

1412	On the non-linear association between serum uric acid levels and all-cause mortality rate in patients with type 2 diabetes mellitus. **2017**, 260, 20-26	15
1411	The evolution of heart failure with reduced ejection fraction pharmacotherapy: What do we have and where are we going?. **2017**, 178, 67-82	2
1410	JDRF Mission Summit 2017. **2017**, 9, 544-546	
1409	Diabetes UK Professional Conference. **2017**, 9, 644-647	
1408	Cardiovascular outcome studies with incretin-based therapies: Comparison between DPP-4 inhibitors and GLP-1 receptor agonists. **2017**, 127, 224-237	11
1407	Mechanisms linking empagliflozin to cardiovascular and renal protection. **2017**, 241, 450-456	24
1406	Evaluating the costs of glycemic response with canagliflozin versus dapagliflozin and empagliflozin as add-on to metformin in patients with type 2 diabetes mellitus in the United Arab Emirates. **2017**, 33, 1155-1163	4
1405	Empagliflozin/linagliptin single-pill combination therapy for patients with type 2 diabetes mellitus. **2017**, 18, 545-549	4
1404	Empagliflozin and Cerebrovascular Events in Patients With Type 2 Diabetes Mellitus at High Cardiovascular Risk. **2017**, 48, 1218-1225	86
1403	Pharmacokinetic drug evaluation of saxagliptin plus dapagliflozin for the treatment of type 2 diabetes. **2017**, 13, 583-592	7
1402	Spotlight on Canagliflozin 300: review of its efficacy and an indirect comparison to other SGLT-2 inhibitors and long-acting GLP-1 receptor agonists. **2017**, 10, 633-647	1
1401	Effect of US Food and Drug Administration's Cardiovascular Safety Guidance on Diabetes Drug Development. **2017**, 102, 290-296	9
1400	Cardiovascular safety of liraglutide for the treatment of type 2 diabetes. **2017**, 16, 627-635	2
1399	Primary proximal tubule hyperreabsorption and impaired tubular transport counterregulation determine glomerular hyperfiltration in diabetes: a modeling analysis. **2017**, 312, F819-F835	46
1398	Efficacy and safety of canagliflozin in patients with type 2 diabetes based on history of cardiovascular disease or cardiovascular risk factors: a post hoc analysis of pooled data. **2017**, 16, 40	14
1397	Dapagliflozin once daily plus exenatide once weekly in obese adults without diabetes: Sustained reductions in body weight, glycaemia and blood pressure over 1 year. **2017**, 19, 1276-1288	37
1396	CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM - 2017 EXECUTIVE SUMMARY. **2017**, 23, 207-238	302
1395	SODIUM GLUCOSE COTRANSPORTER 2 AND DIPEPTIDYL PEPTIDASE-4 INHIBITION: PROMISE OF A DYNAMIC DUO. **2017**, 23, 831-840	9

1394	Current Pharmacological Therapies in Heart Failure Patients. **2017**, 24, 107-114	15
1393	Type 1 diabetes mellitus. **2017**, 3, 17016	430
1392	The use of sodium-glucose cotransporter 2 inhibitors in patients with type 2 diabetes and hypertension: a focus on African-American populations. **2017**, 129, 421-429	0
1391	Multimodality Strategy for Cardiovascular Risk Assessment: Performance in 2 Population-Based Cohorts. **2017**, 135, 2119-2132	51
1390	Canagliflozin as an Initial Therapy in Drug-Naïve Subjects with Type 2 Diabetes Mellitus: A Potential Involvement of Atherogenic Lipids in its Glycemic Efficacy. **2017**, 17, 313-320	7
1389	Baseline characteristics of patients enrolled in the Exenatide Study of Cardiovascular Event Lowering (EXSCEL). **2017**, 187, 1-9	39
1388	Integrated cardiovascular safety: multifaceted considerations in drug development and therapeutic use. **2017**, 16, 481-492	3
1387	Improving glycaemic control in type 2 diabetes: Stimulate insulin secretion or provide beta-cell rest?. **2017**, 19, 1205-1213	39
1386	Reflections on using non-inferiority randomised placebo controlled trials in assessing cardiovascular safety of new agents for treatment of type 2 diabetes. **2017**, 22, 54-56	1
1385	[Spanish adaptation of the 2016 European Guidelines on cardiovascular disease prevention in clinical practice]. **2017**, 31, 255-268	2
1384	Pharmacologic Therapy for Type 2 Diabetes: Synopsis of the 2017 American Diabetes Association Standards of Medical Care in Diabetes. **2017**, 166, 572-578	78
1383	Should Side Effects Influence the Selection of Antidiabetic Therapies in Type 2 Diabetes?. **2017**, 17, 21	22
1382	Genetically Driven Hyperglycemia Increases Risk of Coronary Artery Disease Separately From Type 2 Diabetes. **2017**, 40, 687-693	34
1381	Promise of SGLT2 Inhibitors in Heart Failure: Diabetes and Beyond. **2017**, 19, 23	58
1380	Animal models for assessing the impact of natural products on the aetiology and metabolic pathophysiology of Type 2 diabetes. **2017**, 89, 1242-1251	38
1379	Changes in Glycemic Control and Body Weight After Initiation of Dapagliflozin or Basal Insulin Supported Oral Therapy in Type 2 Diabetes: A Primary Care Database Study. **2017**, 11, 590-596	4
1378	Cardiovascular inflammation is reduced with methotrexate in diabetes. **2017**, 432, 159-167	8
1377	Euglycemic ketosis in patients with type 2 diabetes on SGLT2-inhibitor therapy-an emerging problem and solutions offered by diabetes technology. **2017**, 56, 212-216	19

1376	Effect of sacubitril/valsartan versus enalapril on glycaemic control in patients with heart failure and diabetes: a post-hoc analysis from the PARADIGM-HF trial. **2017**, 5, 333-340	164
1375	Empa's New Clothes: The Untold Story of the Empa-Reg Outcome Trial. **2017**, 19, 324-327	3
1374	2016 European Guidelines on cardiovascular disease prevention in clinical practice : The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts). **2017**, 24, 321-419	54
1373	Transitions, Introductions, and a Notable Announcement From the US FDA in December 2016. **2017**, 51, 140-141	0
1372	Report from the 2nd Cardiovascular Outcome Trial (CVOT) Summit of the Diabetes and Cardiovascular Disease (D&CVD) EASD Study Group. **2017**, 16, 35	11
1371	Differential Effects of Dapagliflozin on Cardiovascular Risk Factors at Varying Degrees of Renal Function. **2017**, 12, 751-759	89
1370	Hypofibrinolysis in diabetes: a therapeutic target for the reduction of cardiovascular risk. **2017**, 16, 34	68
1369	Proximal Tubulopathy: Prime Mover and Key Therapeutic Target in Diabetic Kidney Disease. **2017**, 66, 791-800	133
1368	Management of Atherosclerotic Cardiovascular Disease Risk Factors in the Older Adult Patient With Diabetes. **2017**, 40, 476-484	7
1367	Renal Handling of Ketones in Response to Sodium-Glucose Cotransporter 2 Inhibition in Patients With Type 2 Diabetes. **2017**, 40, 771-776	93
1366	Is HbA 65 Years Old?. **2017**, 40, 526-528	9
1365	Sodium-Glucose Co-transporter 2 (SGLT2) Inhibitor: Comparing Trial Data and Real-World Use. **2017**, 8, 365-376	33
1364	Metabolic Modulators in Heart Disease: Past, Present, and Future. **2017**, 33, 838-849	86
1363	Novel antidiabetic medications for non-alcoholic fatty liver disease with type 2 diabetes mellitus. **2017**, 47, 266-280	44
1362	Second line initiation of insulin compared with DPP-4 inhibitors after metformin monotherapy is associated with increased risk of all-cause mortality, cardiovascular events, and severe hypoglycemia. **2017**, 123, 199-208	35
1361	Real-world effectiveness and safety of dapagliflozin therapy added to a GLP1 receptor agonist in patients with type 2 diabetes. **2017**, 27, 129-137	12
1360	Understanding the impact of hypoglycemia on the cardiovascular system. **2017**, 12, 21-33	18
1359	Effects on □and □cell function of sequentially adding empagliflozin and linagliptin to therapy in people with type 2 diabetes previously receiving metformin: An exploratory mechanistic study. **2017**, 19, 489-495	12

1358	Imaging oxygen metabolism with hyperpolarized magnetic resonance: a novel approach for the examination of cardiac and renal function. **2017**, 37,	11
1357	Which treatment for type 2 diabetes associated with non-alcoholic fatty liver disease?. **2017**, 49, 235-240	29
1356	Protocol of GLUcose COntrol Safety and Efficacy in type 2 DIabetes, a NETwork meta-analysis: GLUCOSE DINET protocol-Rational and design. **2017**, 31, 258-264	3
1355	Emerging roles of sodium-glucose cotransporter 2 inhibitors in cardiology. **2017**, 69, 501-507	22
1354	Impact of empagliflozin on diabetic kidney disease. **2017**, 8, 658-660	0
1353	Possible survivorship bias rather than reverse causality in EMPA-REG OUTCOME. **2017**, 127, 290	3
1352	Drug therapy for ectopic fat: myth or reality?. **2017**, 15, 71-72	1
1351	The year in cardiology 2016: heart failure. **2017**, 38, 705-711	1
1350	Canagliflozin use in Type I diabetes mellitus. **2017**, 129, 336-339	
1349	SGLT2 Inhibitors: A Systematic Review of Diabetic Ketoacidosis and Related Risk Factors in the Primary Literature. **2017**, 37, 187-194	101
1348	Lessons from a cardiovascular outcome trial with liraglutide in type 2 diabetes. **2017**, 8, 431-433	6
1347	Emerging drugs for the treatment of obesity. **2017**, 22, 87-99	16
1346	Effect of long-term glycemic variability on estimated glomerular filtration rate decline among patients with type 2 diabetes mellitus: Insights from the Diabetic Nephropathy Cohort in Singapore. **2017**, 9, 908-919	17
1345	Metformin in adults with type 1 diabetes: Design and methods of REducing with MetfOrmin Vascular Adverse Lesions (REMOVAL): An international multicentre trial. **2017**, 19, 509-516	24
1344	Reverse causality in Empa-Reg Outcome: The proverbial elephant?. **2017**, 127, 288-289	2
1343	Renal, metabolic and cardiovascular considerations of SGLT2 inhibition. **2017**, 13, 11-26	265
1342	Pharmacokinetic Characteristics and Clinical Efficacy of an SGLT2 Inhibitor Plus DPP-4 Inhibitor Combination Therapy in Type 2 Diabetes. **2017**, 56, 703-718	28
1341	Clinical and Echocardiographic Characteristics and Cardiovascular Outcomes According to Diabetes Status in Patients With Heart Failure and Preserved Ejection Fraction: A Report From the I-Preserve Trial (Irbesartan in Heart Failure With Preserved Ejection Fraction). **2017**, 135, 724-735	100

1340	8. Pharmacologic Approaches to Glycemic Treatment. **2017**, 40, S64-S74	307
1339	9. Cardiovascular Disease and Risk Management. **2017**, 40, S75-S87	174
1338	Diabetes mellitus and cardiovascular clinical characteristics of Spanish women with stable ischaemic heart disease: Data from the SIRENA study. **2017**, 123, 82-86	3
1337	Understanding and overcoming metformin gastrointestinal intolerance. **2017**, 19, 473-481	83
1336	Factors Affecting Canagliflozin-Induced Transient Urine Volume Increase in Patients with Type 2 Diabetes Mellitus. **2017**, 34, 436-451	76
1335	Incretin-related drugs and cardiovascular events: A comparison of GLP-1 analogue and DPP-4 inhibitor. **2017**, 69, 508-510	2
1334	The Cardio-Renal Interrelationship. **2017**, 59, 636-648	27
1333	10. Microvascular Complications and Foot Care. **2017**, 40, S88-S98	110
1332	Resolving the KgA1c paradox in the management of type 2 diabetes mellitus. **2017**, 11 Suppl 1, S159-S168	
1331	Liraglutide for weight management: benefits and risks. **2017**, 33, 537-539	1
1330	Differentiation of Diabetes by Pathophysiology, Natural History, and Prognosis. **2017**, 66, 241-255	292
1329	Longer-term safety and tolerability of canagliflozin in patients with type 2 diabetes: a pooled analysis. **2017**, 33, 553-562	24
1328	Cardiovascular and All-Cause Mortality Risk Associated With Urinary Excretion of 8-oxoGuo, a Biomarker for RNA Oxidation, in Patients With Type 2 Diabetes: A Prospective Cohort Study. **2017**, 40, 1771-1778	36
1327	The Infamous, Famous Sulfonylureas and Cardiovascular Safety: Much Ado About Nothing?. **2017**, 17, 124	13
1326	Use of Canagliflozin in Combination With and Compared to Incretin-Based Therapies in Type 2 Diabetes. **2017**, 35, 141-153	1
1325	Therapy: SGLT inhibition in T1DM - definite benefit with manageable risk. **2017**, 13, 698-699	4
1324	SGLT2 Inhibitors Through the Windows of EMPA-REG and CANVAS Trials: A Review. **2017**, 8, 1245-1251	34
1323	Cardiac Involvement in Diabetes: The Dark Side of the Moon. **2017**, 70, 1717-1719	4

1322	The Role of Sodium-Glucose Cotransporter 2 Inhibitors in the Management of Type 2 Diabetes. **2017**, 41, 517-523	9
1321	Closing the gap between evidence and practice in chronic kidney disease. **2017**, 7, 114-121	8
1320	Insulin Therapy Increases Cardiovascular Risk in Type 2 Diabetes. **2017**, 60, 422-434	55
1319	Is glycemia control in Canadians with diabetes individualized? A cross-sectional observational study. **2017**, 5, e000316	5
1318	Prevalence of Prediabetes and Undiagnosed Diabetes in Patients with HFpEF and HFrEF and Associated Clinical Outcomes. **2017**, 31, 545-549	35
1317	Treating Disease Mechanisms in Patients With Heart Failure and Diabetes Mellitus. **2017**, 14, 445-453	5
1316	Pathogenesis, Clinical Features and Treatment of Diabetic Cardiomyopathy. **2018**, 1067, 197-217	35
1315	Causes of Death in a Contemporary Cohort of Patients With Type 2 Diabetes and Atherosclerotic Cardiovascular Disease: Insights From the TECOS Trial. **2017**, 40, 1763-1770	46
1314	Dapagliflozin and saxagliptin tablets for adults with type 2 diabetes. **2017**, 10, 1303-1316	4
1313	Orale Triple-Therapie â□sinnvolle Strategie oder nur Verzögerungstaktik?. **2017**, 13, 416-420	
1312	Orale Triple-Therapie â□sinnvolle Strategie oder nur Verzögerungstaktik?. **2017**, 13, 412-415	
1311	Effekt von Canagliflozin auf kardiovaskuläre und renale Endpunkte. **2017**, 13, 444-445	
1310	The diabetic heart utilizes ketone bodies as an energy source. **2017**, 77, 65-72	78
1309	Cancer risk in the EMPA-REG OUTCOME trial. Reply to Shaikh AMY [letter] and Kohler S, Lee J, George JT et al [letter]. **2017**, 60, 2538-2539	2
1308	Challenges in Choosing a Medication for Type 2 Diabetes. **2017**, 19, 557-559	1
1307	Diabetic Nephropathy: a Tangled Web to Unweave. **2017**, 31, 579-592	91
1306	Treatment of Dyslipidemia in Diabetes: Recent Advances and Remaining Questions. **2017**, 17, 112	18
1305	HbA Outcomes in Patients Treated With Canagliflozin Versus Sitagliptin in US Health Plans. **2017**, 39, 2061-2072	5

1304	Is the Way to Someone's Heart Through Their Stomach? The Cardiorenal Paradox of Incretin-Based Hypoglycemic Drugs in Heart Failure. **2017**, 10,	10
1303	Cost of Glycemic Target Achievement with Sodium Glucose Co-transporter 2 Inhibitors in Patients with Type 2 Diabetes in the UK. **2017**, 8, 1175-1185	3
1302	Heart Failure With Mid-Range (Borderline) Ejection Fraction: Clinical Implications and Future Directions. **2017**, 5, 763-771	103
1301	The autonomic nervous system and cardiac GLP-1 receptors control heart rate in mice. **2017**, 6, 1339-1349	45
1300	Biological Phenotypes of Heart Failure With Preserved Ejection Fraction. **2017**, 70, 2186-2200	107
1299	The Ethics of Conducting Clinical Trials With Sodium-Glucose Cotransporter-2 Inhibitors in Heart Failure: Is Placebo Assignment Justified in Patients With Comorbid Diabetes Mellitus and Heart Failure?. **2017**, 136, 1459-1461	5
1298	Activation and Inhibition of Sodium-Hydrogen Exchanger Is a Mechanism That Links the Pathophysiology and Treatment of Diabetes Mellitus With That of Heart Failure. **2017**, 136, 1548-1559	119
1297	Renal and Cardiovascular Effects of sodium-glucose cotransporter 2 (SGLT2) inhibition in combination with loop Diuretics in diabetic patients with Chronic Heart Failure (RECEDE-CHF): protocol for a randomised controlled double-blind cross-over trial. **2017**, 7, e018097	31
1296	Review of the top 5 cardiology studies of 2015-16. **2017**, 150, 380-386	2
1295	Inkretinbasierte Diabetesmedikamente. **2017**, 13, 498-504	
1294	Insulin and Its Cardiovascular Effects: What Is the Current Evidence?. **2017**, 17, 120	19
1293	Sodium Glucose Cotransporter-2 Inhibition in Heart Failure: Potential Mechanisms, Clinical Applications, and Summary of Clinical Trials. **2017**, 136, 1643-1658	256
1292	Bariatric Surgery Resistance: Using Preoperative Lifestyle Medicine and/or Pharmacology for Metabolic Responsiveness. **2017**, 27, 3281-3291	13
1291	Medikamentöse Therapie der Herzinsuffizienz. **2017**, 46, 476-483	
1290	The potential role and rationale for treatment of heart failure with sodium-glucose co-transporter 2 inhibitors. **2017**, 19, 1390-1400	111
1289	A Loss-of-Function Splice Acceptor Variant in Is Protective for Type 2 Diabetes. **2017**, 66, 2903-2914	32
1288	The shifting paradigm in the treatment of type 2 diabetes mellitus-A cardiologist's perspective. **2017**, 40, 970-973	4
1287	Cardiac Computed Tomography Angiographic Findings as Predictors of Late Heart Failure in an Asymptomatic Diabetic Cohort: An 8-Year Prospective Follow-Up Study. **2017**, 138, 218-227	3

1286	Acute Kidney Injury in Patients on SGLT2 Inhibitors: A Propensity-Matched Analysis. **2017**, 40, 1479-1485		99
1285	Composite Primary End Points in Cardiovascular Outcomes Trials Involving Type 2 Diabetes Patients: Should Unstable Angina Be Included in the Primary End Point?. **2017**, 40, 1144-1151		30
1284	Should we screen for type 2 diabetes among asymptomatic individuals? Yes. **2017**, 60, 2148-2152		13
1283	The effect of SGLT2 inhibitors on cardiovascular events and renal function. **2017**, 10, 1251-1261		9
1282	Cardiovascular Actions and Clinical Outcomes With Glucagon-Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors. **2017**, 136, 849-870		279
1281	[How to Retard Progression of Chronic Kidney Disease]. **2017**, 142, 1282-1289		1
1280	Is atrial fibrillation another manifestation of organ damage in diabetes?. **2017**, 5, 761-762		1
1279	A New Chapter for Diabetic Kidney Disease. *New England Journal of Medicine*, **2017**, 377, 885-887	59.2	16
1278	Liraglutide and Renal Outcomes in Type 2 Diabetes. *New England Journal of Medicine*, **2017**, 377, 839-848	59.2	599
1277	SGLT2 inhibitors and cancer: why further evidence is required. **2017**, 60, 2536-2537		8
1276	Prophylaxe und Therapie der diabetischen Nephropathie. **2017**, 12, 407-413		1
1275	Effects of the Selective Sodium-Glucose Cotransporter 2 Inhibitor Empagliflozin on Vascular Function and Central Hemodynamics in Patients With Type 2 Diabetes Mellitus. **2017**, 136, 1167-1169		78
1274	Diabetes mellitus â diagnostische und therapeutische Strategien. **2017**, 13, 251-266		
1273	Bolstering your armamentarium with SGLT2 inhibitors. **2017**, 42, 28-34		1
1272	Mind the Gap: Current Challenges and Future State of Heart Failure Care. **2017**, 33, 1434-1449		13
1271	Pharmacological management of type 2 diabetes: what's new in 2017?. **2017**, 10, 1383-1394		16
1270	NMDAR antagonists for the treatment of diabetes mellitus-Current status and future directions. **2017**, 19 Suppl 1, 95-106		12
1269	arrestin-2 is involved in irisin induced glucose metabolism in type 2 diabetes via p38 MAPK signaling. **2017**, 360, 199-204		24

1268	Practical Ways to Achieve Targets in Diabetes Care 2017. **2017**, 9, 978-982		
1267	Clinical significance of diabetes likely induced by statins: Evidence from a large population-based cohort. **2017**, 133, 60-68		12
1266	SGLT2 inhibitors in type 1 diabetes: knocked down, but up again?. **2017**, 5, 841-843		8
1265	Pioglitazone versus sulfonylureas: cardiovascular outcomes with older diabetes drugs. **2017**, 5, 845-847		1
1264	Treatment of diabetic mice with the SGLT2 inhibitor TA-1887 antagonizes diabetic cachexia and decreases mortality. **2017**, 3, 12		26
1263	Adjunctive Treatments for Type 1 Diabetes. *New England Journal of Medicine*, **2017**, 377, 2390-2391	59.2	10
1262	Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes. *New England Journal of Medicine*, **2017**, 377, 1228-1239	59.2	1017
1261	Diabetes-mediated myelopoiesis and the relationship to cardiovascular risk. **2017**, 1402, 31-42		27
1260	Skeletal fragility in diabetes. **2017**, 1402, 18-30		30
1259	Diabetes Research and Care Through the Ages. **2017**, 40, 1302-1313		7
1258	A safety evaluation of empagliflozin plus linagliptin for treating type 2 diabetes. **2017**, 16, 1399-1405		6
1257	Reducing the Global Burden of Cardiovascular Disease, Part 2: Prevention and Treatment of Cardiovascular Disease. **2017**, 121, 695-710		134
1256	Rationale, Design, and Baseline Characteristics of the Utopia Trial for Preventing Diabetic Atherosclerosis Using an SGLT2 Inhibitor: A Prospective, Randomized, Open-Label, Parallel-Group Comparative Study. **2017**, 8, 999-1013		9
1255	Epigenetic programming, early life nutrition and the risk of metabolic disease. **2017**, 266, 31-40		72
1254	Effect of Empagliflozin on the Metabolic Signature of Patients With Type 2 Diabetes Mellitus and Cardiovascular Disease. **2017**, 136, 969-972		75
1253	Recent Insights into Pharmacologic Cardiovascular Risk Reduction in Type 2 Diabetes Mellitus. **2017** , 31, 459-470		2
1252	2017 Comprehensive Update of the Canadian Cardiovascular Society Guidelines for the Management of Heart Failure. **2017**, 33, 1342-1433		330
1251	Real-world use and modeled impact of glucose-lowering therapies evaluated in recent cardiovascular outcomes trials: An NCDR Research to Practice project. **2017**, 24, 1637-1645		73

1250	Can we reconcile 'the obesity paradox' with recent cardiovascular outcome trials in diabetes?. **2017**, 7, 255-259	1
1249	Finding serendipity. **2017**, 102, 1044-1045	
1248	SGLT2 inhibitors and risk of cancer in type 2 diabetes: a systematic review and meta-analysis of randomised controlled trials. **2017**, 60, 1862-1872	80
1247	Diabetes Mellitus, Microalbuminuria, and Subclinical Cardiac Disease: Identification and Monitoring of Individuals at Risk of Heart Failure. **2017**, 6,	41
1246	Can we go beyond surrogates?. **2017**, 9, 976-977	2
1245	Cardiovascular Outcome Trial Update in Diabetes: New Evidence, Remaining Questions. **2017**, 17, 67	3
1244	Diabetes Mellitus Following Renal Transplantation: Clinical and Pharmacological Considerations for the Elderly Patient. **2017**, 34, 589-601	
1243	Is It Time to Change the Type 2 Diabetes Treatment Paradigm? Yes! GLP-1 RAs Should Replace Metformin in the Type 2 Diabetes Algorithm. **2017**, 40, 1121-1127	32
1242	Is It Time to Change the Type 2 Diabetes Treatment Paradigm? No! Metformin Should Remain the Foundation Therapy for Type 2 Diabetes. **2017**, 40, 1128-1132	21
1241	The effect of empagliflozin on muscle sympathetic nerve activity in patients with type II diabetes mellitus. **2017**, 11, 604-612	44
1240	[New European guidelines for cardiovascular prevention and its Spanish adaptation]. **2017**, 49, 201-203	0
1239	Mechanistic Insights of Empagliflozin-Mediated Cardiac Benefits: Nearing the Starting Line : Editorial to: "Empagliflozin Improves Left Ventricular Diastolic Dysfunction in a Genetic Model of Type 2 Diabetes" by N. Hammoudi et al. **2017**, 31, 229-232	3
1238	Diabetesassoziierte Nierener kran kung. **2017**, 13, 365-380	
1237	Ketoacidosis associated with SGLT2 inhibitor treatment: Analysis of FAERS data. **2017**, 33, e2924	91
1236	Electronic clinical decision support system and multifactorial risk factor control in patients with type 2 diabetes in primary health care. **2017**, 44, e35-e37	1
1235	Efficacy and safety of once-weekly semaglutide for the treatment of type 2 diabetes. **2017**, 26, 1083-1089	10
1234	Diabetes in the Elderly. **2017**, 179-187	
1233	Individualisation du traitement de lâĦyperglycĥie du diabĒe de type 2 : choix selon la classe thŕapeutique, ou selon la molĉule: Quel poids accorder aux rŝultats des grandes ţudes de sĉuritˇcardiovasculaire exigềs par la FDA ?. **2017**, 11, 2S2-2S14	

1232	Introduction. **2017**, 130, S1-S3	8
1231	Historique des tudes cardiovasculaires : de lâ GDPâ aux derni es tudes. **2017**, 11, 2S15-2S26	7
1230	S curit cardiovasculaire des agonistes du r cepteur du glucagon-like peptide-1 et des inhibiteurs du co-transporteur sodium-glucose de type 2 : focus sur les r sultats des grands essais dâ intervention. **2017**, 11, 2S27-2S36	
1229	Effect of sodium-glucose co-transporter-2 inhibitors on impaired ventricular repolarization in people with Type 2 diabetes. **2017**, 34, 1367-1371	14
1228	Reality and Truth: Balancing the Hope and the Hype of Real-World Evidence. **2017**, 136, 260-262	8
1227	Liraglutide preserves renal function in overweight diabetic patients with stage 3 chronic kidney disease. **2017**, 44, e28-e29	6
1226	Insuficiencia card aca. Generalidades. **2017**, 12, 2085-2091	1
1225	tudes LEADER et EMPA-REG OUTCOME : implications en pratique clinique. **2017**, 11, 2S49-2S55	
1224	Risk Factors for Mortality Among Individuals With Peripheral Arterial Disease. **2017**, 120, 862-867	15
1223	Clinical characteristics and mortality in patients treated in a Multidisciplinary Diabetic Foot Unit. **2017**, 64, 241-249	8
1222	Empagliflozin in the management of diabetes mellitus after cardiac transplantationResearch Correspondenceretain-->. **2017**, 36, 914-916	7
1221	Diabetic ketoacidosis in patients under treatment with sodium-glucose cotransporter type 2 inhibitors. **2017**, 149, 311-312	4
1220	In Vitro Selection of Cell-Internalizing DNA Aptamers in a Model System of Inflammatory Kidney Disease. **2017**, 8, 198-210	13
1219	[Spanish adaptation of the 2016 European Guidelines on cardiovascular disease prevention in clinical practice]. **2017**, 43, 295-311	1
1218	Microvascular effects of glucagon-like peptide-1 receptor agonists in type 2 diabetes: a meta-analysis of randomized controlled trials. **2017**, 54, 933-941	40
1217	[Combination of oral antidiabetic drugs: What fits together?]. **2017**, 159, 47-52	
1216	[Main novelties of the last set of European guidelines for the management of heart failure]. **2017**, 46, 758-765	1
1215	Cardiovascular benefits and safety of non-insulin medications used in the treatment of type 2 diabetes mellitus. **2017**, 129, 811-821	32

1214	Acid-base and electrolyte disorders associated with the use of antidiabetic drugs. **2017**, 16, 1121-1132	12
1213	Update on SGLT2 Inhibitors-New Data Released at the American Diabetes Association. **2017**, 16, 93-95	12
1212	Comparison of Ipragliflozin and Pioglitazone Effects on Nonalcoholic Fatty Liver Disease in Patients With Type 2 Diabetes: A Randomized, 24-Week, Open-Label, Active-Controlled Trial. **2017**, 40, 1364-1372	154
1211	Why Are Diabetes Medications So Expensive and What Can Be Done to Control Their Cost?. **2017**, 17, 71	28
1210	Leaving the Glucocentric View: Can SGLT2 Inhibitors Halt CVD in Patients With Type 2 Diabetes?. **2017**, 70, 713-714	
1209	Sodium glucose co-transporter 2 inhibitor luseogliflozin in the management of type 2 diabetes: a drug safety evaluation. **2017**, 16, 1211-1218	15
1208	Incidence of cardiovascular events and vascular interventions in patients with type 2 diabetes. **2017** , 248, 301-307	20
1207	Impact of metformin on cardiovascular disease: a meta-analysis of randomised trials among people with type 2 diabetes. **2017**, 60, 1620-1629	231
1206	Risk stratification of patients with diabetes and the role of sodium glucose co-transporter inhibitors 2 during Ramadan fasting. **2017**, 131, 217-218	4
1205	Framing and managing cardiovascular risk in chronic kidney disease: from native to transplanted kidney. **2017**, 3, 70-77	2
1204	Cardiovascular disease leads to a new algorithm for diabetes treatment. **2017**, 11, 1126-1133	12
1203	Effects of Sodium-Glucose Cotransporter 2 Inhibitors for the Treatment of Patients With Heart Failure: Proposal of a Novel Mechanism of Action. **2017**, 2, 1025-1029	217
1202	Heart failure - what's new and what's changed?. **2017**, 17, 341-346	1
1201	The impact of dapagliflozin on HbA1c, systolic blood pressure and weight: a review of dapagliflozin use in a Scottish city. **2017**, 34, 129-130	
1200	60 years of metformin use: a glance at the past and a look to the future. **2017**, 60, 1561-1565	63
1199	Diabetes Update 2017. **2017**, 13, 302-312	3
1198	Hemodynamic effects by glucagon-like peptide-1 receptor analogues: what should be measured?. **2017**, 35, 953-954	0
1197	Primary Prevention of Cardiovascular Disease in Diabetes Mellitus. **2017**, 70, 883-893	68

1196	Metformin: new insights into an archetypal cardiometabolic drug. **2017**, 6, 92-94	
1195	Renal glucose metabolism in normal physiological conditions and in diabetes. **2017**, 133, 1-9	62
1194	Obesity-related glomerulopathy: pathogenesis, pathologic, clinical characteristics and treatment. **2017**, 11, 340-348	38
1193	Development and validation of Risk Equations for Complications Of type 2 Diabetes (RECODe) using individual participant data from randomised trials. **2017**, 5, 788-798	72
1192	Empagliflozin Prevents Worsening of Cardiac Function in an Experimental Model of Pressure Overload-Induced Heart Failure. **2017**, 2, 347-354	87
1191	Cardiovascular mortality and morbidity in patients with type 2 diabetes following initiation of sodium-glucose co-transporter-2 inhibitors versus other glucose-lowering drugs (CVD-REAL Nordic): a multinational observational analysis. **2017**, 5, 709-717	208
1190	Diabetes mellitus: Cardiovascular and renal benefits of SGLT2 inhibition: insights from CANVAS. **2017**, 13, 517-518	9
1189	Mortality in older people with diabetes: A review of current research. **2017**, 14, 20-25	0
1188	Empagliflozin and the Prevention of Heart Failure: Will Reverse Translation Lead to New Paradigms for the Treatment of Heart Failure?. **2017**, 2, 355-357	0
1187	A comprehensive review of the FDA-approved labels of diabetes drugs: Indications, safety, and emerging cardiovascular safety data. **2017**, 31, 1719-1727	43
1186	Comparative Effectiveness for Glycemic Control in Older Adults with Diabetes. **2017**, 6, 175-186	12
1185	Gefäßprotektion durch Antidiabetika über die Glukosesenkung hinaus. **2017**, 17, 43-46	
1184	SGLT2 inhibitors in the real world: too good to be true?. **2017**, 5, 673-675	9
1183	With regard to the papers by Kumar et al. and de Leeuw and de Boer addressing the cardiovascular safety and efficacy of anti-diabetic drugs. **2017**, 3, 75-76	2
1182	Fracture risk associated with common medications used in treating type 2 diabetes mellitus. **2017**, 74, 1143-1151	20
1181	Insights Into the Recognition and Management of SGLT2-Inhibitor-Associated Ketoacidosis: It's Not Just Euglycemic Diabetic Ketoacidosis. **2017**, 41, 499-503	19
1180	Ipragliflozin, a sodium glucose co-transporter 2 inhibitor, reduces intrahepatic lipid content and abdominal visceral fat volume in patients with type 2 diabetes. **2017**, 18, 1433-1438	40
1179	Will Canagliflozin Lend Credence to the Potential Effects of Sodium-Glucose Co-Transporter 2 Inhibitors on Renal Endpoints in Diabetic Nephropathy. **2017**, 46, 459-461	2

1178	ERBP guideline on management of patients with diabetes and chronic kidney disease stage 3B or higher. Metformin for all?. **2017**, 37, 567-571		5
1177	Semaglutid â□ein neuer langwirksamer GLP-1-Rezeptor-Agonist mit nachgewiesener kardiovaskulâ□er Ereignisreduktion bei Typ-2-Diabetes. **2017**, 12, 141-148		
1176	Choosing Dipeptidyl Peptidase-4 Inhibitors, Sodium-glucose Cotransporter-2 Inhibitors, or Both, as Add-ons to Metformin: Patient Baseline Characteristics Are Crucial. **2017**, 39, 2438-2447		6
1175	Chronic kidney disease. **2017**, 3, 17088		261
1174	Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. *New England Journal of Medicine*, **2017**, 377, 2099	59.2	123
1173	Does the evidence support population-wide screening for type 2 diabetes? No. **2017**, 60, 2153-2156		6
1172	Liraglutide and Renal Outcomes in Type 2 Diabetes. *New England Journal of Medicine*, **2017**, 377, 2197-2198	59.2	25
1171	Neue Antidiabetika und kardiovaskulâ□e Outcome-Studien. **2017**, 12, 273-285		1
1170	Glycaemic studies: Food for thought and fuel for debate. **2017**, 14, 379-380		
1169	Reply: Diabetic Hypertensives and Diastolic Dysfunction: Use of Calcium-Channel Blockers-A Clinical Concern. **2017**, 5, 851		
1168	The Role of Sympatho-Inhibition in Combination Treatment of Obesity-Related Hypertension. **2017**, 19, 99		10
1167	Cardiovascular Outcome Trials of Diabetes and Obesity Drugs: Implications for Conditional Approval and Early Phase Clinical Development. **2017**, 31, 399-421		2
1166	The CANVAS trial programme raises more questions than answers. **2017**, 34, 232-233		1
1165	Common variable immunodeficiency associated granulomatous and lymphocytic interstitial lung disease successfully treated with a combination regimen of rituximab and azathioprine. **2017**, 149, 312-313		
1164	Diabetic ketoacidosis in patients under treatment with sodium-glucose cotransporter type 2 inhibitors. **2017**, 149, 311-312		
1163	Efficacy and safety of glucagon-like peptide-1 agonists on macrovascular and microvascular events in type 2 diabetes mellitus: A meta-analysis. **2017**, 27, 1081-1088		16
1162	Acute renal failure with sodium-glucose-cotransporter-2 inhibitors: Analysis of the FDA adverse event report system database. **2017**, 27, 1108-1113		47
1161	[Hypertension and diabetes - dangerous syntropy]. **2017**, 159, 42-45		

1160	Cardiovascular safety outcomes of new antidiabetic therapies. **2017**, 74, 970-976	4
1159	Empagliflozin Improves Left Ventricular Diastolic Dysfunction in a Genetic Model of Type 2 Diabetes. **2017**, 31, 233-246	72
1158	The SGLT2 inhibitor empagliflozin improves the primary diabetic complications in ZDF rats. **2017**, 13, 370-385	130
1157	Prolonged Ketosis in a Patient With Euglycemic Diabetic Ketoacidosis Secondary to Dapagliflozin. **2017**, 5, 2324709617710040	17
1156	Introduction. **2017**, 120, S1-S3	
1155	Role of SGLT2 Inhibitors in Patients with Diabetes Mellitus and Heart Failure. **2017**, 14, 275-283	10
1154	Harnessing basic and clinic tools to evaluate SGLT2 inhibitor nephrotoxicity. **2017**, 313, F951-F954	13
1153	[New pharmacologic therapies for chronic heart failure]. **2017**, 58, 990-999	3
1152	Cardiovascular Safety of Antidiabetic Drugs in the Hospital Setting. **2017**, 17, 64	1
1151	Tubulointerstitial fibrosis can sensitize the kidney to subsequent glomerular injury. **2017**, 92, 1395-1403	24
1150	Response by Zinman et al to Letter Regarding Article, "Empagliflozin and Cerebrovascular Events in Patients With Type 2 Diabetes Mellitus at High Cardiovascular Risk". **2017**, 48, e256-e257	
1149	Oral Pharmacologic Treatment of Type 2 Diabetes Mellitus. **2017**, 167, 75-76	3
1148	ERBP guideline on management of patients with diabetes and chronic kidney disease stage 3B or higher. Metformin for all?. **2017**, 37, 567-571	6
1147	Do Sugar-Sweetened Beverages Cause Obesity and Diabetes?. **2017**, 167, 72-73	
1146	Considerations and treatment options for patients with comorbid atrial fibrillation and diabetes mellitus. **2017**, 18, 1101-1114	7
1145	Sodium-glucose cotransporter-2 inhibitors: Expanding oral treatment options for type 2 diabetes mellitus. **2017**, 42, 8-15	1
1144	Do Sugar-Sweetened Beverages Cause Obesity and Diabetes?. **2017**, 167, 71-72	1
1143	Oral Pharmacologic Treatment of Type 2 Diabetes Mellitus. **2017**, 167, 73-74	

1142	Oral Pharmacologic Treatment of Type 2 Diabetes Mellitus. **2017**, 167, 74-75	1
1141	Amelioration of arterial pressure lability: an unmissable target for diabetes management. **2017**, 40, 629-631	0
1140	Do Sugar-Sweetened Beverages Cause Obesity and Diabetes?. **2017**, 167, 72	0
1139	Antihyperglycemic agents and cardiovascular outcomes: recent insights. **2017**, 32, 642-650	2
1138	Prognostic Impact of Diabetes and Prediabetes on Survival Outcomes in Patients With Chronic Heart Failure: A Post-Hoc Analysis of the GISSI-HF (Gruppo Italiano per lo Studio della Sopravvivenza nella Insufficienza Cardiaca-Heart Failure) Trial. **2017**, 6,	39
1137	Cardiac Stress and Inflammatory Markers as Predictors of Heart Failure in Patients With Type 2 Diabetes: The ADVANCE Trial. **2017**, 40, 1203-1209	27
1136	Cardiovascular disease prevention strategies for type 2 diabetes mellitus. **2017**, 18, 1243-1260	30
1135	The safety of albiglutide for the treatment of type 2 diabetes. **2017**, 16, 1089-1097	4
1134	Insulin stimulates uric acid reabsorption via regulating urate transporter 1 and ATP-binding cassette subfamily G member 2. **2017**, 313, F826-F834	59
1133	Diabetes und Zentralnervensys tem. **2017**, 13, 47-62	
1132	Antidiabetika bei ltteren, multimorbiden Patienten. **2017**, 13, 91-99	
1131	Renale und kardiale Effekte von SGLT2-Inhibitoren. **2017**, 12, 90-96	
1130	Effects of empagliflozin on the urinary albumin-to-creatinine ratio in patients with type 2 diabetes and established cardiovascular disease: an exploratory analysis from the EMPA-REG OUTCOME randomised, placebo-controlled trial. **2017**, 5, 610-621	217
1129	SGLT2 inhibition: a new era in renoprotective medicine?. **2017**, 5, 569-571	6
1128	Effects of SGLT2 inhibitors on UTIs and genital infections in type 2 diabetes mellitus: a systematic review and meta-analysis. **2017**, 7, 2824	100
1127	Combination SGLT2 inhibitor and GLP-1 receptor agonist therapy: a complementary approach to the treatment of type 2 diabetes. **2017**, 129, 686-697	32
1126	Metabolic cardiomyopathies - fighting the next epidemic. **2017**, 113, 367-369	6
1125	SGLT-2 Inhibitors in Heart Failure: Implications for the Kidneys. **2017**, 14, 331-337	8

1124	SGLT2 inhibitors as add on therapy in type 2 diabetes: a real world study. **2017**, 16, 27	12
1123	Kommentar zu den Leitlinien der Europ□ischen Gesellschaft f□r Kardiologie (ESC) zur Diagnostik und Behandlung der akuten und chronischen Herzinsuffizienz. **2017**, 11, 183-192	9
1122	Evaluation of metabolic parameters and body composition in Japanese patients with type 2 diabetes mellitus who were administered tofogliflozin for 48 weeks. **2017**, 8, 205-211	6
1121	Modern peptide biomarkers and echocardiography in cardiac healthy haemodialysis patients. **2017**, 18, 175	2
1120	Are potentially clinically meaningful benefits misinterpreted in cardiovascular randomized trials? A systematic examination of statistical significance, clinical significance, and authors' conclusions. **2017**, 15, 58	3
1119	Effects of the SGLT2 inhibitor dapagliflozin on HDL cholesterol, particle size, and cholesterol efflux capacity in patients with type 2 diabetes: a randomized placebo-controlled trial. **2017**, 16, 42	49
1118	Effects of exenatide on cardiac function, perfusion, and energetics in type 2 diabetic patients with cardiomyopathy: a randomized controlled trial against insulin glargine. **2017**, 16, 67	11
1117	Sex difference in the risk for exercise-induced albuminuria correlates with hemoglobin A1C and abnormal exercise ECG test findings. **2017**, 16, 79	13
1116	Clinical effects, cardiovascular and renal outcomes associated with rapid-acting insulin analogs among individuals with type 2 diabetes: a nation-wide observational cohort study. **2017**, 3, 5	3
1115	Heart Failure with Preserved Ejection Fraction and Future Pharmacological Strategies: a Glance in the Crystal Ball. **2017**, 19, 70	18
1114	Targeting Mitochondrial Calcium Handling and Reactive Oxygen Species in Heart Failure. **2017**, 14, 338-349	50
1113	Dapagliflozin therapy for type 2 diabetes in primary care: Changes in HbA1c, weight and blood pressure over 2 years follow-up. **2017**, 11, 437-444	13
1112	Translational science in chronic kidney disease. **2017**, 131, 1617-1629	13
1111	Pioglitazone and cardiovascular risk reduction: time for a second look?. **2017**, 6, 55-61	
1110	The emergence of cardiodiabetology. **2017**, 6, 3-7	1
1109	Nonalcoholic fatty liver disease: implications for cardiovascular risk. **2017**, 6, 62-72	7
1108	Composite End Points in Clinical Research: A Time for Reappraisal. **2017**, 135, 2299-2307	44
1107	Einfluss von Empagliflozin auf zerebrovaskul□re Ereignisse. **2017**, 13, 270-271	

1106	Individualized, patient-centered use of lixisenatide for the treatment of type 2 diabetes mellitus. **2017**, 13, 311-321	3
1105	Bone Fractures with Sodium-Glucose Co-transporter-2 Inhibitors: How Real is the Risk?. **2017**, 40, 115-119	11
1104	Cardiovascular outcomes with sodium-glucose cotransporter-2 inhibitors in patients with type II diabetes mellitus: A meta-analysis of placebo-controlled randomized trials. **2017**, 228, 352-358	52
1103	Liraglutide improves cardiac function in patients with type 2 diabetes and chronic heart failure. **2017**, 57, 464-473	41
1102	Empagliflozin: Role in Treatment Options for Patients with Type 2 Diabetes Mellitus. **2017**, 8, 33-53	12
1101	Urinary tract and genital infections in patients with type 2 diabetes treated with sodium-glucose co-transporter 2 inhibitors: A meta-analysis of randomized controlled trials. **2017**, 19, 348-355	106
1100	Essentials of SGLT2 Inhibitors in Diabetes. **2017**,	1
1099	Satisfying the Regulatory Requirements for New Antidiabetic Drugs for Type 2 Diabetes Most Expeditiously. **2017**, 251-275	
1098	Place of sodium-glucose cotransporter-2 inhibitors in East Asian subjects with type 2 diabetes mellitus: Insights into the management of Asian phenotype. **2017**, 31, 494-503	14
1097	Efficacy and safety of empagliflozin in type 2 diabetes mellitus: a meta-analysis of randomized controlled trials. **2017**, 129, 382-392	18
1096	Excess Cardiovascular Risk in Women Relative to Men Referred for Coronary Angiography Is Associated With Severely Impaired Coronary Flow Reserve, Not Obstructive Disease. **2017**, 135, 566-577	148
1095	A new era in the management of type 2 diabetes: Is cardioprotection at long last a reality?. **2017**, 228, 198-200	5
1094	Cardiovascular Effects of Glucose-lowering Therapies for Type 2 Diabetes: New Drugs in Perspective. **2017**, 39, 1012-1025	12
1093	Need for Outcome Scenario Analysis of Clinical Trials in Diabetes. **2017**, 11, 327-334	1
1092	The Na-D-glucose cotransporters SGLT1 and SGLT2 are targets for the treatment of diabetes and cancer. **2017**, 170, 148-165	65
1091	Beneficial effects of sodium-glucose cotransporter 2 inhibitors for preservation of pancreatic β-cell function and reduction of insulin resistance. **2017**, 9, 219-225	33
1090	Preventive effect of ipragliflozin on nocturnal hypoglycemia in patients with type 2 diabetes treated with basal-bolus insulin therapy: An open-label, single-center, parallel, randomized control study. **2017**, 8, 341-345	8
1089	Empagliflozin decreases myocardial cytoplasmic Na through inhibition of the cardiac Na/H exchanger in rats and rabbits. **2017**, 60, 568-573	310

1088	Metabolomics and Metabolic Diseases: Where Do We Stand?. **2017**, 25, 43-56	339
1087	Toe amputations with SGLT-2 inhibitors: data from randomized clinical trials. **2017**, 54, 411-413	10
1086	Therapeutic Targeting of Cellular Stress to Prevent Cardiovascular Disease: A Review of the Evidence. **2017**, 17, 83-95	7
1085	Effects of sodium-glucose co-transporter 2 inhibitors on metabolism: unanswered questions and controversies. **2017**, 13, 399-408	15
1084	Evaluation of the pharmacokinetics, pharmacodynamics and clinical efficacy of empagliflozin for the treatment of type 2 diabetes. **2017**, 13, 211-223	12
1083	Canagliflozin Slows Progression of Renal Function Decline Independently of Glycemic Effects. **2017**, 28, 368-375	220
1082	Cardiovascular Safety in Drug Development and Therapeutic Use. **2017**,	4
1081	Effects of SGLT-2 inhibitors on mortality and cardiovascular events: a comprehensive meta-analysis of randomized controlled trials. **2017**, 54, 19-36	57
1080	Effects of antidiabetic drugs on the incidence of macrovascular complications and mortality in type 2 diabetes mellitus: a new perspective on sodium-glucose co-transporter 2 inhibitors. **2017**, 49, 51-62	13
1079	Prescription of oral hypoglycemic agents for patients with type 2 diabetes mellitus: A retrospective cohort study using a Japanese hospital database. **2017**, 8, 227-234	32
1078	The Fatty Kidney: Obesity and Renal Disease. **2017**, 136, 273-276	30
1077	SGLT2 Inhibitors-Sweet Success for Diabetic Kidney Disease?. **2017**, 28, 7-10	16
1076	With regard to the paper by Zannad et al. entitled Assessment of cardiovascular risk of new drugs for the treatment of diabetes mellitus: risk assessment versus risk aversion. **2017**, 3, 7-8	4
1075	Hemoglobin A levels and risk of sudden cardiac death: A nested case-control study. **2017**, 14, 72-78	9
1074	Diabetic ketosis during hyperglycemic crisis is associated with decreased all-cause mortality in patients with type 2 diabetes mellitus. **2017**, 55, 139-143	16
1073	Following the LEADER - why this and other recent trials signal a major paradigm shift in the management of type 2 diabetes. **2017**, 31, 517-519	6
1072	Impact of empagliflozin in patients with diabetes and heart failure. **2017**, 27, 144-151	12
1071	Trends in Drug Utilization, Glycemic Control, and Rates of Severe Hypoglycemia, 2006-2013. **2017**, 40, 468-475	181

1070	Heart failure outcomes in clinical trials of glucose-lowering agents in patients with diabetes. **2017**, 19, 43-53	76
1069	Prospective study of the impact of diabetes mellitus newly diagnosed by glycated hemoglobin on outcomes in patients undergoing percutaneous coronary intervention. **2017**, 37, 69-74	9
1068	European Society of Cardiology 2016 Congress. **2017**, 9, 8-13	
1067	[New recommendations of 2016 European Guidelines on cardiovascular disease prevention]. **2017**, 43, 330-331	
1066	Safety assessment of combination therapies in the treatment of obesity: focus on naltrexone/bupropion extended release and phentermine-topiramate extended release. **2017**, 16, 27-39	24
1065	Type 2 diabetes and cardiovascular disease: A metabolic overview of recent clinical trials. **2017**, 31, 291-294	2
1064	Could metformin be used in patients with diabetes and advanced chronic kidney disease?. **2017**, 19, 156-161	4
1063	Combination therapy with GLP-1 analogues and SGLT-2 inhibitors in the management of diabesity: the real world experience. **2017**, 55, 173-178	21
1062	Efficacy and safety of DPP-4 inhibitors in patients with type 2 diabetes: Meta-analysis of placebo-controlled randomized clinical trials. **2017**, 43, 48-58	71
1061	Editorial commentary: Anti-glycemic drugs and heart failure-A new era. **2017**, 27, 152-154	
1060	Cardiovascular safety of therapies for type 2 diabetes. **2017**, 16, 13-25	5
1059	Diabetes for Cardiologists: Practical Issues in Diagnosis and Management. **2017**, 33, 366-377	19
1058	Management of Overt Diabetic Kidney Disease and Uremia. **2017**, 77-115	
1057	Long-term studies of treatments for type 2 diabetes. **2017**, 129, 352-365	8
1056	Are diuretic additives fit for uncontrolled hypertensive patients receiving telmisartan and amlodipine treatment?. **2017**, 40, 346-347	
1055	Targeting renal glucose reabsorption to treat hyperglycaemia: the pleiotropic effects of SGLT2 inhibition. **2017**, 60, 215-225	288
1054	Long-term mortality after acute myocardial infarction among individuals with and without diabetes: A systematic review and meta-analysis of studies in the post-reperfusion era. **2017**, 19, 364-374	16
1053	The beneficial effects of empagliflozin, an SGLT2 inhibitor, on atherosclerosis in ApoE mice fed a western diet. **2017**, 60, 364-376	137

1052	Meta-Analysis of Impact of Diabetes Mellitus on Outcomes After Transcatheter Aortic Valve Implantation. **2017**, 119, 623-629	13
1051	Sex Differences in Metabolic Cardiomyopathy. **2017**, 113, 370-377	26
1050	The impact of glucose-lowering medications on cardiovascular disease. **2018**, 7, 13-17	
1049	Prevalence of cardiovascular disease and evaluation of standard of care in type 2 diabetes: a nationwide study in primary care. **2017**, 6, 145-151	21
1048	The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) Study Rationale, Design, and Baseline Characteristics. **2017**, 46, 462-472	149
1047	Lesinurad: what the nephrologist should know. **2017**, 10, 679-687	21
1046	Clinical and Genetic Features of Patients With Type 2 Diabetes and Renal Glycosuria. **2017**, 102, 1548-1556	14
1045	Pour une m□decine de la personne ^ l□□re du num□rique. **2017**, 11, 734-738	2
1044	Response to comment on the editorial by Turner et al. on assessment of cardiovascular risk of new drugs for the treatment of diabetes mellitus: risk assessment vs. risk aversion by Zannad et al. **2017**, 3, 131	1
1043	Pharmacological approaches to cardio-renal syndrome: a role for the inodilator levosimendan. **2017**, 19, C22-C28	7
1042	Mechanism of cardiovascular disease benefit of glucagon-like peptide 1 agonists. **2018**, 7, 18-23	3
1041	Platelets, Haemostasis and Inflammation. **2017**,	2
1040	Randomized Trial of the Effects of Insulin and Metformin on Myocardial Injury and Stress in Diabetes Mellitus: A Post Hoc Exploratory Analysis. **2017**, 6,	6
1039	Personalizing Type 2 Diabetes Management: Use of a Patient-Centered Approach to Individualizing A1C Goals and Pharmacological Regimens. **2017**, 35, 321-328	0
1038	Mechanisms of Platelet Activation in Diabetes Mellitus. **2017**, 137-152	2
1037	American Association of Diabetes Educators 2017. **2017**, 9, 1054-1057	1
1036	Consommation des antidiab□tiques oraux. Une □tude comparative dans les cinq principaux pays europ□ens. **2017**, 11, IIS6-IIS15	
1035	Vascular failure and recent anti-diabetic drugs. **2017**, 1, 2-8	3

1034 Effect of Liraglutide on Type B Insulin Resistance Syndrome and Insulin Allergy in Type 2 Diabetes: A Case Report. **2017**, 8, 1191-1194 6

1033 Essential and unnecessary medicines for diabetes. **2017**, 26, 59-74

1032 Sekundärprävention bei koronarer Herzkrankheit – Was gibt es Neues?. **2017**, 6, 340-347

1031 Metabolische Chirurgie zur Prävention des Typ-2-Diabetes. **2017**, 13, 403-407

1030 Empagliflozin reduziert das Risiko für Mortalität sowie makro- und mikrovaskuläre Komplikationen bei Patienten mit Typ-2-Diabetes und bestehender kardiovaskulärer Erkrankung. **2017**, 12, 294-306

1029 Wirkung von SGLT-2-Inhibitoren auf eine gestörte ventrikuläre Repolarisation. **2017**, 13, 583-585

1028 Einfluss von Empagliflozin auf die Albuminurie in der EMPA-REG OUTCOME-Studie. **2017**, 13, 517-518

1027 Accès à l'innovation thérapeutique : télémédecine et nouveaux médicaments en diabétologie. **2017**, 11, IIS28-IIS37 1

1026 Gute Gründe für Sitagliptin. **2017**, 11, 59-59

1025 Achterbahnfahrt mit Schreck und Jubel. **2017**, 11, 3-4

1024 [Cardiovascular protection of diabetic patient with chronic renal disease and particular case of end-stage renal disease in elderly patients]. **2017**, 13, 6S16-6S24 4

1023 Combination therapy of oral hypoglycemic agents in patients with type 2 diabetes mellitus. **2017**, 32, 974-983 16

1022 Frequency of Genital Infections According to Body Mass Index in Dapagliflozin-treated Patients with Type 2 Diabetes Mellitus. **2017**, 04, e1-e4

1021 Effects of glucose-lowering agents on ischemic stroke. **2017**, 8, 270-277 3

1020 Blutzucker, Blutdruck und Blutfette. **2017**, 15, 142-144

1019 Highlights vom ADA 2017. **2017**, 15, 190-193

1018 The impact of antihypertensives on kidney disease. **2017**, 6, 611 3

1017 The Effect of Tofogliflozin Treatment on Postprandial Glucose and Lipid Metabolism in Japanese Men With Type 2 Diabetes: A Pilot Study. **2017**, 9, 403-409 4

1016	Empagliflozin reduces albuminuria-a promise for better cardiorenal protection from the EMPA-REG OUTCOME trial. **2017**, 5, 478	1
1015	More Attention Should Be Paid to Abnormalities of Circadian Blood Pressure Rhythm in Heart Failure Patients. **2017**, 81, 153-154	
1014	Role of New Therapies in Reducing Mortality and Major Morbidity in Patients with Systolic Heart Failure. **2017**,	
1013	Heart failure: an underestimated therapeutic target in diabetes. **2018**, 7, 10-12	2
1012	Integrating cardioprotective glucose-lowering medications into clinical practice. **2018**, 7, 24-27	
1011	Postprandial Hyperlipidemia and Remnant Lipoproteins. **2017**, 24, 95-109	72
1010	ROK and Arteriolar Myogenic Tone Generation: Molecular Evidence in Health and Disease. **2017**, 8, 87	12
1009	Sodiumâ□lucose Cotransporters. **2017**, 491-511	0
1008	Advances in the management of cardiovascular risk for patients with type 2 diabetes: perspectives from the Academy for Cardiovascular Risk, Outcomes and Safety Studies in Type 2 Diabetes. **2017**, 13, 69-79	6
1007	Comparison of the efficacy and safety of 10-mg empagliflozin every day versus every other day in Japanese patients with Type 2 Diabetes Mellitus: a pilot trial. **2017**, 64, 50-57	1
1006	Analisi di Impatto Sul Budget di Empagliflozin Nel Trattamento Dei Pazienti Con Diabete di tipo 2 e Malattia Cardiovascolare Accertata. **2017**, 4, grhta.5000263	0
1005	Canagliflozin in the treatment of type 2 diabetes: an evidence-based review of its place in therapy. **2017**, 12, 1-10	5
1004	Heart Failure in Patients with Diabetes Mellitus. **2017**, 3, 52-55	65
1003	2017 update on the relationship between diabetes and colorectal cancer: epidemiology, potential molecular mechanisms and therapeutic implications. **2017**, 8, 18456-18485	84
1002	Empagliflozin for Type 2 Diabetes Mellitus: An Overview of Phase 3 Clinical Trials. **2017**, 13, 405-423	88
1001	Dapagliflozin: Cardiovascular Safety and Benefits in Type 2 Diabetes Mellitus. **2017**, 9, e1751	4
1000	SGLT2 Inhibitors as a Therapeutic Option for Diabetic Nephropathy. **2017**, 18,	93
999	Targeting Obesity and Diabetes to Treat Heart Failure with Preserved Ejection Fraction. **2017**, 8, 160	38

998	Effects on Subclinical Heart Failure in Type 2 Diabetic Subjects on Liraglutide Treatment vs. Glimepiride Both in Combination with Metformin: A Randomized Open Parallel-Group Study. **2017**, 8, 325	13
997	The Landscape of Glucose-Lowering Therapy and Cardiovascular Outcomes: From Barren Land to Metropolis. **2017**, 2017, 9257930	0
996	Euglycemic Diabetic Ketoacidosis with Persistent Diuresis Treated with Canagliflozin. **2017**, 56, 187-190	15
995	Macrovascular Complications in Patients with Diabetes and Prediabetes. **2017**, 2017, 7839101	99
994	Current Therapeutic Options for Heart Failure in Elderly Patients. **2017**, 2017, 1483873	5
993	Diabetes Mellitus Treatment. **2017**, 288-293	3
992	Asian Perspective of the EMPA-REG OUTCOME Study. **2017**, 81, 155-157	1
991	New Antihyperglycemic Drugs and Heart Failure: Synopsis of Basic and Clinical Data. **2017**, 2017, 1253425	8
990	A Double-Blinded Randomized Study Investigating a Possible Anti-Inflammatory Effect of Saxagliptin versus Placebo as Add-On Therapy in Patients with Both Type 2 Diabetes And Stable Coronary Artery Disease. **2017**, 2017, 5380638	1
989	Empagliflozin Increases Short-Term Urinary Volume Output in Artificially Induced Syndrome of Inappropriate Antidiuresis. **2017**, 2017, 7815690	11
988	Lipids: A Suitable Therapeutic Target in Diabetic Neuropathy?. **2017**, 2017, 6943851	21
987	Effect of Dipeptidyl Peptidase-4 Inhibitors on Cardiovascular Outcome and Cardiac Function in Patients With Diabetes and Heart Failure - Insights From the Ibaraki Cardiac Assessment Study-Heart Failure (ICAS-HF) Registry. **2017**, 81, 1662-1669	6
986	Use of SGLT-2 inhibitors in the treatment of type 2 diabetes mellitus. **2017**, 63, 636-641	13
985	The Effect and Safety of Dapagliflozin in Patients with Type 2 Diabetes: A Single-Institution Pharmacovigilance Review. **2017**, 18, 275	
984	Differential cardiovascular profiles of sodium-glucose cotransporter 2 inhibitors: critical evaluation of empagliflozin. **2017**, 13, 603-611	5
983	The Difference between SGLT2 and DPP-4 Inhibitors on Glucose Fluctuation in Patients with Type 2 Diabetes. **2017**, 04,	
982	The SGLT2 Inhibitor Luseogliflozin Rapidly Normalizes Aortic mRNA Levels of Inflammation-Related but Not Lipid-Metabolism-Related Genes and Suppresses Atherosclerosis in Diabetic ApoE KO Mice. **2017**, 18,	44
981	Combination Therapy of Oral Hypoglycemic Agents in Patients with Type 2 Diabetes Mellitus. **2017**, 41, 357-366	17

980	Canagliflozin improves risk factors of metabolic syndrome in patients with type 2 diabetes mellitus and metabolic syndrome. **2017**, 10, 47-55	10
979	Novel approaches for treating hypertension. **2017**, 6, 80	4
978	Efficacy and Safety of SGLT2 Inhibitors in Reducing Glycated Hemoglobin and Weight in Emirati Patients With Type 2 Diabetes. **2017**, 9, 499-507	10
977	Relevance of positive cardiovascular outcome trial results in clinical practice: perspectives from the Academy for Cardiovascular Risk, Outcomes and Safety Studies in Type 2 Diabetes (ACROSS T2D). **2017**, 13, 1569-1576	3
976	Comparative effectiveness of oral antidiabetic drugs in preventing cardiovascular mortality and morbidity: A network meta-analysis. **2017**, 12, e0177646	27
975	Successful Withdrawal from Dobutamine by Canagliflozin in a Diabetic Patient with Stage D Heart Failure. **2017**, 58, 978-981	1
974	Reconsideration of Secondary Risk Management Strategies in Patients with Ischemic Heart Disease. **2017**, 39, 11-24	2
973	Effectiveness of dapagliflozin on vascular endothelial function and glycemic control in patients with early-stage type 2 diabetes mellitus: DEFENCE study. **2017**, 16, 84	134
972	Heart failure hospitalization risk associated with use of two classes of oral antidiabetic medications: an observational, real-world analysis. **2017**, 16, 93	21
971	Relation between low-density lipoprotein cholesterol/apolipoprotein B ratio and triglyceride-rich lipoproteins in patients with coronary artery disease and type 2 diabetes mellitus: a cross-sectional study. **2017**, 16, 123	21
970	Updates on cardiovascular outcome trials in diabetes. **2017**, 16, 128	36
969	Increased amputation risk with canagliflozin treatment: behind the large cardiovascular benefit?. **2017**, 16, 129	28
968	Impact of empagliflozin on subclinical left ventricular dysfunctions and on the mechanisms involved in myocardial disease progression in type 2 diabetes: rationale and design of the EMPA-HEART trial. **2017**, 16, 130	36
967	Dapagliflozin acutely improves endothelial dysfunction, reduces aortic stiffness and renal resistive index in type 2 diabetic patients: a pilot study. **2017**, 16, 138	189
966	Translating recent results from the Cardiovascular Outcomes Trials into clinical practice: recommendations from the Central and Eastern European Diabetes Expert Group (CEEDEG). **2017**, 16, 137	9
965	Dipeptidyl peptidase-4 inhibitor decreases the risk of atrial fibrillation in patients with type 2 diabetes: a nationwide cohort study in Taiwan. **2017**, 16, 159	28
964	Brazilian guidelines on prevention of cardiovascular disease in patients with diabetes: a position statement from the Brazilian Diabetes Society (SBD), the Brazilian Cardiology Society (SBC) and the Brazilian Endocrinology and Metabolism Society (SBEM). **2017**, 9, 53	15
963	Canagliflozin reduces epicardial fat in patients with type 2 diabetes mellitus. **2017**, 9, 78	71

962	Effectiveness of long-term treatment with SGLT2 inhibitors: real-world evidence from a specialized diabetes center. **2017**, 9, 96	11
961	Kardiovaskulï¿½re Risikoreduktion durch Antidiabetika ï¿½ber Glukosesenkung hinaus. **2017**, 11, 32-36	1
960	SGLT2 inhibitors and cardiovascular outcomes. **2017**, 55, 111-112	
959	Diabetes mellitus Typ´2. **2017**,	
958	Coronary Artery Disease and Type 2 Diabetes Mellitus. **2017**, 58, 475-480	79
957	Empagliflozin and Cardiovascular Outcomes in Asian Patients With Type 2 Diabetes and Established Cardiovascular Disease - Results From EMPA-REG OUTCOME. **2017**, 81, 227-234	80
956	Kardiovaskulï¿½re Outcome-Studien in der Diabetologie â€ein ï¿½berblick. **2017**, 10, 119-121	
955	Cardiovascular outcome studies with glucagon-like peptide 1 receptor agonists-what will REWIND add?. **2017**, 5, 476	4
954	. **2017**, 109, 1-31	16
953	Diabetic cardiomyopathy: where we are and where we are going. **2017**, 32, 404-421	84
952	[Management of diabetes in patients with hypertension]. **2017**, 34 Suppl 2, 30-34	1
951	Neue ESC-Leitlinien zur Herzinsuffizienz 2016 â€Was hat sich fï¿½r den Praxisalltag geï¿½ndert?. **2017**, 13, 11-16	
950	Diabetes mellitus and stroke: A clinical update. **2017**, 8, 235-248	64
949	Recent advances in understanding/managing type 2 diabetes mellitus. **2017**, 6,	2
948	Following the results of the EMPA-REG OUTCOME trial with empagliflozin, is it possible to speak of a class effect?. **2017**, 10, 23-26	5
947	Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors and Stroke. **2017**, 81, 898	2
946	New anti-diabetic agents. **2017**, 60, 992	
945	Diabetes-Related Cardiac Dysfunction. **2017**, 32, 171-179	30

944	Current Drug Therapy in Chronic Heart Failure: the New Guidelines of the European Society of Cardiology (ESC). **2017**, 47, 543-554	20
943	Liraglutide reduced a composite renal outcome at a median 4 y in patients with type 2 diabetes and high CV risk. **2017**, 167, JC66	
942	Sodium-glucose cotransporter 2 inhibitors combined with dipeptidyl peptidase-4 inhibitors in the management of type 2 diabetes: a review of current clinical evidence and rationale. **2017**, 11, 923-937	2
941	Spotlight on ertugliflozin and its potential in the treatment of type 2 diabetes: evidence to date. **2017**, 11, 2905-2919	36
940	Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors and Stroke - Reply. **2017**, 81, 899	1
939	Antidiabetic Drugs as Antihypertensives: New Data on the Horizon. **2017**, 16, 70-78	3
938	Antihyperglycemic Agent Therapy for Adult Patients with Type 2 Diabetes Mellitus 2017: A Position Statement of the Korean Diabetes Association. **2017**, 41, 337-348	38
937	Monotherapy in Patients with Type 2 Diabetes Mellitus. **2017**, 41, 349-356	12
936	An evidence-based practice-oriented review focusing on canagliflozin in the management of type 2 diabetes. **2017**, 13, 43-54	5
935	Antihyperglycemic Medications and Cardiovascular Risk Reduction. **2017**, 13, 86-90	5
934	Effects of glycaemic management on diabetic kidney disease. **2017**, 8, 172-186	35
933	Treatment target of diabetes for prevention of coronary artery disease. **2017**, 23, 170-173	
932	Atypical Ketoacidosis and Protracted Hyperglycosuria after Treatment with Ipragliflozin, an SGLT2 Inhibitor. **2017**, 56, 1673-1678	6
931	Primary and secondary prevention in diabetic patients: are we not aggressive enough?. **2017**, 18 Suppl 1, e83-e90	
930	Cardiovascular benefits of the newer medications for treating type 2 diabetes mellitus. **2017**, 9, 2124-2134	19
929	Diabetes. **2018**, 119-136	
928	The Antidiabetic Armamentarium: Reducing the Residual Cardiovascular Risk with HbA-Lowering Medications : Editorial to: "GLP-1 Receptor Agonists and Cardiovascular Disease: A Meta-Analysis of Recent Cardiac Outcome Trials" by Jia X, Alam M, Ye Y et al. **2018**, 32, 1-3	
927	Nocturnal hypertension in diabetes: Potential target of sodium/glucose cotransporter 2 (SGLT2) inhibition. **2018**, 20, 424-428	12

926	Place des inhibiteurs des SGLT2 dans le traitement du patient diabtique de type 2. **2018**, 12, 22-30		8
925	Treatment of type 2 diabetes mellitus in elderly patients. **2018**, 218, 74-88		3
924	RSSDI clinical practice recommendations for the management of type 2 diabetes mellitus 2017. **2018**, 38, 1-115		57
923	Comprehensive renoprotective effects of ipragliflozin on early diabetic nephropathy in mice. **2018**, 8, 4029		36
922	SGLT1: A potential target for human ischemic and hypertrophic heart?. **2018**, 257, 37		2
921	Economic Burden of Cardiovascular Disease in Type 2 Diabetes: A Systematic Review. **2018**, 21, 881-890		93
920	Effects of Sotagliflozin Added to Insulin in Type 1 Diabetes. *New England Journal of Medicine*, **2018**, 378, 967-968	59.2	12
919	Dulaglutide as add-on therapy to SGLT2 inhibitors in patients with inadequately controlled type 2 diabetes (AWARD-10): a 24-week, randomised, double-blind, placebo-controlled trial. **2018**, 6, 370-381		137
918	Basic Concepts in Insulin Resistance and Diabetes Treatment. **2018**, 19-35		3
917	2018 consensus of the Taiwan Society of Cardiology and the Diabetes Association of Republic of China (Taiwan) on the pharmacological management of patients with type 2 diabetes and cardiovascular diseases. **2018**, 81, 189-222		14
916	SGLT2 inhibitors and renal outcomes in type 2 diabetes with or without renal impairment: A systematic review and meta-analysis. **2018**, 12, 265-283		48
915	What are the cardiovascular effects of the newer classes of drugs for type 2 diabetes?. **2018**, 31, 12-14		
914	Work-loss years among people diagnosed with diabetes: a reappraisal from a life course perspective. **2018**, 55, 485-491		10
913	Rþondeurs et non-rþondeurs aux antidiabtiques. Dans lâttente de la pharmacoghtique, savoir rvaluer leur efficacit, surtout en regard de leurs co. **2018**, 12, 5-7		
912	Response by Kosiborod et al to Letters Regarding Article, "Lower Risk of Heart Failure and Death in Patients Initiated on Sodium-Glucose Cotransporter-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL Study (Comparative Effectiveness of Cardiovascular Outcomes in New Users of Sodium-Glucose Cotransporter-2 Inhibitors)". **2018**, 137, 989-991		6
911	The cost of cardiovascular-disease-related death in patients with type 2 diabetes mellitus. **2018**, 34, 1081-1087		4
910	Pharmacological management of diabetes in severe mental illness: a comprehensive clinical review of efficacy, safety and tolerability. **2018**, 11, 411-424		6
909	Real-world evaluation of the DESMOND type 2 diabetes education and self-management programme. **2018**, 35, 19-22a		8

908	The heart failure burden of type 2 diabetes mellitus-a review of pathophysiology and interventions. **2018**, 23, 303-323	27
907	The impact of oral anti-diabetic medications on heart failure: lessons learned from preclinical studies. **2018**, 23, 337-346	2
906	SGLT2 inhibition reduces atherosclerosis by enhancing lipoprotein clearance in Ldlr type 1 diabetic mice. **2018**, 271, 166-176	32
905	Use and effectiveness of dapagliflozin in routine clinical practice: An Italian multicentre retrospective study. **2018**, 20, 1781-1786	25
904	Type 2 diabetes mellitus and heart failure: a position statement from the Heart Failure Association of the European Society of Cardiology. **2018**, 20, 853-872	264
903	Targeting Other Modifiable Risk Factors for the Prevention of Heart Failure: Diabetes, Smoking, Obesity, and Inactivity. **2018**, 12, 1	
902	Abnormal Myocardial Dietary Fatty Acid Metabolism and Diabetic Cardiomyopathy. **2018**, 34, 605-614	32
901	SGLT-2 inhibitors and the risk of infections: a systematic review and meta-analysis of randomized controlled trials. **2018**, 55, 503-514	91
900	Treatment with insulin is associated with worse outcome in patients with chronic heart failure and diabetes. **2018**, 20, 888-895	65
899	Empagliflozin Induces Transient Diuresis Without Changing Long-Term Overall Fluid Balance in Japanese Patients With Type 2 Diabetes. **2018**, 9, 863-871	33
898	Does Altered Uric Acid Metabolism Contribute to Diabetic Kidney Disease Pathophysiology?. **2018**, 18, 18	9
897	Market licensing of type 2 diabetes medicinal products based on patient-relevant hard outcomes: is there hope?. **2018**, 4, 4-5	
896	Post-Myocardial Infarction Heart Failure. **2018**, 6, 179-186	103
895	NGM282 for treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. **2018**, 391, 1174-1185	256
894	Do sulphonylureas still have a place in clinical practice?. **2018**, 6, 821-832	61
893	Heart Failure With Preserved Ejection Fraction in Diabetes: Mechanisms and Management. **2018**, 34, 632-643	41
892	Risks of diabetic foot syndrome and amputation associated with sodium glucose co-transporter 2 inhibitors: A Meta-analysis of Randomized Controlled Trials. **2018**, 44, 410-414	35
891	Sodium-glucose cotransporter-2 inhibitors induced eu-glycemic diabetic ketoacidosis: The first report in a type 2 diabetic (T2D) Taiwanese and literature review of possible pathophysiology and contributing factors. **2018**, 117, 849-854	4

890	Antidiabetic drugs for stroke prevention in patients with type-2 diabetes. The neurologist's point of view. **2018**, 150, 275-281	1
889	Glucose-Lowering Therapies and Heart Failure in Type 2 Diabetes Mellitus: Mechanistic Links, Clinical Data, and Future Directions. **2018**, 137, 1060-1073	20
888	Mechanisms of physiological and pathological cardiac hypertrophy. **2018**, 15, 387-407	468
887	Glycemic control of type 2 diabetes mellitus across stages of renal impairment: information for primary care providers. **2018**, 130, 381-393	17
886	Do the SGLT-2 Inhibitors Offer More than Hypoglycemic Activity?. **2018**, 32, 213-222	32
885	Dapagliflozin-Associated Diabetic Ketoacidosis. **2018**, 25, e765-e766	2
884	Metabolic Karma-The Atherogenic Legacy of Diabetes: The 2017 Edwin Bierman Award Lecture. **2018**, 67, 785-790	15
883	The effect of antidiabetic medications on non-alcoholic fatty liver disease (NAFLD). **2018**, 17, 219-229	31
882	Clinical assessment and treatment of diabetes in patients with chronic kidney disease. **2018**, 218, 305-315	1
881	SGLT2 Inhibitors: Cardiovascular Benefits Beyond Glycemic Control. **2018**, 6, 34-39	1
880	Cardiovascular Disease in Japanese Patients with Type 2 Diabetes Mellitus. **2018**, 11, 2-14	4
879	Treatment of Diabetes in People With Heart Failure. **2018**, 42 Suppl 1, S196-S200	17
878	Pharmacologic Glycemic Management of Type 2 Diabetes in Adults. **2018**, 42 Suppl 1, S88-S103	108
877	Pharmacokinetic and pharmacodynamic profile of the sodium-glucose co-transporter-2 inhibitor empagliflozin in young people with Type 2 diabetes: a randomized trial. **2018**, 35, 1096-1104	18
876	ONE-YEAR TIME ANALYSIS IN AN ACADEMIC DIABETES CLINIC: QUANTIFYING OUR BURDEN. **2018**, 24, 489-491	5
875	Diabetes in Older People. **2018**, 42 Suppl 1, S283-S295	45
874	Relation of Aortic Stiffness to Left Ventricular Remodeling in Younger Adults With Type 2 Diabetes. **2018**, 67, 1395-1400	21
873	Association Between Use of Sodium-Glucose Cotransporter 2 Inhibitors, Glucagon-like Peptide 1 Agonists, and Dipeptidyl Peptidase 4 Inhibitors With All-Cause Mortality in Patients With Type 2 Diabetes: A Systematic Review and Meta-analysis. **2018**, 319, 1580-1591	216

872	The Potential Role of SGLT2 Inhibitors in the Treatment of Type 1 Diabetes Mellitus. **2018**, 78, 717-726	43
871	The 2018 update of the American College of Physicians glycaemic management recommendations: An invitation to continued inertia?. **2018**, 20, 1809-1811	3
870	Early effects of empagliflozin on exercise tolerance in patients with heart failure: A pilot study. **2018**, 41, 476-480	14
869	The role of pollutants in type 2 diabetes mellitus (T2DM) and their prospective impact on phytomedicinal treatment strategies. **2018**, 190, 262	5
868	Sodium-Glucose Cotransporter-2 Inhibition in Type 2 Diabetes Mellitus: A Review of Large-Scale Cardiovascular Outcome Studies and Possible Mechanisms of Benefit. **2018**, 26, 312-320	4
867	Are the effects of drugs to prevent and to treat heart failure always concordant? The statin paradox and its implications for understanding the actions of antidiabetic medications. **2018**, 20, 1100-1105	13
866	SGLT2 inhibitor plus DPP-4 inhibitor as combination therapy for type 2 diabetes: A systematic review and meta-analysis. **2018**, 20, 1972-1976	15
865	Sodium-glucose co-transporter-2 inhibitors and the risk of ketoacidosis in patients with type 2 diabetes mellitus: A nationwide population-based cohort study. **2018**, 20, 1852-1858	30
864	In Response. **2018**, 126, 1792-1793	
863	Influence of Diabetes on Trends in Perioperative Cardiovascular Events. **2018**, 41, 1268-1274	20
862	Japanese Clinical Practice Guideline for Diabetes 2016. **2018**, 9, 657	136
861	Combination Treatment of SGLT2 Inhibitors and GLP-1 Receptor Agonists: Symbiotic Effects on Metabolism and Cardiorenal Risk. **2018**, 9, 919-926	23
860	[Cardioprotection and diabetes mellitus - which antidiabetic agents seem to do better]. **2018**, 160, 65-70	
859	Glucose-lowering treatment in cardiovascular and peripheral artery disease. **2018**, 39, 86-98	4
858	Drug repurposing in kidney disease. **2018**, 94, 40-48	28
857	Risk of Incident Heart Failure in Patients With Diabetes and Asymptomatic Left Ventricular Systolic Dysfunction. **2018**, 41, 1285-1291	23
856	Drug therapies in chronic heart failure: a focus on reduced ejection fraction. **2018**, 18, 138-145	7
855	Usefulness of a clinical risk score to predict the response to cardiac resynchronization therapy. **2018**, 260, 82-87	13

854	Potential Benefits of Sodium-Glucose Cotransporter-2 Inhibitors in the Perioperative Period. **2018**, 127, 306-307	1
853	Genetic diversity of dihydrochalcone content in Malus germplasm. **2018**, 65, 1485-1502	8
852	Contrasting effects on the risk of macrovascular and microvascular events of antihyperglycemic drugs that enhance sodium excretion and lower blood pressure. **2018**, 35, 707-713	3
851	Leptin-Aldosterone-Neprilysin Axis: Identification of Its Distinctive Role in the Pathogenesis of the Three Phenotypes of Heart Failure in People With Obesity. **2018**, 137, 1614-1631	105
850	Efficacy and safety of sodium-glucose cotransporter 2 inhibitors in patients with type 2 diabetes and moderate renal function impairment: A systematic review and meta-analysis. **2018**, 140, 295-303	15
849	Effects of empagliflozin on cardiorespiratory fitness and significant interaction of loop diuretics. **2018**, 20, 2014-2018	13
848	Beneficial Effect of the SGLT2 Inhibitor Empagliflozin on Glucose Homeostasis and Cardiovascular Parameters in the Cohen Rosenthal Diabetic Hypertensive (CRDH) Rat. **2018**, 23, 358-371	12
847	Hyperpolarized ketone body metabolism in the rat heart. **2018**, 31, e3912	21
846	Cardiovascular Protection in People With Diabetes. **2018**, 42 Suppl 1, S162-S169	30
845	Basal-Bolus Insulin Therapy with Gla-300 During Hospitalization Reduces Nocturnal Hypoglycemia in Patients with Type 2 Diabetes Mellitus: A Randomized Controlled Study. **2018**, 9, 1049-1059	4
844	Hyperglycemic Emergencies in Adults. **2018**, 42 Suppl 1, S109-S114	28
843	CKD in diabetes: diabetic kidney disease versus nondiabetic kidney disease. **2018**, 14, 361-377	203
842	Legacy Effect of Intensive Blood Glucose Control on Cardiovascular Outcomes in Patients With Type 2 Diabetes and Very High Risk or Secondary Prevention of Cardiovascular Disease: A Meta-analysis of Randomized Controlled Trials. **2018**, 40, 776-788.e3	9
841	Coronary artery disease severity modifies associations between glycemic control and both mortality and myocardial infarction. **2018**, 32, 480-487	4
840	MECHANISMS IN ENDOCRINOLOGY: Diabetic cardiomyopathy: pathophysiology and potential metabolic interventions state of the art review. **2018**, 178, R127-R139	33
839	Documented coronary atherothrombosis as the cause of death in post-discharge patients after coronary revascularization. **2018**, 19, 597-606	
838	Type 2 Diabetes and the Reduction of Cardiovascular Risk: Sorting Out the Actors and the Roles. **2018**, 34, 532-535	1
837	Regulation of intestinal lipid and lipoprotein metabolism by the proglucagon-derived peptides glucagon like peptide 1 and glucagon like peptide 2. **2018**, 29, 95-103	15

836	Sodium-glucose co-transporter-2 inhibitors as add-on therapy to insulin for type 1 diabetes mellitus: Systematic review and meta-analysis of randomized controlled trials. **2018**, 20, 1755-1761	49
835	Effects of canagliflozin versus glimepiride on adipokines and inflammatory biomarkers in type 2 diabetes. **2018**, 85, 32-37	116
834	Mitochondrial dysfunction in diabetic kidney disease. **2018**, 14, 291-312	178
833	Interaction Between the Sodium-Glucose-Linked Transporter 2 Inhibitor Dapagliflozin and the Loop Diuretic Bumetanide in Normal Human Subjects. **2018**, 7,	60
832	Designing Medical, Point of Care Sensors to Aid Health Care Providers in Diagnosing and Managing Diseases: Addressing Pertinent Issues and Some Contemporary Opportunities. **2018**, 30, 310-313	
831	Pathophysiological Links Between Diabetes and Blood Pressure. **2018**, 34, 585-594	24
830	The Genetic Link Between Diabetes and Atherosclerosis. **2018**, 34, 565-574	7
829	Cardiorenal interactions. **2018**, 60, e144-e147	1
828	Treatment of type 2 diabetes mellitus in elderly patients. **2018**, 218, 74-88	22
827	Uric Acid and Diabetic Nephropathy Risk. **2018**, 192, 103-109	19
826	Type 2 Diabetes and Thiazide Diuretics. **2018**, 18, 6	15
825	Clinical features and therapeutic perspectives on hypertension in diabetics. **2018**, 41, 213-229	11
824	Effects of empagliflozin on risk for cardiovascular death and heart failure hospitalization across the spectrum of heart failure risk in the EMPA-REG OUTCOME® trial. **2018**, 39, 363-370	171
823	Effectiveness and Safety of a Novel Care Model for the Management of Type 2 Diabetes at 1 Year: An Open-Label, Non-Randomized, Controlled Study. **2018**, 9, 583-612	173
822	The Presence of Prediabetes in Patients With Heart Failure-A New Venue for the Sodium-Glucose Co-Transporter 2 Inhibition?. **2018**, 27, e29-e30	
821	The anti-diabetic drug dapagliflozin induces vasodilation via activation of PKG and Kv channels. **2018**, 197, 46-55	47
820	[Treatment of type 2 diabetes mellitus in elderly patients]. **2018**, 53, 89-99	8
819	SGLT-2 inhibitors and the risk of lower-limb amputation: Is this a class effect?. **2018**, 20, 1531-1534	62

818	Diabetic Cardiomyopathy: An Update of Mechanisms Contributing to This Clinical Entity. **2018**, 122, 624-638	613
817	Diabetes medications and cardiovascular disease: at long last progress. **2018**, 25, 87-93	9
816	Sodium-glucose co-transporter 2 inhibitors and cardiovascular outcomes: A systematic review and meta-analysis. **2018**, 25, 495-502	66
815	Protective role of melatonin in cardiac ischemia-reperfusion injury: From pathogenesis to targeted therapy. **2018**, 64, e12471	158
814	Counterpoint to the hypothesis that SGLT2 inhibitors protect the heart by antagonizing leptin. **2018**, 20, 1367-1368	2
813	Perspectives on diabetes mortality as the result of residual confounding and reverse causality by common disease. **2018**, 20, 1342-1349	3
812	MECHANISMS IN ENDOCRINOLOGY: SGLT2 inhibitors: clinical benefits by restoration of normal diurnal metabolism?. **2018**, 178, R113-R125	51
811	Incremental burden of type 2 diabetes in patients experiencing cardiovascular hospitalizations. **2018**, 34, 1005-1012	
810	Precision Medicine in Type 2 Diabetes: Clinical Markers of Insulin Resistance Are Associated With Altered Short- and Long-term Glycemic Response to DPP-4 Inhibitor Therapy. **2018**, 41, 705-712	36
809	Are physicians neglecting the risk of heart failure in diabetic patients who are receiving sulfonylureas? Lessons from the TOSCA.IT trial. **2018**, 20, 49-51	9
808	A systematic review of urinary bladder hypertrophy in experimental diabetes: Part I. Streptozotocin-induced rat models. **2018**, 37, 1212-1219	12
807	Implications of Underlying Mechanisms for the Recognition and Management of Diabetic Cardiomyopathy. **2018**, 71, 339-351	138
806	Cardiovascular Mortality Reduction With Empagliflozin in Patients With Type 2 Diabetes and Cardiovascular Disease. **2018**, 71, 364-367	28
805	A comparative safety review between GLP-1 receptor agonists and SGLT2 inhibitors for diabetes treatment. **2018**, 17, 293-302	22
804	Hypertension and Diabetes Mellitus: Coprediction and Time Trajectories. **2018**, 71, 422-428	76
803	Association of Bariatric Surgery vs Medical Obesity Treatment With Long-term Medical Complications and Obesity-Related Comorbidities. **2018**, 319, 291-301	166
802	Dapagliflozin and Empagliflozin Ameliorate Hepatic Dysfunction Among Chinese Subjects with Diabetes in Part Through Glycemic Improvement: A Single-Center, Retrospective, Observational Study. **2018**, 9, 285-295	21
801	Intra- and inter-subject variability for increases in serum ketone bodies in patients with type 2 diabetes treated with the sodium glucose co-transporter 2 inhibitor canagliflozin. **2018**, 20, 1321-1326	31

800	[Prevention of cardiovascular diseases]. **2018**, 43, 87-100	1
799	Cost-Effectiveness of Empagliflozin for the Treatment of Patients with Type 2 Diabetes Mellitus at Increased Cardiovascular Risk in Greece. **2018**, 38, 417-426	27
798	[Chronic Kidney Disease - Update 2018]. **2018**, 143, 169-173	3
797	Diabetes in the older patient: heterogeneity requires individualisation of therapeutic strategies. **2018**, 61, 1503-1516	40
796	Post-Liver Transplantation Diabetes Mellitus: A Review of Relevance and Approach to Treatment. **2018**, 9, 521-543	34
795	Comparing SGLT-2 inhibitors to DPP-4 inhibitors as an add-on therapy to metformin in patients with type 2 diabetes: A systematic review and meta-analysis. **2018**, 44, 112-120	24
794	Intensive Blood Glucose Control and Vascular Outcomes in Patients with Type 2 Diabetes Mellitus. **2018**, 47, 81-96	30
793	Personalizing Glucose-Lowering Therapy in Patients with Type 2 Diabetes and Cardiovascular Disease. **2018**, 47, 137-152	6
792	The Evolving Epidemiology of Atherosclerotic Cardiovascular Disease in People with Diabetes. **2018** , 47, 1-32	12
791	Sulfated modification of polysaccharides: Synthesis, characterization and bioactivities. **2018**, 74, 147-157	110
790	Diabetes and ischaemic stroke: a deadly association. **2018**, 39, 2387-2389	3
789	Trends in Diabetes Treatment and Monitoring among Medicare Beneficiaries. **2018**, 33, 471-480	12
788	Cost-Effectiveness Analysis of Canagliflozin 300´mg Versus Dapagliflozin 10´mg Added to Metformin in Patients with Type 2 Diabetes in the United States. **2018**, 9, 565-581	10
787	The design and rationale for the Dapagliflozin Effect on Cardiovascular Events (DECLARE)-TIMI 58 Trial. **2018**, 200, 83-89	89
786	A new class of drugs for heart failure: SGLT2 inhibitors reduce sympathetic overactivity. **2018**, 71, 471-476	88
785	Cardiovascular benefits of SGLT2 inhibition in diabetes and chronic kidney diseases. **2018**, 222, e13050	10
784	Assessment of Cardiovascular Risk With Glucagon-Like Peptide 1 Receptor Agonists in Patients With Type 2 Diabetes Using an Alternative Measure to the Hazard Ratio. **2018**, 52, 632-638	6
783	The pharmacological management of metabolic syndrome. **2018**, 11, 397-410	56

782	Effect of immediate and prolonged GLP-1 receptor agonist administration on uric acid and kidney clearance: Post-hoc analyses of four clinical trials. **2018**, 20, 1235-1245	19
781	Major adverse cardiovascular event reduction with GLP-1 and SGLT2 agents: evidence and clinical potential. **2018**, 9, 33-50	26
780	SGLT2 Inhibitors and Mechanisms of Hypertension. **2018**, 20, 1	50
779	New Diabetes Medications Raise New Perioperative Concerns for the Anesthesiologist. **2018**, 126, 390-392	2
778	Hypertension with diabetes mellitus complications. **2018**, 41, 147-156	43
777	Cardiovascular Safety, Long-Term Noncardiovascular Safety, and Efficacy of Sodium-Glucose Cotransporter 2 Inhibitors in Patients With Type 2 Diabetes Mellitus: A Systemic Review and Meta-Analysis With Trial Sequential Analysis. **2018**, 7,	66
776	Practice pearl: liraglutide and cardiovascular and renal events in type 2 diabetes. **2018**, 130, 154-158	5
775	Mortality Reduction in EMPA-REG OUTCOME Trial: Beyond the Antidiabetes Effect. **2018**, 41, 219-223	11
774	No Impact of Pre-existing Cardiovascular Disease on Prescribing Patterns of Sulphonylureas in Denmark - A Registry-based Nationwide Study. **2018**, 122, 606-611	1
773	Do sodium-glucose co-transporter-2 inhibitors prevent heart failure with a preserved ejection fraction by counterbalancing the effects of leptin? A novel hypothesis. **2018**, 20, 1361-1366	52
772	Clinical impact of oral antidiabetic medications in heart failure patients. **2018**, 23, 325-335	7
771	Effect of glucose-lowering therapies on heart failure. **2018**, 15, 282-291	34
770	A review of GLP-1 receptor agonists: Evolution and advancement, through the lens of randomised controlled trials. **2018**, 20 Suppl 1, 22-33	118
769	External validity, generalisability, applicability and directness: a brief primer. **2018**, 23, 17-19	20
768	Powerful diuretics: A common denominator in landmark hypertension and type 2 diabetes mellitus trials. **2018**, 20, 136-142	1
767	The influence of anti-hyperglycemic drug therapy on cardiovascular and heart failure outcomes in patients with type 2 diabetes mellitus. **2018**, 23, 445-459	4
766	Angiotensin-Converting Enzyme Inhibitors vs. Angiotensin Receptor Blockers for the Treatment of Hypertension in Adults With Type 2 Diabetes: Why We Favour Angiotensin Receptor Blockers. **2018**, 42, 118-123	4
765	Network meta-analysis of cardiovascular outcomes in randomized controlled trials of new antidiabetic drugs. **2018**, 254, 291-296	23

764	Characteristics Associated With Decreased or Increased Mortality Risk From Glycemic Therapy Among Patients With Type 2 Diabetes and High Cardiovascular Risk: Machine Learning Analysis of the ACCORD Trial. **2018**, 41, 604-612	35
763	Heart Failure: Epidemiology, Pathophysiology, and Management of Heart Failure in Diabetes Mellitus. **2018**, 47, 117-135	16
762	Antidiabetic drugs for stroke prevention in patients with type-2 diabetes. The neurologist's point of view. **2018**, 150, 275-281	4
761	Management of diabetes in older adults. **2018**, 28, 206-218	30
760	Selection of the Best of 2017 in Clinical Cardiology. Therapeutic Novelties. **2018**, 71, 60	
759	[Safety of SGLT2 inhibitors. A review of the adverse drug reactions registered in a national database]. **2018**, 44, 23-29	4
758	Which place of pharmacological approaches beyond continuous positive airway pressure to treat vascular disease related to obstructive sleep apnea?. **2018**, 186, 45-59	5
757	American Heart Association 2017. **2018**, 10, 271-275	1
756	SGLT2 inhibitor empagliflozin: finally at the latter stage of understanding?. **2018**, 93, 22-24	6
755	Treatment of Hypertension to Prevent and Treat Heart Failure in Diabetic Patients Should Include Sodium Glucose Co-Transporter 2 Inhibitors. **2018**, 6, 85	1
754	Novel therapies for diabetic kidney disease. **2018**, 8, 18-25	23
753	Type 2 diabetes: glycaemic control. **2018**, 241-313	
752	Keeping the right track in the treatment of patients with type 2 diabetes. **2018**, 20, 52-54	2
751	Stuck in a Bind With Phosphate Binders. **2018**, 71, 254-256	
750	Population Pharmacokinetic- Pharmacodynamic Analysis to Characterize the Effect of Empagliflozin on Renal Glucose Threshold in Patients With Type 1 Diabetes Mellitus. **2018**, 58, 640-649	7
749	Cardiovascular outcomes with canagliflozin - is it on the CANVAS?. **2018**, 19, 163-166	4
748	Lower Risk of Death With SGLT2 Inhibitors in Observational Studies: Real or Bias?. **2018**, 41, 6-10	78
747	Cardiovascular Outcomes Trials in Type 2 Diabetes: Where Do We Go From Here? Reflections From a Editors' Expert Forum. **2018**, 41, 14-31	263

746	Heart Failure: The Most Important, Preventable, and Treatable Cardiovascular Complication of Type 2 Diabetes. **2018**, 41, 11-13	49
745	DECLARE-TIMI 58: Participants' baseline characteristics. **2018**, 20, 1102-1110	80
744	Short and medium-term efficacy of sodium glucose co-transporter-2 (SGLT-2) inhibitors: A meta-analysis of randomized clinical trials. **2018**, 20, 1213-1222	25
743	Heart failure with preserved ejection fraction: Classification based upon phenotype is essential for diagnosis and treatment. **2018**, 28, 392-400	18
742	Direct cardiovascular impact of SGLT2 inhibitors: mechanisms and effects. **2018**, 23, 419-437	53
741	Age affects the prognostic impact of diabetes in chronic heart failure. **2018**, 55, 271-278	5
740	Potential impact of SGLT2 inhibitors on left ventricular diastolic function in patients with diabetes mellitus. **2018**, 23, 439-444	15
739	Effects of Ipragliflozin on Postprandial Glucose Metabolism and Gut Peptides in Type 2 Diabetes: A Pilot Study. **2018**, 9, 403-411	6
738	Glucosuria and all-cause mortality among general screening participants. **2018**, 22, 850-859	5
737	Running Out of Success in HF Therapy ?. **2018**, 24, 63-64	
736	GLP-1 receptor agonists and cardiovascular protection: A class effect or not?. **2018**, 44, 193-196	15
735	Epigenetic Contribution to the Development and Progression of Vascular Diabetic Complications. **2018**, 29, 1074-1091	6
734	Should We Be Combining GLP-1 Receptor Agonists and SGLT2 Inhibitors in Treating Diabetes?. **2018**, 131, 461-463	4
733	Sodium/Glucose Cotransporter 2 Inhibitors in Patients With Diabetes Mellitus and Chronic Kidney Disease: Turning the Page. **2018**, 137, 130-133	7
732	Have we really demonstrated the cardiovascular safety of anti-hyperglycaemic drugs? Rethinking the concepts of macrovascular and microvascular disease in type 2 diabetes. **2018**, 20, 1089-1095	4
731	Effects of exenatide once weekly plus dapagliflozin, exenatide once weekly, or dapagliflozin, added to metformin monotherapy, on body weight, systolic blood pressure, and triglycerides in patients with type 2 diabetes in the DURATION-8 study. **2018**, 20, 1515-1519	28
730	Tofogliflozin decreases body fat mass and improves peripheral insulin resistance. **2018**, 20, 1311-1315	23
729	Long-term safety and efficacy of tofogliflozin as add-on to insulin in patients with type 2 diabetes: Results from a 52-week, multicentre, randomized, double-blind, open-label extension, Phase 4 study in Japan (J-STEP/INS). **2018**, 20, 1176-1185	19

728	When metformin is not enough: Pros and cons of SGLT2 and DPP-4 inhibitors as a second line therapy. **2018**, 34, e2981	12
727	Heart failure risk and major cardiovascular events in diabetes: an overview of within-group differences in non-insulin antidiabetic treatment. **2018**, 23, 469-479	4
726	From the editor: A run of success in treating atherosclerotic vascular disease. **2018**, 12, 1-2	
725	Cardiovascular outcomes in diabetic kidney disease: insights from recent clinical trials. **2018**, 8, 8-17	6
724	Non-insulin antidiabetic pharmacotherapy in patients with established cardiovascular disease: a position paper of the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy. **2018**, 39, 2274-2281	12
723	Cardioprotective anti-hyperglycaemic medications: a review of clinical trials. **2018**, 39, 2368-2375	26
722	Changes in patient characteristics, glucose lowering treatment, glycemic control and complications in type 2 diabetes in general practices (Disease Analyzer, Germany: 2008-2016). **2018**, 130, 244-250	6
721	Unsweetening the Heart: Possible Pleiotropic Effects of SGLT2 Inhibitors on Cardio and Cerebrovascular Alterations in Resistant Hypertensive Subjects. **2018**, 31, 274-280	3
720	Empagliflozin rescues diabetic myocardial microvascular injury via AMPK-mediated inhibition of mitochondrial fission. **2018**, 15, 335-346	246
719	Canagliflozin and cardiovascular and renal events in type 2 diabetes. **2018**, 130, 149-153	21
718	The year in cardiology 2017: heart failure. **2018**, 39, 832-839	4
717	Selecci□n de lo mejor del a□o 2017 en cardiolog□a cl□nica. Novedades terap□uticas. **2018**, 71, 60	2
716	Exploring heart failure events in contemporary cardiovascular outcomes trials in type 2 diabetes mellitus. **2018**, 16, 123-131	
715	The year in cardiology 2017: prevention. **2018**, 39, 345-353	3
714	Pharmacological Prevention of Cardiovascular Outcomes in Diabetes Mellitus: Established and Emerging Agents. **2018**, 78, 203-214	5
713	High Basolateral Glucose Increases Sodium-Glucose Cotransporter 2 and Reduces Sirtuin-1 in Renal Tubules through Glucose Transporter-2 Detection. **2018**, 8, 6791	70
712	Cardiovascular magnetic resonance measures of aortic stiffness in asymptomatic patients with type 2 diabetes: association with glycaemic control and clinical outcomes. **2018**, 17, 35	10
711	Rationale, design, and baseline characteristics of the CArdiovascular safety and Renal Microvascular outcomE study with LINAgliptin (CARMELINA): a randomized, double-blind, placebo-controlled clinical trial in patients with type 2 diabetes and high cardio-renal risk. **2018**, 17, 39	57

710	Empagliflozin influences blood viscosity and wall shear stress in subjects with type 2 diabetes mellitus compared with incretin-based therapy. **2018**, 17, 52	33
709	Antidiabetic treatment patterns and specialty care utilization among patients with type 2 diabetes and cardiovascular disease. **2018**, 17, 54	17
708	SGLT2 inhibition via dapagliflozin improves generalized vascular dysfunction and alters the gut microbiota in type 2 diabetic mice. **2018**, 17, 62	92
707	Dapagliflozin improves treatment satisfaction in overweight patients with type 2 diabetes mellitus: a patient reported outcome study (PRO study). **2018**, 10, 11	14
706	The effect of antidiabetic medications on the cardiovascular system: a critical appraisal of current data. **2018**, 17, 83-95	2
705	Are the favorable cardiovascular outcomes of empagliflozin treatment explained by its effects on multiple cardiometabolic risk factors? A simulation of the results of the EMPA-REG OUTCOME trial. **2018**, 141, 181-189	11
704	Renal protection by sodium-glucose cotransporter 2 inhibitors and its underlying mechanisms in diabetic kidney disease. **2018**, 32, 720-725	30
703	DPP-4 inhibitors and GLP-1RAs: cardiovascular safety and benefits. **2022**, 9,	0
702	Canagliflozin Inhibits Human Endothelial Cell Inflammation through the Induction of Heme Oxygenase-1. **2022**, 23, 8777	2
701	Safety and effectiveness of empagliflozin and linagliptin fixed-dose combination therapy in Japanese patients with type 2 diabetes: final results of a one-year post-marketing surveillance study. 1-11	
700	Dapagliflozin acutely improves kidney function in type 2 diabetes mellitus. The PRECARE study. **2022**, 183, 106374	0
699	Cardiorenal protection of SGLT2 inhibitorsâPerspectives from metabolic reprogramming. **2022**, 83, 104215	1
698	Empagliflozin improves cardiac mitochondrial function and survival through energy regulation in a murine model of heart failure.. **2022**, 931, 175194	0
697	County-level variation in cardioprotective antihyperglycemic prescribing among medicare beneficiaries. **2022**, 11, 100370	
696	Glucose control independent mechanisms involved in the cardiovascular benefits of glucagon-like peptide-1 receptor agonists. **2022**, 153, 113517	
695	SGLT2-inhibitors are effective and safe in the elderly: The SOLD study. **2022**, 183, 106396	0
694	How can we optimise health technology assessment and reimbursement decisions to accelerate access to new cardiovascular medicines?. **2022**, 365, 61-68	
693	MCAD activation by empagliflozin promotes fatty acid oxidation and reduces lipid deposition in NASH. **2022**, 69, 415-430	0

692	Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Sotagliflozin After Multiple Ascending Doses in Chinese Healthy Subjects. Volume 16, 2967-2980	0
691	NLRP3 Inflammasome/Pyroptosis: A Key Driving Force in Diabetic Cardiomyopathy. **2022**, 23, 10632	1
690	Beyond HbA1c cardiovascular protection in type 2 diabetes mellitus. 1-7	0
689	Real-World Treatment Patterns of Glucose-Lowering Agents Among Patients with Type 2 Diabetes Mellitus and Cardiovascular Disease or At Risk for Cardiovascular Disease: An Observational, Cross-Sectional, Retrospective Study.	0
688	Dissecting the reduction in cardiovascular death with SGLT2 inhibitors: Potential contribution of effects on ventricular arrhythmias and sudden cardiac death?. **2022**, 8, 100107	0
687	Sodium-glucose cotransporter-2 (SGLT2) expression in diabetic and non-diabetic failing human cardiomyocytes. **2022**, 184, 106448	0
686	Assessing the Risk Minimization Activity in Risk Management Plans for Sodium-Glucose Cotransporter-2 Inhibitors (SGLT2). **2021**, 47, 464-476	0
685	Effect of Dapagliflozin in Combination with Lobeglitazone and Metformin in Korean Patients with Type 2 Diabetes in Real-World Clinical Practice. **2022**, 63, 825	0
684	Therapie von Begleiterkrankungen: Diabetes mellitus und Dyslipoproteinämie. **2022**, 211-225	0
683	SGLT2 Inhibitors in Patients with Chronic Kidney Disease and Heart Disease: A Literature Review. **2022**, 18, 62-72	0
682	Renal Effects of SGLT2 Inhibitors and Potential Clinical Implications: Beyond the Heart. 4,	0
681	Herz und Diabetes. **2022**, 1-14	0
680	Comparison of the effects of exenatide and insulin glargine on right and left ventricular myocardial deformation as shown by 2D-speckle-tracking echocardiograms. **2022**, 25, 1094	0
679	Therapeutic peptidomimetics in metabolic diseases. **2022**, 521-550	0
678	Under-utilisation of cardioprotective glucose-lowering medication in diabetics living with HIV. **2022** ,	0
677	Flozins in heart failure â new reimbursement indication. **2022**, 20, 19-25	0
676	Evaluating Impact of Empagliflozin on Lipid Profile of Patients of Type 2 Diabetes Mellitus. **2022**, 9, 20-24	0
675	Novel Targets for a Combination of Mechanical Unloading with Pharmacotherapy in Advanced Heart Failure. **2022**, 23, 9886	0

674	Interleukin-6 and Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes: New Insights From CANVAS.	1
673	Development and validation of a model to predict cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke in patients with type 2 diabetes mellitus and established atherosclerotic cardiovascular disease. **2022**, 21,	0
672	Evaluating the Application of Chronic Heart Failure Therapies and Developing Treatments in Individuals With Recent Myocardial Infarction.	1
671	Using real-world data for supporting regulatory decision making: Comparison of cardiovascular and safety outcomes of an empagliflozin randomized clinical trial versus real-world data. 13,	0
670	Diabetic Cardiomyopathy: Pathophysiology and Novel Therapies. **2022**, 1,	0
669	The protective effects of SGLT-2 inhibitors, GLP-1 receptor agonists, and RAAS blockers against renal injury in patients with type 2 diabetes.	0
668	Diabetes Mellitus Type 2, Prediabetes, and Chronic Heart Failure.	0
667	Effects of Sodium-Glucose Co-Transporter-2 Inhibition on Pulmonary Arterial Stiffness and Right Ventricular Function in Heart Failure with Reduced Ejection Fraction. **2022**, 58, 1128	0
666	Protective or inhibitory effect of pharmacological therapy on cardiac ischemic preconditioning: a literature review. **2022**, 20,	0
665	Meta-analysis of the association between new hypoglycemic agents and digestive diseases. **2022**, 101, e30072	0
664	Glifozins and Atrial Fibrillation. **2022**,	0
663	Tratamiento farmacol□gico del paciente que vive con diabetes mellitus tipo 2. **2022**, 36, 81-105	0
662	How many and who are patients with heart failure eligible to SGLT2 inhibitors? Responses from the combination of administrative healthcare and primary care databases. **2022**,	0
661	Glucose/Fructose Delivery to the Distal Nephron Activates the Sodium-Chloride Cotransporter via the Calcium-Sensing Receptor. ASN.2021121544	0
660	A review of potential mechanisms and uses of SGLT2 inhibitors in ischemia-reperfusion phenomena. **2022**, 13, 683-695	0
659	Erhalt von Leistungsf□higkeit und Lebensqualit□t bei chronischer Herzinsuffizienz (Teil 2).	0
658	SGLT2 Inhibition, Choline Metabolites, and Cardiometabolic Diseases: A Mediation Mendelian Randomization Study.	1
657	Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).	12

656	Prescription Patterns of Cardiovascular- and Kidney-Protective Therapies Among Patients With Type 2 Diabetes and Chronic Kidney Disease.	0
655	Glycemia Reduction in Type 2 Diabetes â Microvascular and Cardiovascular Outcomes. **2022**, 387, 1075-1088	4
654	Heterogeneity in cardiovascular deaths or hospitalizations for heart failure from cardiovascular outcome trials is linked to weight: A meta-regression analysis.	0
653	Yaï hastalarda SGLT2 inhibitï kullanï m: laboratuvar deï rlendirilmesi. **2022**, 3, 142-146	0
652	Impact of breakthrough trials on prescription trends of sodium-glucose cotransporter-2 inhibitors in Japan: An interrupted time-series analysis.	1
651	Dapagliflozin attenuates diabetes-induced diastolic dysfunction and cardiac fibrosis by regulating SGK1 signaling. **2022**, 20,	0
650	Effects of Antidiabetic Medications on the Risk of Bone Fracture in Patients With Type 2 Diabetes Mellitus. 2633559X2211227	0
649	Electrocardiographic changes associated with SGLT2 inhibitors and non-SGLT2 inhibitors: A multi-center retrospective study. 9,	0
648	Kardiovaskulï e Prï vention bei Diabetes mellitus Typ 2: Gewichtsreduktion beseitigt nicht das kardiale Risiko.	0
647	The dual role of empagliflozin: Cardio renal protection in T2DM patients. **2022**, 81, 104555	0
646	Updated S2k Clinical Practice Guideline on Non-alcoholic Fatty Liver Disease (NAFLD) issued by the German Society of Gastroenterology, Digestive and Metabolic Diseases (DGVS) â April 2022 â AWMF Registration No.: 021â025. **2022**, 60, e733-e801	0
645	Influence of sodium-glucose Co-transporter 2 inhibitors on clinical and biochemical markers of dehydration during the Holy Ramadan. **2022**, 16, 102606	1
644	Sodiumâ Glucose Cotransporter 2 Inhibitors and the Short-term Risk of Bladder Cancer: An International Multisite Cohort Study.	0
643	Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).	16
642	Study protocol for a randomised, double-blind, placebo-controlled crossover trial assessing the impact of the SGLT2 inhibitor empagliflozin on postprandial hypoglycaemia after gastric bypass. **2022**, 12, e060668	0
641	Recent Advances in the Emerging Therapeutic Strategies for Diabetic Kidney Diseases. **2022**, 23, 10882	0
640	Comparison of the blood pressure management between sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide 1 receptor agonists. **2022**, 12,	0
639	Aldehyde Dehydrogenase 2 Activator Augments the Beneficial Effects of Empagliflozin in Mice with Diabetes-Associated HFpEF. **2022**, 23, 10439	1

638	Sodium-glucose Cotransporter 2 Inhibitors and Urinary Tract Infection: Is there room for real concern?. 10.34067/KID.0005722022	1
637	Intravital imaging of hemodynamic glomerular effects of enalapril or/and empagliflozin in STZ-diabetic mice. 13,	0
636	Empagliflozin reduces cardiorenal events, healthcare resource use and mortality in Sweden compared to dipeptidyl peptidase-4 inhibitors: real world evidence from the Nordic EMPRISE study.	0
635	Benefits of Taking Sodium-Glucose Cotransporter 2 Inhibitors in Patients With Type 2 Diabetes Mellitus and Cardiovascular Disease: A Systematic Review. **2022**,	0
634	Is there a paradigm shift in preventing diabetic heart failure? A review of SGLT2 inhibitors. **2022**, 47,	0
633	Comparative effectiveness of empagliflozin in reducing the burden of recurrent cardiovascular hospitalizations among older adults with diabetes in routine clinical care. **2022**,	0
632	Larger effect size in composite kidney outcomes than in major cardiovascular events associated with sodium-glucose cotransporter-2 (SGLT2) inhibitors compared with glucagon-like peptide-1 receptor agonists (GLP -1 RAs) : A pooled analysis of type 2 diabetes trials.	0
631	Potential Benefits of Sodium-Glucose Transporter-2 Inhibitors in the Symptomatic and Functional Status of Patients With Heart Failure: A Systematic Review and Meta-Analysis. **2022**,	0
630	New insights and advances of sodium-glucose cotransporter 2 inhibitors in heart failure. 9,	0
629	Effect of empagliflozin on left ventricular contractility and peak oxygen uptake in subjects with type 2 diabetes without heart disease: results of the EMPA-HEART trial. **2022**, 21,	0
628	Sodium-glucose Co-transporter-2 inhibitors (SGLT2I): A class of drugs with promising cardiorenal protective effects beyond glycemic control. **2022**, 81, 104536	0
627	Emerging Treatment Approaches to Improve Outcomes in Patients with Heart Failure. Publish Ahead of Print,	0
626	Treatment of Diabetes and Osteoporosisâ A Reciprocal Risk?. **2022**, 10, 2191	0
625	Anti-inflammatory role of SGLT2 inhibitors as part of their anti-atherosclerotic activity: Data from basic science and clinical trials. 9,	3
624	Sodiumâglucose cotransporter 2 inhibitor ameliorates high fat diet-induced hypothalamicâpituitaryâovarian axis disorders.	0
623	The Sodiumâglucose Co-Transporter-2 (SGLT2) Inhibitors Reduce Platelet Activation and Thrombus Formation by Lowering NOX2-Related Oxidative Stress: A Pilot Study. **2022**, 11, 1878	1
622	The role of microRNAs in the pathophysiology, diagnosis, and treatment of diabetic cardiomyopathy.	1
621	Cost-Effectiveness of Dapagliflozin for Chronic Kidney Disease in Japan. **2022**,	0

620	Coronary Microvascular Dysfunction in Diabetes Mellitus: Pathogenetic Mechanisms and Potential Therapeutic Options. **2022**, 10, 2274	2
619	Aktualisierte S2k-Leitlinie nicht-alkoholische Fettlebererkrankung der Deutschen Gesellschaft fî.. Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS) â April 2022 â AWMF-Registernummer: 021â025. **2022**, 60, 1346-1421	0
618	Ethnic and socioeconomic disparities in initiation of second-line antidiabetic treatment in people with type 2 diabetes in England: a cross-sectional study.	0
617	In-hospital arrhythmic burden reduction in diabetic patients with acute myocardial infarction treated with SGLT2-inhibitors: Insights from the SGLT2-I AMI PROTECT study. 9,	1
616	Characteristics of new users of recent antidiabetic drugs in Canada and the United Kingdom. **2022**, 22,	0
615	Impact of cardiovascular disease on health care economic burden and resource utilization: a retrospective cohort study in adults in the United States with type 2 diabetes with or without stroke, myocardial infarction, and peripheral arterial disease. 1-10	0
614	Mechanisms underlying the blood pressure-lowering effects of empagliflozin, losartan and their combination in people with type 2 diabetes: A secondary analysis of a randomized crossover trial.	0
613	A Reassessment of the Causal Effects of Dysglycemia on Atherosclerotic and Thrombotic Events. **2022**, 71, 2075-2077	0
612	Hypoglykæmie unter SGLT2-Inhibition bei einem Patienten mit HFrEF ohne Diabetes mellitus. **2022**, 147, 1195-1198	0
611	ISPAD Clinical Practice Consensus Guidelines 2022: Type 2 diabetes in children and adolescents.	2
610	The Role of NLRP3 Inflammasome in Diabetic Cardiomyopathy and Its Therapeutic Implications. **2022**, 2022, 1-19	0
609	Risk of major adverse limb events in patients with type 2 diabetes mellitus receiving sodium glucose cotransporter 2 inhibitors and glucagon-like peptide-1 receptor agonists: A population-based retrospective cohort study. 13,	0
608	Sacubitril/Valsartan in Patients With Heart Failure and Concomitant End-Stage Kidney Disease. **2022**, 11,	1
607	Modern Approaches for the Treatment of Heart Failure: Recent Advances and Future Perspectives. **2022**, 14, 1964	0
606	Effects of luseogliflozin and voglibose on high-risk lipid profiles and inflammatory markers in diabetes patients with heart failure. **2022**, 12,	0
605	SGLT2 inhibitors improve kidney function and morphology by regulating renal metabolic reprogramming in mice with diabetic kidney disease. **2022**, 20,	0
604	Sodium-glucose cotransporter-2 inhibitors: A treatment option for recurrent vasovagal syndrome?. **2022**, 155309	0
603	Cannabinoid Signaling in the Diabetic Proximal Tubule: Of Mice and Men. **2022**,	0

602	Patient preferences for newer oral therapies in type 2 diabetes. **2022**,	0
601	The effect of SGLT-2i administration on red blood cell distribution width in patients with heart failure and type 2 diabetes mellitus: A randomized study. 9,	0
600	A 5-year trend in the use of sodium-glucose co-transporter 2 inhibitors and other oral antidiabetic drugs in a Middle Eastern country.	0
599	Use of Glucose-Lowering Agents in Diabetes and Chronic Kidney Disease. **2022**,	0
598	Targets and management of hypertension in heart failure: focusing on the stages of heart failure. **2022**, 24, 1218-1225	0
597	Current Status of Dapagliflozin in Congestive Heart Failure. **2022**,	0
596	Diabetes and cardiovascular risk according to gender: an overview of epidemiological data from the early Framingham reports to the cardiovascular outcomes trials. **2022**,	0
595	A 96-Week, Double-Blind, Randomized, Controlled Trial Comparing Bexagliflozin to Glimepiride as an Adjunct to Metformin for the Treatment of Type 2 Diabetes in Adults.	0
594	Can Empagliflozin Improve Left Ventricular Strain Parameters in Patients with Type-2 Diabetes Mellitus and Normal Ejection Fraction?. 390-399	0
593	Obesity as a modifier of the cardiovascular effectiveness of sodium-glucose cotransporter-2 inhibitors in type 2 diabetes. **2022**, 192, 110094	0
592	Multi-omics insights into potential mechanism of SGLT2 inhibitors cardiovascular benefit in diabetic cardiomyopathy. 9,	0
591	Sodium Glucose Cotransporter 2 Inhibitors, Amputation Risk, and Fracture Risk. **2022**, 18, 645-654	1
590	Sodium-glucose cotransporter 2 inhibitors and the risk of pneumonia and septic shock: A systematic review and meta-analysis.	1
589	Effects of empagliflozin on cardiovascular and renal outcomes in heart failure with reduced ejection fraction according to age: A secondary analysis of EMPEROR-Reduced.	1
588	Prise en charge de lâ̈rtђopathie des membres infђieurs chez les patients diabђiques prŝentant une plaie du pied. **2022**,	0
587	Sodium-Glucose Cotransporter-2 Inhibitors: Impact on Atherosclerosis and Atherosclerotic Cardiovascular Disease Events. **2022**, 18, 597-607	0
586	SGLT2 Inhibitors in Type 2 Diabetes Mellitus. **2022**, 18, 551-559	0
585	Diabetic Kidney Disease Back in Focus: Management Field Guide for Health Care Professionals in the 21st Century. **2022**, 97, 1904-1919	0

584	First-Line Therapy for Type 2 Diabetes With Sodiumâ€Glucose Cotransporter-2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists.	4
583	Actualization of Positions of Gliflozins in Treatment Algorithms for Patients with Heart Failure: Chronology of Success. **2022**, 30, 411-421	0
582	The effect of allopurinol on cardiovascular outcomes in patients with type 2 diabetes: a systematic review.	0
581	Renoprotective Effects of SGLT2 Inhibitors. **2022**, 18, 539-549	0
580	SGLT2 Inhibitors in Heart Failure with Reduced Ejection Fraction. **2022**, 18, 561-577	0
579	The presence of sodium glucose co-transporter 2 in mesangial cells and pericytes and its roles in mesangial lesions and in capillaries under diabetic and ischemic conditions. **2022**, 192, 110096	0
578	The role of sodium-glucose co-transporter-2 inhibitors in frail older adults with or without type 2 diabetes mellitus. **2022**, 51,	0
577	From screening to treatment: the new landscape of diabetic kidney disease. **2022**, 20,	0
576	Impact of psychological status on cardiovascular diseases: Is it time for upgrading risk score charts?. **2022**, 359, 42-43	0
575	SGLT2 Inhibitors and Heart Failure with Preserved Ejection Fraction. **2022**, 18, 579-586	0
574	Response to comment on â proteomic surrogate for cardiovascular outcomes that is sensitive to multiple mechanisms of change in riskâ**2022**, 14,	1
573	Cardiovascular disease management in Australian adults with type 2 diabetes: insights from the CAPTURE study.	0
572	Optimization of Drug Therapy for Heart Failure With Reduced Ejection Fraction Based on Gender.	0
571	Longitudinal Adherence to Diabetes Quality Indicators and Cardiac Disease: A Nationwide Population-Based Historical Cohort Study of Patients With Pharmacologically Treated Diabetes. **2022**, 11,	0
570	SGLT2 Inhibitors Are Lifesavers in Heart Failure. **2022**, 18, xi-xiv	0
569	SGLT2 Inhibitors and Safety in Older Patients. **2022**, 18, 635-643	0
568	Mechanism of canagliflozin-induced vasodilation in resistance mesenteric arteries and the regulation of systemic blood pressure. **2022**, 150, 211-222	0
567	â Missed Therapeutic Opportunity? SGLT-2 Inhibitor Use in General Medicine Patients With Heart Failure: A Retrospective Audit of Admissions to a Tertiary Health Serviceâ**2022**, 16, 117954682211336	0

566	Risk Factors of Patients with Peripheral Arterial Disease. **2022**, 49-59	0
565	Novel Drugs for Kidney Diseases Treatment. **2022**, 127-140	0
564	Pathogenesis of Coronary Artery Disease in Chronic Kidney Disease: Strategies to Identify and Target Specific Populations. **2022**, 189-198	0
563	A retrospective analysis of the incidence, outcome and factors associated with the occurrence of euglycemic ketoacidosis in diabetic patients on sodium glucose co-transporter â2 inhibitors undergoing cardiac surgery. **2022**, 25, 460	0
562	Evaluation of clinical practice regarding SGLT2 inhibitor use in patients with type 2 diabetes mellitus and established coronary artery disease in James Cook University Hospital. **2022**, 22, 88-89	0
561	Key updates to the management of type 2 diabetes in adults: how to embrace and embed the new NICE guidance. **2022**, 39, 6-8	0
560	EMPAGLIFLOZIN SAFETY AND EFFICACY IN SOUTH INDIAN POPULATION. **2022**, 22-23	0
559	The Benefit of Sodium-Glucose Co-Transporter Inhibition in Heart Failure: The Role of the Kidney. **2022**, 23, 11987	0
558	Real-world characteristics, modern antidiabetic treatment patterns, and comorbidities of patients with type 2 diabetes in central and Eastern Europe: retrospective cross-sectional and longitudinal evaluations in the CORDIALLY study. **2022**, 21,	0
557	Diabetes Mellitus and Heart Failure. **2022**, 12, 1698	0
556	Comparison of cardiovascular and renal outcomes between dapagliflozin and empagliflozin in patients with type 2 diabetes without prior cardiovascular or renal disease. **2022**, 17, e0269414	0
555	Tofogliflozin, a sodium-glucose cotransporter 2 inhibitor, improves pulmonary vascular remodeling due to left heart disease in mice. **2022**,	0
554	Preoperative evaluation and perioperative management of patients undergoing major vascular surgery. **2022**, 27, 496-512	0
553	Pharmacologic Treatment of Type 2 Diabetes in the U.S., Sweden, and Israel.	0
552	Assessment of Additional Risk Factors for Cardiovascular Disease and Awareness Among Adult Patients With Diabetes Mellitus: A Cross-Sectional Study From Northern Sri Lanka. **2022**,	0
551	PhysiciansâConsiderations and Practice Recommendations Regarding the Use of Sodium-Glucose Cotransporter-2 Inhibitors. **2022**, 11, 6051	1
550	The DAPA-DIET study: Metabolic response to Dapagliflozin combined with dietary carbohydrate restriction in patients with Type 2 Diabetes Mellitus and ObesityâA longitudinal cohort study.	0
549	Adverse cardiovascular, limb, and renal outcomes in patients with diabetes after peripheral artery disease revascularization treated with sodium glucose cotransporter 2 inhibitors versus dipeptidyl peptidase-4 inhibitors Cover title: SGLT2i versus DPP4i in T2D patients after PAD revascularization.	0

548	Positionspapier zur Diagnostik und Therapie der peripheren arteriellen Verschlusskrankheit (pAVK) bei Menschen mit Diabetes mellitus â Gemeinsame Stellungnahme der Deutschen Diabetes Gesellschaft (DDG), der Deutschen Gesellschaft fî.Angiologie (DGA), der Deutschen Gesellschaft fî.Interventionelle Radiologie und minimal-invasive Therapie (DeGIR) sowie der Deutschen	0
547	New principles for the treatment of chronic heart failure: the phenomenon of sodium-glucose cotransporter type 2 inhibitors. **2022**, 44-51	0
546	Greenness Assessment of Chromatographic Methods Used for Analysis of Empagliflozin: A Comparative Study. **2022**, 9, 275	1
545	Healthcare Resource Utilization and Costs for Empagliflozin Versus Glucagon-Like Peptide-1 Receptor Agonists in Routine Clinical Care in Denmark.	0
544	Effect of SGLT2 inhibitors on the course of chronic heart failure in patients with type 2 diabetes mellitus. **2022**, 16, 10-16	0
543	Effect of Dapagliflozin on Left Ventricular Diastolic Function in Diabetics - A Prospective Interventional Study. 7, 137-142	0
542	Diabetes mellitus und Herz. **2022**, 17, S323-S326	0
541	AWARE. A web application to rapidly assess cardiovascular risk in Type 2 Diabetes Mellitus..	0
540	Ketones: the double-edged sword of SGLT2 inhibitors?.	1
539	Obesity as a risk factor for cardiac arrhythmias. **2022**, 1, e000308	0
538	Making sense of a therapeutics randomised controlled trial. **2022**, 2022, 18-21	0
537	Impact of empagliflozin on left atrial mechanical and conduction functions in patients with type 2 diabetes mellitus.	0
536	Inhibition of Sodium-glucose Cotransporter 2 Suppresses Renal Stone Formation. **2022**, 106524	0
535	Optimal Management of Heart Failure and Chronic Obstructive Pulmonary Disease: Clinical Challenges. Volume 15, 7961-7975	0
534	The Profile of Glucose Lowering Therapy in Persons with Type 2 Diabetes Mellitus in an Aging Russian Population. **2022**, 12, 1689	0
533	Benefits of SGLT2 inhibitors in arrhythmias. 9,	0
532	Cardiovascular and renal efficacy and safety of sodium-glucose cotransporter-2 inhibitors in patients without diabetes: a systematic review and meta-analysis of randomised placebo-controlled trials. **2022**, 12, e060655	2
531	Association of sodium-glucose cotransporter 2 inhibitors with cardiovascular outcome and safety events: A meta-analysis of randomized controlled clinical trials. 9,	0

530	Network meta-analysis on the efficacy and safety of finerenone versus SGLT2 inhibitors on reducing new-onset of atrial fibrillation in patients with type 2 diabetes mellitus and chronic kidney disease. **2022**, 14,	1
529	Disparities in SGLT2 Inhibitor or Glucagon-Like Peptide 1 Receptor Agonist Initiation Among Medicare Insured Adults With CKD in the United States. **2022**, 100564	0
528	The quest for the mechanism responsible for the cardiovascular benefits of novel antidiabetic agents. **2022**,	0
527	Safety of sodiumâglucose c otransporter ´2 inhibitors in Asian type 2 diabetes populations.	0
526	Clinical perspectives on the use of the GIP/GLP-1 receptor agonist tirzepatide for the treatment of type-2 diabetes and obesity. 13,	1
525	Comparative Effectiveness of Empagliflozin vs Liraglutide or Sitagliptin in Older Adults With Diverse Patient Characteristics. **2022**, 5, e2237606	0
524	A Case of SGLT2 Inhibitor-Induced Euglycemic Diabetic Ketoacidosis. **2022**,	0
523	Hematocrit elevation after SGLT2 inhibitor administration may be associated with the degree of proximal tubular damage. **2022**, 101, e31122	0
522	Repurposing SGLT-2 Inhibitors to Target Aging: Available Evidence and Molecular Mechanisms. **2022**, 23, 12325	0
521	Empagliflozin Is Not Renoprotective in Non-Diabetic Rat Models of Chronic Kidney Disease. **2022**, 10, 2509	0
520	Steroidal or non-steroidal MRAs: should we still enable RAASi use through K binders?.	0
519	SGLT2 inhibitors for the composite of cardiorenal outcome in patients with chronic kidney disease: A systematic review and meta-analysis of randomized controlled trials. **2022**, 175354	2
518	Gaps in our knowledge of managing inpatient dysglycaemia and diabetes in non-critically ill adults: A call for further research.	1
517	Emerging roles of sodium-glucose co-transporter inhibitors. **2022**, 33, 11-17	0
516	Sodium-Glucose Cotransporter 2 Inhibitors and New-onset Type 2 Diabetes in Adults with Prediabetes: Systematic Review and Meta-analysis of Randomized Controlled Trials.	0
515	Cardioprotective Effect of Empagliflozin in Rats with Isoproterenol-Induced Myocardial Infarction: Evaluation of Lipid Profile, Oxidative Stress, Inflammation, DNA Damage, and Apoptosis.	0
514	Cardiac Autonomic Neuropathy in Type 1 and 2 Diabetes: Epidemiology, Pathophysiology, and Management. **2022**,	0
513	The prescribing pattern of sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists in patient with type two diabetes mellitus: A two-center retrospective cross-sectional study. 10,	2

512	Efficacy of Sodium-Glucose Cotransporter 2 Inhibitors on Outcomes´After Catheter Ablation for´Atrial Fibrillation. **2022**,	1
511	The role of blood pressure management in stroke prevention: current status and future prospects. **2022**, 20, 829-838	0
510	COOrdinating CaRDIology CliNics RAndomized Trial of Interventions to Improve OutcomEs (COORDINATE) â Diabetes: Rationale and Design. **2022**,	1
509	Diabetes mellitus im Alter. **2022**, 17, S226-S236	0
508	An Update on the Current and Emerging Use of Thiazolidinediones for Type 2 Diabetes. **2022**, 58, 1475	0
507	Association of Sodium-Glucose Cotransporter-2 Inhibitors With Incident Atrial Fibrillation in Older Adults With Type 2 Diabetes. **2022**, 5, e2235995	0
506	Sodium-glucose co-transporter-2 inhibitors in type 2 diabetes: Are clinical trial benefits for heart failure reflected in real-world clinical practice? A systematic review and meta-analysis of observational studies.	0
505	Mediating effect of vascular risk factors underlying the link between gestational diabetes and cardiovascular disease. **2022**, 20,	0
504	Glucose-lowering agents and risk of ventricular arrhythmias and sudden cardiac death: a comprehensive review ranging from sulphonylureas to SGLT2 inhibitors. **2022**, 101405	0
503	Metabolomic analysis of the effect of canagliflozin on HFpEF rats and its underlying mechanism.	0
502	KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease. **2022**, 102, S1-S127	8
501	Musculoskeletal complications in patients with diabetes mellitus. **2022**, 37, 1099-1110	0
500	Metabolomic profiling in kidney cells treated with a sodium glucose-cotransporter 2 inhibitor.	0
499	Knowledge domain and emerging trends in empagliflozin for heart failure: A bibliometric and visualized analysis. 9,	0
498	Contemporary choice of glucose lowering agents in heart failure patients with type 2 diabetes.	0
497	Effect of empagliflozin on cytoskeletal repair in the hippocampus of obese mice. 16,	0
496	APOL1 Genotype, Proteinuria, and the Risk of Kidney Failure: A Secondary Analysis of the AASK (African American Study of Kidney Disease and Hypertension) and CRIC (Chronic Renal Insufficiency Cohort) Studies. **2022**, 100563	0
495	Prevalence of cardiovascular events among patients with type 2 diabetes in the west region of Saudi Arabia. **2022**,	0

494	Mechanisms and pharmacotherapy of hypertension associated with type 2 diabetes. **2022**, 206, 115304	0
493	Pharmacotherapy of type 2 diabetes: An update and future directions. **2022**, 137, 155332	3
492	Distinctive effects of SGLT2 inhibitors on angiogenesis in zebrafish embryos. **2022**, 156, 113882	0
491	Age, sex, race, BMI, and duration of diabetes differences in cardiovascular outcomes with glucose lowering drugs in type 2 diabetes: A systematic review and meta-analysis. **2022**, 54, 101697	0
490	The treatment of diabetes in advanced liver disease: Change of a paradigm. **2023**, 28, 100772	0
489	Budget Impact Analysis of Empagliflozin in the Treatment of Patients With Type 2 Diabetes With Established Cardiovascular Disease in South Africa. **2023**, 33, 91-98	0
488	Cardiovascular Risk Factor Control in Type 2 Diabetes Mellitus and New Trial Evidence. 83-89	0
487	Multidisciplinary Approach to Management and Care of Patients with Type 2 Diabetes Mellitus. 73-81	1
486	Diabetes Mellitus in Acromegaly. **2022**, 103-110	0
485	Session Two: Changing the Type 2 Diabetes Mellitus Management Paradigm with Fixed-Ratio Combinations. 46-55	0
484	Editorâ Pick: How Can We Develop More Effective Strategies for Type 2 Diabetes Mellitus Prevention? A Paradigm Shift from a Glucose-Centric to a Beta Cell-Centric Concept of Diabetes. 46-52	0
483	Rewriting Medical Textbooks: The Kidney as a Window to the Heart â The Role of Sodiumâ Glucose Transport Protein 2 Inhibitors in Cardiovascular and Renal Disease in Type 2 Diabetes Mellitus. 36-45	0
482	Effect of a Six-week Endurance Exercise Program and Empagliflozin Consumption on Some Structural and Functional Indices of the Heart in Male Diabetic Rats. **2022**, 30, 1-11	0
481	Sodium-glucose co-transporter 2 inhibitors in 2022: mechanisms of cardiorenal benefit. **2022**, 7, 216-224	0
480	MECHANISMS OF THE INFLUENCE OF SODIUM-GLUCOSE COTRANSPORTER-2 INHIBITORS ON LDL RECEPTOR FUNCTION AND CARDIOVASCULAR RISK IN TYPE 2 DM (literature review). **2022**,	0
479	Secondary causes of elevated hemoglobin in patients undergoing molecular testing for suspected polycythemia vera in southwestern Ontario: a chart review. **2022**, 10, E988-E992	0
478	Assessment of Atherosclerotic Cardiovascular Disease Risk in Primary Prevention. **2022**, 42, 397-403	0
477	Model-based predictions on health benefits and budget impact of implementing empagliflozin in people with type 2 diabetes and established cardiovascular disease.	0

476	Burden of established cardiovascular disease in people with type 2 diabetes and matched controls: Hospital-based care, days absent from work, costs, and mortality.	0
475	Inadequate Use of Newer Treatments and Glycemic Control by Cardiovascular Risk and Sociodemographic Groups in US Adults with Diabetes in the NIH Precision Medicine Initiative All of Us Research Program.	0
474	A New Chapter in the Treatment of Patients with Heart Failure. The Role of Sodium-Glucose Co-transporter Type 2 Inhibitors. **2022**, 18, 606-613	0
473	Variations in Use of Diabetes Drugs With Cardiovascular Benefits Among Medicaid Patients. **2022**, 5, e2240117	0
472	Depot-specific adipose tissue modulation by SGLT2 inhibitors and GLP1 agonists mediates their cardioprotective effects in metabolic disease. **2022**, 136, 1631-1651	0
471	Estimated Glomerular Filtration Rate (eGFR) Slope Assessment as a Surrogate End-point in Cardiovascular trials: Implications, Impediments, and Future Directions. **2022**, 101508	0
470	Prospective associations of circulating thrombospondin-2 level with heart failure hospitalization, left ventricular remodeling and diastolic function in type 2 diabetes. **2022**, 21,	0
469	Hypertension management in patients with cardiovascular comorbidities.	0
468	SGLT2 Inhibitors Improve Cardiac Failure by Reducing Whole-Body Oxygen Demand: A Hypothesis.	0
467	Sequencing of medical therapy in heart failure with a reduced ejection fraction. heartjnl-2022-321497	0
466	Fat not so bad? The role of ketone bodies and ketogenic diet in the treatment of endothelial dysfunction and hypertension. **2022**, 115346	1
465	Effect of Sodium-Glucose Co-transporter-2 Inhibitors on Ventricular Repolarization Markers in Heart Failure with Reduced Ejection Fraction.	0
464	Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials. **2022**,	10
463	Use of sodium-glucose co-transporter 2 inhibitors in solid organ transplant recipients with pre-existing type 2 or post-transplantation diabetes mellitus: A systematic review. **2022**, 100729	0
462	Alogliptin and Heart Failure Outcomes in Patients With Type 2 Diabetes. 089719002211356	0
461	Care Gaps in Sodium-Glucose Cotransporter-2 Inhibitor and Renin Angiotensin System Inhibitor Prescriptions for Patients with Diabetic Kidney Disease.	0
460	Prescribing Trends of the Sodium Glucose Cotransporter-2 (SGLT-2) Inhibitors Among Different Physician Specialties in Canada (2015-2021).. **2022**,	0
459	Treatment of hypertriglyceridaemia with icosapent ethyl in patients with high/very high cardiovascular risk. Consensus document of the Sociedad Espaêla de Cardiologí [Spanish Society of Cardiology] and the Sociedad Espaêla de Diabetes [Spanish Diabetes Society]. **2022**,	0

458	The challenges and pitfalls of incorporating evidence from cardiovascular outcomes trials in health economic modeling of type 2 diabetes.	0
457	Meta-analysed numbers needed to treat of novel antidiabetic drugs for cardiovascular outcomes.	0
456	Role of Ertugliflozin in the Management of Diabetes Mellitus. **2022**,	0
455	Renal function during hospitalization and outcome in Chinese patients with acute decompensated heart failure: A retrospective study and literature review.	0
454	Diabetic cardiomyopathy: a brief summary on lipid toxicity.	1
453	Low-Dose Empagliflozin as Adjunct to Hybrid Closed-Loop Insulin Therapy in Adults With Suboptimally Controlled Type 1 Diabetes: A Randomized Crossover Controlled Trial.	0
452	Impact of early initiation of sodium-glucose cotransporter 2 inhibitor on cardiovascular outcomes in people with diabetes and known or at risk of atherosclerotic cardiovascular disease: Propensity score matched analysis. **2022**, 17, e0277321	0
451	Implementation, not hesitation, for SGLT2 inhibition as foundational therapy for chronic kidney disease. **2022**,	0
450	Safe use of sodium glucose co-transporter 2 inhibitors in the management of type 2 diabetes.	0
449	Canagliflozin independently reduced plasma volume from conventional diuretics in patients with type 2 diabetes and chronic heart failure: a subanalysis of the CANDLE trial.	0
448	Successful conservative management of left ventricular assist device candidates.	0
447	Instituting a Successful Discharge Plan for Patients With Type 2 Diabetes: Challenges and Solutions. **2022**, 35, 440-451	0
446	The effect of empagliflozin on index of cardio-electrophysiological balance in patients with diabetes mellitus.	0
445	Deficits and Disparities in Early Uptake of Glucagon-Like Peptide 1 Receptor Agonists and SGLT2i Among Medicare-Insured Adults Following a New Diagnosis of Cardiovascular Disease or Heart Failure.	0
444	Rationale and Design of the Aldose Reductase Inhibition for Stabilization of Exercise Capacity in Heart Failure Trial (ARISE-HF) in Patients with High-Risk Diabetic Cardiomyopathy. **2022**,	1
443	Cardiovascular and kidney outcomes of combination therapy with sodium-glucose cotransporter-2 inhibitors and mineralocorticoid receptor antagonists in patients with type 2 diabetes and chronic kidney disease: a systematic review and network meta-analysis. **2022**, 110161	1
442	Euglycemic diabetic ketoacidosis in a patient with type 2 diabetes mellitus 3 days after initiating sodium-glucose cotransporter 2 inhibitor while on an extremely low carbohydrate diet: A case report. **2022**, 10,	0
441	Empagliflozin: A Review in Symptomatic Chronic Heart Failure.	0

440	Impact of sodium-glucose cotransporter-2 inhibitors on heart failure and mortality in patients with cancer. heartjnl-2022-321545	0
439	Risk of hypovolemia associated with sodiumâglucose cotransporter-2 inhibitors treatment: A meta-analysis of randomized controlled trials. 9,	1
438	Guías de práctica clínica: imprescindibles, pero insuficientes. **2022**,	0
437	Empagliflozin in heart failure with preserved ejection fraction: first success in mission impossible. **2022**, 24, I153-I159	0
436	Population-Level Implications of Sodium-Glucose Cotransporter-2 Inhibitors for Heart Failure With Preserved Ejection Fraction in the US.	1
435	Dapagliflozin reduces pulmonary vascular damage and susceptibility to atrial fibrillation in right heart disease.	0
434	Multicomponent integrated care for patients with chronic heart failure: systematic review and meta-analysis.	1
433	Network meta-analysis on the effects of finerenone versus SGLT2 inhibitors and GLP-1 receptor agonists on cardiovascular and renal outcomes in patients with type 2 diabetes mellitus and chronic kidney disease. **2022**, 21,	1
432	NAFLD as the metabolic hallmark of obesity.	0
431	Treatment pattern trends of medications for type 2 diabetes in British Columbia, Canada. **2022**, 10, e002995	0
430	Empagliflozin and Left Ventricular Remodeling in People Without Diabetes:Primary Results of the EMPA-HEART 2 CardioLink-7 Randomized Clinical Trial.	0
429	Empagliflozin suppresses urinary mitochondrial DNA copy numbers and interleukin-1 in type 2 diabetes patients. **2022**, 12,	0
428	Treatment Effect of the SGLT2 Inhibitor Empagliflozin on Chronic Syndrome of Inappropriate Antidiuresis: Results of a Randomized, Double-Blind, Placebo-Controlled, Crossover Trial. ASN.2022050623	1
427	Sodium-glucose co-transporter 2 inhibitors: A comprehensive review from cells to bedside.	0
426	Empagliflozin attenuates trastuzumab-induced cardiotoxicity through suppression of DNA damage and ferroptosis. **2022**, 121207	1
425	An Introduction to the Epidemiology of Chronic Kidney Disease. **2022**, 1-13	0
424	Efficacy and Safety of Dapagliflozin by Baseline Insulin Regimen and Dose: Post Hoc Analyses From DECLARE-TIMI 58.	0
423	Secondary Diseases of the Kidney. **2022**, 366-399	0

422	Projecting the incidence and costs of major cardiovascular and kidney complications of type 2 diabetes with widespread SGLT2i and GLP-1 RA use: a cost-effectiveness analysis.	0
421	PHARMACOKINETIC INVESTIGATION OF REMOGLIFLOZIN IN RAT PLASMA SAMPLES BY HIGH-THROUGHPUT HPLC-MS-MS. 178-185	0
420	Canagliglozin extends life span and leads to less weight gain in C57BL6 male mice.	0
419	Meta-Analysis on the Safety and Efficacy of Sodium Glucose Cotransporters 2 Inhibitors in Patients With Heart Failure With and Without Diabetes. **2023**, 187, 93-99	0
418	Glucocentric Drugs in Cardiovascular Disease Protection and Heart Failure. **2022**, 18, 40-53	0
417	Effect of sodium-glucose cotransporter-2 inhibitors on patients with essential hypertension and pre-hypertension: a meta-analysis. **2022**, 13, 204201882211424	0
416	Efficacy of dapagliflozin and empagliflozin for prevention of cardiovascular complications in patients with type 2 diabetes mellitus: a network meta-analysis. **2022**, 42	0
415	How a New Understanding of Drug or Drug Class Pharmacology Often Drives Drug Development: A Conversation with Steven E. Nissen, MD. **2022**, 18, 54-57	0
414	Effect of new glucose-lowering drugs on stroke in patients with type 2 diabetes: A systematic review and Meta-analysis. **2023**, 37, 108362	0
413	Corrigendum to âMechanisms and pharmacotherapy of hypertension associated with type 2 diabetesâ[Biochem. Pharmacol. 206 (2022) 115304]. **2023**, 207, 115349	0
412	SGLT2 inhibitors reduce adverse kidney and cardiovascular events in patients with advanced diabetic kidney disease: A population-based propensity score-matched cohort study. **2023**, 195, 110200	0
411	Outcomes in diabetic patients treated with SGLT2-Inhibitors with acute myocardial infarction undergoing PCI: The SGLT2-I AMI PROTECT Registry. **2023**, 187, 106597	3
410	Why Are Cardiologists Not Prescribing the New Diabetes Medications?. **2023**, 187, 74-75	0
409	Initiation of sodium-glucose cotransporter-2 inhibitors at lower HbA1c threshold attenuates eGFR decline in type 2 diabetes patients with and without cardiorenal disease: A propensity-matched cohort study. **2023**, 195, 110203	0
408	Post-Transplant Diabetes Mellitus. **2022**, 391-401	0
407	Findings of Sodium-Glucose Cotransporter-2 Inhibitor Kidney Outcome Trials Applied to a Canadian Chronic Kidney Disease Population: A Retrospective Cohort Study. **2022**, 9, 205435812211450	0
406	Intestinal Cholesterol Absorption in Diabetes Mellitus. **2022**,	0
405	The NO-cGMP-PKG Axis in HFpEF: From Pathological Mechanisms to Potential Therapies. **2022**, 0	0

404	Metabolic effects of empagliflozine. **2022**, 38-56	0
403	Combining metabolic surgery with medications for type 2 diabetes: Is there a benefit?. **2022**, 0	0
402	Non-albuminuric Diabetic Kidney Disease Phenotype: Beyond Albuminuria. **2022**, 18, 102	0
401	Constantly Bombarded with New Drugs: Whatâ a Cardiologist to Do?. **2022**, 18, 74-76	0
400	Clinical Evidence and Proposed Mechanisms for Cardiovascular and Kidney Benefits from Sodiumâ Glucose Co-transporter-2 Inhibitors. **2022**, 18, 106	0
399	Sodium-glucose cotransporter 2 inhibitors as the first universal treatment of chronic kidney disease. **2022**, 42, 390-403	0
398	VPS34-dependent control of apical membrane function of proximal tubule cells and nutrient recovery by the kidney. **2022**, 15,	0
397	Cardiovascular and renal outcomes with sodium glucose co-transporter 2 inhibitors in patients with type 2 diabetes mellitus: A system review and network meta-analysis. 13,	0
396	SGLT-2 Inhibitors in Cancer Treatmentâ Mechanisms of Action and Emerging New Perspectives. **2022**, 14, 5811	1
395	Advanced Liver Fibrosis Is Associated with Chronic Kidney Disease in Patients with Type 2 Diabetes Mellitus and Nonalcoholic Fatty Liver Disease (Diabetes Metab J 2022;46:630-9). **2022**, 46, 953-955	0
394	Safety and efficacy of Empagliflozin in Pakistani Muslim patients with type 2 diabetes (SAFE-PAK); a randomized clinical trial. **2022**, 22,	0
393	Efficacy and Safety of Sodium Glucose Cotransporter-2 (SGLT2) Inhibitors in Patients With Diabetes and Chronic Kidney Disease (CKD): A Meta-analysis of Randomized Control Trials. **2022**,	0
392	Sub-analyses of the DAPA-CKD study: new data on the use of sodium-glucose cotransporter type 2 inhibitor in the treatment of chronic kidney disease. **2022**, 94, 1188-1196	0
391	Comparative evaluation new glucagon-like peptide 1 receptor agonist semaglutide and sodium-glucose cotransporter-2 inhibitors empagliflozin on left ventricular diastolic function in patients with arterial hypertension, obesity and type 2 diabetes mellitus. **2022**, 19, 39-48	0
390	Transitioning to GLP-1 RAs and SGLT2 Inhibitors as the First Choice for Managing Cardiometabolic Risk in Type 2 Diabetes. **2022**, 24, 925-937	0
389	The Role of Sodium-Glucose Cotransporter-2 Inhibition in Heart Failure with Preserved Ejection Fraction. **2022**, 10, 166	0
388	Molecular Mechanisms Linking Empagliflozin to Renal Protection in the LLC-PK1 Model of Diabetic Nephropathy. **2022**, 10, 2983	0
387	Comparison of Sodium-Glucose Cotransporter-2 Inhibitor and Glucagon-Like Peptide-1 Receptor Agonist Prescribing in Patients With Diabetes Mellitus With and Without Cardiovascular Disease. **2022**,	0

386	The Impact of Cardiac Comorbidity Sequence at Baseline and Mortality Risk in Type 2 Diabetes Mellitus: A Retrospective Population-Based Cohort Study. **2022**, 12, 1956	0
385	Treatment of HFpEF beyond the SGLT2-Is: Does the Addition of GLP-1 RA Improve Cardiometabolic Risk and Outcomes in Diabetic Patients?. **2022**, 23, 14598	0
384	Cardiorenal diseases in type 2 diabetes mellitus: clinical trials and real-world practice.	0
383	Potential for sodium-glucose cotransporter-2 inhibitors in the management of metabolic syndrome: A systematic review and meta-analysis. 14, 599-616	0
382	Influence of type 2 sodium-glucose co-transporter inhibitors (dapagliflozin) on the indicators of total mortality in patients with type 2 diabetes (CARDIA-MOS study, Moscow). **2022**, 25, 439-448	0
381	Combined Therapy of Low-Dose Angiotensin ReceptorâNeprilysin Inhibitor and SodiumâGlucose Cotransporter-2 Inhibitor Prevents Doxorubicin-Induced Cardiac Dysfunction in Rodent Model with Minimal Adverse Effects. **2022**, 14, 2629	0
380	Efficacy of SGLT2 inhibitors in patients with heart failure: An overview of systematic reviews. **2022**,	0
379	Sodium-Glucose Cotransporter-2 (SGLT-2) Inhibitors and Genital Infections in Patients With Diabetic Mellitus and Concomitant Coronary Artery Disease: A Single-Center Experience. **2022**,	0
378	SGLT2 Inhibitors in Acute Heart Failure: A Meta-Analysis of Randomized Controlled Trials. **2022**, 10, 2356	0
377	Secular trends in the utility of SGLT -2 inhibitors in heart failure patients with type 2 diabetes mellitus across Metro South Health hospitals in South-East Queensland.	0
376	Liraglutide provides cardioprotection through the recovery of mitochondrial dysfunction and oxidative stress in aging hearts.	0
375	Recommendations for Early and Comprehensive Management of Type 2 Diabetes and Its Related Cardio-Renal Complications.	0
374	Cardiovascular outcomes in patients treated with sodium-glucose transport protein 2 inhibitors, a network meta-analysis of randomized trials. 9,	0
373	Diabetic cardiomyopathy: Clinical phenotype and practice. 13,	1
372	Clinical Pharmacy Specialist Collaborative Management and Prescription of Diabetes Medications with Cardiovascular Benefit. 089719002211443	0
371	Efficience et prc̀ision du contrl̂e glycm̂ique dans le diabt̀e ́: symphonie inachevè ?. **2022**,	0
370	Mechanisms of current therapeutic strategies for heart failure: more questions than answers?.	0
369	The International Society for Heart and Lung Transplantation (ISHLT) Guidelines for the Care of Heart Transplant Recipients. **2022**,	0

368	Managing Diabetes. **2022**,	0
367	The Impact of Pharmacist Intervention to Improve Medication Access for Patients with Diabetes. **2022**,	0
366	A genetically supported drug repurposing pipeline for diabetes treatment using electronic health records.	0
365	Effects of the Sodium-Glucose Cotransporter Inhibitors on Cardiovascular Death and All-Cause Mortality: A Systematic Review and Meta-analysis of Randomized Placebo-Controlled Clinical Trials.	0
364	Heart failure with reduced ejection fraction and the intersection of cardio-renal-metabolic medicine #CaReMe. **2022**, 24, L29-L37	0
363	Sodiumâ□lucose Cotransporter 2 Inhibitor Treatment and Risk of Atrial Fibrillation: Scandinavian Cohort Study.	0
362	13. Older Adults: Standards of Care in Diabetesâ□023. **2023**, 46, S216-S229	2
361	Pharmacological treatment of CVD. **2022**, 9, 1-3	0
360	Reduction of cardiac adipose tissue volume with short-term empagliflozin treatment in patients with type 2 diabetes: a sub-study from the SIMPLE randomized clinical trial.	0
359	Gender disparities in time-to-initiation of cardioprotective glucose-lowering drugs in patients with type 2 diabetes and cardiovascular disease: a Danish nationwide cohort study. **2022**, 21,	0
358	Liver autophagy-induced valine and leucine in plasma reflect the metabolic effect of sodium glucose co-transporter 2 inhibitor dapagliflozin. **2022**, 86, 104342	0
357	Les inhibiteurs des SGLT2 réduisent le risque de fibrillation auriculaire, dâ□rythmies ventriculaires et de mort subite. **2022**,	0
356	Heart failure with preserved left ventricular ejection fraction amidst diabetes mellitus: from general mechanisms to possible therapy tactics. **2022**, 13, 115-123	0
355	Early treatment with a sodium-glucose co-transporter 2 inhibitor in high-risk patients with acute heart failure: rationale for and design of the EMPA-AHF trial. **2022**,	0
354	The membrane-associated protein 17 (MAP17) is upregulated in response to empagliflozin on top of RAS blockade in experimental diabetic nephropathy.	0
353	The anti-hypertensive effects of sodium-glucose cotransporter-2 inhibitors. 1-20	0
352	10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetesâ□023. **2023**, 46, S158-S190	7
351	SGLT2 Inhibition Benefits in Cardiorenal Risk in Men and Women.	0

350	Use of Sodium-Glucose Transport Protein 2 (SGLT2) Inhibitor Remogliflozin and Possibility of Acute Kidney Injury in Type-2 Diabetes. **2022**,	0
349	The effects of mineralocorticoid receptor antagonists on cardiovascular outcomes in patients with end-stage renal disease and heart failure.	2
348	Therapeutics in Metabolic Diseases. **2023**, 255-273	0
347	Diabetic Kidney Care Redefined with a New Way into Remission. **2022**,	0
346	Coronary Atherosclerosis Burden and Progression to Guide Clinical Decision Making: A Report from the American College of Cardiology Innovations in Prevention Working Group. **2022**,	0
345	A European multinational cost-effectiveness analysis of empagliflozin in heart failure with reduced ejection fraction.	0
344	A consensus statement from the Japan Diabetes Society (JDS): a proposed algorithm for pharmacotherapy in people with type 2 diabetes.	0
343	Efficacy and Safety of Empagliflozin in Patients with Type 2 Diabetes Mellitus Fasting During Ramadan: A Real-World Study from Bangladesh. Volume 15, 4011-4021	0
342	Reflecting on the advancements of HFrEF therapies over the last two decades and predicting what is yet to come. **2022**, 24, L2-L9	0
341	Diab□e de type 2´: prescriptions de traitements non appropriès et observance insuffisante remettent en cause les bñfices cardio-rñaux attendus. Un gouffre entre RCT, consensus dâ□xperts et vraie vie¹. **2022**,	0
340	Effects of Dapagliflozin on Hospitalizations in Patients With Chronic Kidney Disease.	0
339	Comparison the effects of finerenone and SGLT2i on cardiovascular and renal outcomes in patients with type 2 diabetes mellitus: A network meta-analysis. 13,	0
338	Mechanotransduction regulates inflammation responses of epicardial adipocytes in cardiovascular diseases. 13,	0
337	Sodium-glucose co-transporter 2 inhibitors in patients with chronic kidney disease. **2022**, 108330	0
336	Pleiotropic effect of sodium-glucose cotransporter 2 inhibitors on blood pressure. 9,	0
335	Comparison of gliclazide vs linagliptin on hypoglycemia and cardiovascular events in type 2 diabetes mellitus: A systematic review. 13, 1168-1183	0
334	The Importance of SGLT-2 Inhibitors as Both the Prevention and the Treatment of Diabetic Cardiomyopathy. **2022**, 11, 2500	0
333	Long-Term Prognostic Impact of Sex in Patients with Chronic Coronary Syndrome: A 17-Year Prospective Cohort Study.	0

332	Factors affecting prescription of sodium-glucose co-transporter 2 inhibitors in patients with type 2 diabetes mellitus with established cardiovascular disease/ chronic kidney disease in Hong Kong: a qualitative study. **2022**, 23,	0
331	Risk scores for predicting incident heart failure admission in patients with chronic coronary syndromes: validation in a prospective, monocentric, long-term, cohort study.	0
330	Cardiometabolic risk reductions in patients with type 2 diabetes mellitus newly treated with a sodiumâglucose cotransporter 2 inhibitor versus a dipeptidyl peptidase-4 inhibitor: A real-world administrative database study in Japan.	0
329	Novel glucose-lowering drugs and the risk of acute kidney injury in routine care; the Stockholm CREAtinine Measurements (SCREAM) project.	0
328	Comparison of the Effects of Empagliflozin and Sotagliflozin on a Zebrafish Diabetic Heart Failure with Reduced Ejection Fraction Model.	0
327	Are arrhythmias the drivers of sudden cardiac death in heart failure with preserved ejection fraction? A review.	0
326	Empagliflozin benefits in patients with heart failure and preserved ejection fraction.	0
325	Sodiumâglucose cotransporter inhibitors and kidney fibrosis: review of the current evidence and related mechanisms.	1
324	Renal outcomes with sodium-glucose cotransporters 2 inhibitors. 13,	0
323	New Insights into the Use of EmpagliflozinâA Comprehensive Review. **2022**, 10, 3294	0
322	Hyponatremia Demystified: Integrating Physiology to Shape Clinical Practice. **2022**,	0
321	Renal Disease in Patients with Type 2 Diabetes: Magnitude of the Problem, Risk Factors and Preventive Strategies. **2022**, 104159	0
320	Sodium-glucose cotransporter-2 inhibitor prescribing practices.	0
319	Benefits of Intensified Reductions in Blood Glucose and in Blood Pressure for Patients with Type 2 Diabetes. **2022**, 104160	0
318	Comprehensive Oral Diabetes Medication Resource 2022. **2023**, 11, 42-49	0
317	Diabetes medication following heart transplantation: a focus on novel cardioprotective therapiesâ joint review from endocrinologists and cardiologists.	0
316	Statistical power for MACE and individual secondary endpoints in cardiovascular outcomes trials for type 2 diabetes: a systematic review. **2022**, 12,	0
315	Nationwide cardiovascular risk categorization: applying the European Society of Cardiology (ESC) guidelines to the Swedish National Diabetes Register.	0

314	CHAnges in Diuretic Medication Prescribing and Surrogate Laboratory Parameters After Initiating EmpagliflOziN in Veterans (CHAMPION Cohort Study).	0
313	Efficacy and safety of janagliflozin as add-on therapy to metformin in Chinese patients with type 2 diabetes inadequately controlled with metformin alone: A multicentre, randomized, double-blind, placebo-controlled, phase 3 trial.	0
312	The International Society for Heart and Lung Transplantation (ISHLT) Guidelines for the Care of Heart Transplant Recipients. **2022**,	0
311	11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetesâ2023. **2023**, 46, S191-S202	0
310	Dapagliflozin improves pancreatic islet function by attenuating microvascular endothelial dysfunction in type 2 diabetes.	0
309	A consensus statement from the Japan Diabetes Society: A proposed algorithm for pharmacotherapy in people with type 2 diabetes.	0
308	Antidiabetic agents: Do they hit the right targets?. **2022**, 2, 225-243	0
307	Empagliflozin protects mice against diet-induced obesity, insulin resistance and hepatic steatosis.	0
306	Bibliometric and visualized analysis of sodiumâglucose cotransporter 2 inhibitors. 13,	0
305	The impact of SGLT2-inhibitor therapy on platelet function in type 2 diabetes mellitus. **2023**, 6, 140-144	0
304	Canagliflozin Improves Myocardial Perfusion, Fibrosis, and Function in a Swine Model of Chronic Myocardial Ischemia. **2023**, 12,	0
303	Obesity and diabetes: the final frontier.	1
302	Diabetes Mellitus at an Elderly Age.	0
301	Insights into efficacy and safety of dapagliflozin treatment for the management in older adults with type 2 diabetes: a systematic review and meta-analysis. 1-10	0
300	Empagliflozin attenuates arrhythmogenesis in diabetic cardiomyopathy by normalizing intracellular Ca2+ handling in ventricular cardiomyocytes.	0
299	Chronic Kidney Disease âAnother Step Forward. **2023**, 388, 179-180	0
298	A Proposition on the Test Concerning the Existence of Responders. **2022**, 51, 19-29	0
297	New Antidiabetic Agents: Relevance to Cardiovascular Outcomes. **2023**, 337-349	0

296	Antioxidant Phytochemicals as Potential Therapy for Diabetic Complications. **2023**, 12, 123	2
295	Neutral effect of SGLT2 inhibitors on lipoprotein metabolism: From clinical evidence to molecular mechanisms.. **2023**, 106667	0
294	Beneficial Effects of Dipeptidyl Peptidase-4 Inhibitors on Heart Failure With Preserved Ejection Fraction and Diabetes. **2023**,	0
293	Effects of SGLT2 inhibitors and GLP1-receptor agonists on cardiovascular and limb events in peripheral artery disease: A review. 1358863X2211438	0
292	The effect of dapagliflozin on myocardial ischemiaâ□□eperfusion injury in diabetic rats.	0
291	Cardiovascular and renal outcomes among patients with type 2 diabetes using SGLT2 inhibitors added to metformin: a population-based cohort study from the UK. **2023**, 11, e003072	0
290	Recent Pharmacological Options in Type 2 Diabetes and Synergic Mechanism in Cardiovascular Disease. **2023**, 24, 1646	0
289	Alert-LDL-2: adherence to guidelines and goals attainment in the treatment of diabetic patients with dyslipidemia.	0
288	Cardiovascular, renal, and lower limb outcomes in patients with type 2 diabetes after percutaneous coronary intervention and treated with sodiumâ□glucose cotransporter 2 inhibitors versus dipeptidyl peptidase-4 inhibitors.	0
287	Mechanisms of SGLT2 Inhibitors in Heart Failure and Their Clinical Value. **2023**, 81, 4-14	0
286	Canagliflozin Pretreatment Attenuates Myocardial Dysfunction and Improves Postcardiac Arrest Outcomes After Cardiac Arrest and Cardiopulmonary Resuscitation in Mice.	0
285	Evolution of care in cirrhosis: Preventing hepatic decompensation through pharmacotherapy. 29, 61-74	0
284	Atherosclerotic Cardiovascular Disease Prevention in the Older Adult: Part 2. **2023**, 67-138	0
283	The effect of SGLT-2 inhibitors on cardiorespiratory fitness capacity: A systematic review and meta-analysis. 13,	0
282	Role of glycemic control in elective percutaneous coronary interventions in patients with type 2 diabetes. **2023**, 27, 5137	0
281	Little at a time: trying to understand the battery of benefits of sodiumâ□glucose contransporter 2 inhibitors in heart failure.	0
280	Diabetic Chronic Kidney Disease in Type 2 Diabetes Mellitus (Albuminuric/Non-albuminuric). **2023**, 243-269	0
279	Effects of sodium-glucose cotransporter 2 inhibitors, mineralocorticoid receptor antagonists, and their combination on albuminuria in diabetic patients.	1

278	Adverse cardiovascular, limb, and renal outcomes in patients with diabetes after peripheral artery disease revascularization treated with sodium glucose cotransporter 2 inhibitors versus dipeptidyl peptidase-4 inhibitors. **2023**, 15,	0
277	Diabetic kidney disease in type 2 diabetes: a consensus statement from the Swiss Societies of Diabetes and Nephrology. **2023**, 153, 40004	0
276	Control of Blood Glucose and Cardiovascular Risk Profile. **2023**, 451-469	0
275	Emulating a target trial using primary care electronic health records: SGLT-2i medications and Hemoglobin A1c.	0
274	Recent advances in molecular mechanisms of acute kidney injury in patients with diabetes mellitus. 13,	0
273	Baseline eGFR, albuminuria and renal outcomes in patients with SGLT2 inhibitor treatment: an updated meta-analysis.	0
272	Efficacy and Safety of Janagliflozin Monotherapy in Chinese Patients with Type 2 Diabetes Mellitus Inadequately Controlled on Diet and Exercise: A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 3 Trial.	0
271	Evaluation of sodium-glucose cotransporter 2 inhibitors for renal prognosis and mortality in diabetes patients with heart failure on diuretics.	0
270	Gliflozins: From Antidiabetic Drugs to Cornerstone in Heart Failure TherapyâA Boost to Their Utilization and Multidisciplinary Approach in the Management of Heart Failure. **2023**, 12, 379	1
269	Die Biomarker BNP und NT-proBNP.	0
268	Novel Therapeutics for Type 2 Diabetes, Obesity, and Heart Failure. **2023**, 43, 1-7	0
267	Empagliflozin inhibits excessive autophagy through the AMPK/GSK3□signaling pathway in diabetic cardiomyopathy.	0
266	Effect of sodium-glucose co-transporter 2 inhibitors on plasma potassium: A meta-analysis. **2023**, 196, 110239	0
265	Empagliflozin cardiovascular and renal effectiveness and safety compared to dipeptidyl peptidase-4 inhibitors across 11 countries in Europe and Asia: Results from the EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study. **2023**, 49, 101418	0
264	The effectiveness and value of tirzepatide for type 2 diabetes mellitus. **2022**, 28, 680-684	0
263	Empagliflozin: Validation of Stability-Indicating LC Method and in silico Toxicity Studies.	0
262	From Kidney Protection to Stroke Prevention: The Potential Role of Sodium Glucose Cotransporter-2 Inhibitors. **2023**, 24, 351	0
261	Multinational Patterns of Second-line Anti-hyperglycemic Drug Initiation Across Cardiovascular Risk Groups: A Federated Pharmacoepidemiologic Evaluation in LEGEND-T2DM.	0

260	Clinical spotlight intervention to accelerate translation of evidence-based practices in primary care. **2022**, 11, e002032	1
259	Use of sodiumâglucose co-transporter 2 inhibitors and glucagon-like peptide-1 receptor agonists according to the 2019 ESC guidelines and the 2019 ADA/EASD consensus report in a national population of patients with type 2 diabetes.	0
258	Cardiometabolic Effects of Empagliflozin in Patients Undergoing Elective Percutaneous Coronary Intervention for Type 2 Diabetes Mellitus. **2022**, 62, 64-72	0
257	AWARE. A web application to rapidly assess cardiovascular risk in Type 2 Diabetes Mellitus..	0
256	Clinical efficacy of SGLT2 inhibitors with different SGLT1/SGLT2 selectivity in cardiovascular outcomes among patients with and without heart failure: A systematic review and meta-analysis of randomized trials. **2022**, 101, e32489	0
255	Pyuria Is Associated with Dysbiosis of the Urinary Microbiota in Type 2 Diabetes Patients Receiving Sodiumâglucose Cotransporter 2 Inhibitors. **2023**, 14, 34-41	1
254	Preliminary mechanism of inhibitor of SGLT2 in fatty liver cold ischemia injury. **2022**,	0
253	The effect of sodium-glucose co-transporter 2 inhibitors on stroke and atrial fibrillation: A systematic review and meta-analysis. **2022**, 101582	0
252	quand un néphrologue doit-il prescrire un iSGLT2 ? Indications of SGLT2 inhibitors in kidney disease: who, why and when?. **2022**, 18, 6S17-6S24	0
251	Assessment of the Safety, Efficacy, and Benefit of Empagliflozin in Patients With Type 2 Diabetes Mellitus (T2DM) and Heart Failure With Reduced Ejection Fraction (HFrEF) at High Risk for Cardiovascular Events. **2022**,	0
250	Comparative evaluation of clinical outcomes of dapagliflozin and empagliflozin in type-2 diabetes mellitus.	0
249	Preparing for Colonoscopy in People with Diabetes: A Review with Suggestions for Clinical Practice.	0
248	Targeted drug delivery strategy: a bridge to the therapy of diabetic kidney´disease. **2023**, 30,	0
247	Diabetes mellitus. **2022**, 267-285	0
246	Empagliflozin reduces arrhythmogenic effects in rat neonatal and human iPSC-derived cardiomyocytes and improves cytosolic calcium handling at least partially independent of NHE1.	0
245	Heterogeneity in cardiovascular death or hospitalization for heart failure benefits with flozins is linked to weight.	0
244	SGLT2 Inhibitors: The Sweet Success for Kidneys. **2023**, 74, 369-384	0
243	Glycemic Control and Reduction of Cardiorenal Risk Following Bariatric Surgery. **2023**, 987-995	0

242	Indirect comparison of SGLT2 inhibitors in patients with established heart failure: evidence based on Bayesian methods.	0
241	Risk Amplifiers for Vascular Disease and CKD in South Asians. **2023**, Publish Ahead of Print,	0
240	Glifozinas en el tratamiento de la diabetes tipo 2: m□s all□de los beneficios en el control metab□lico. **2023**, 6, 49-64	0
239	Efficacy and safety of empagliflozin: a â□real-worldâ□experience from Saudi Arabia. **2023**, 43, 50-56	0
238	Empagliflozin is associated with lower risk of cardiovascular events and all-cause mortality in routine care in East Asia: Results from the EMPRISE study.	0
237	SGLT2 Inhibitors in Diabetic and Non-Diabetic Chronic Kidney Disease. **2023**, 11, 279	0
236	The real-world safety profile of sodium-glucose co-transporter-2 inhibitors among older adults (â□75´years): a retrospective, pharmacovigilance study. **2023**, 22,	0
235	Evolution of sodium-glucose co-transporter 2 inhibitors from a glucose-lowering drug to a pivotal therapeutic agent for cardio-renal-metabolic syndrome. 14,	0
234	Impact of baseline kidney function on the effects of SGLT2 inhibitors on kidney and heart failure outcomes: a systematic review and meta-analysis of randomized controlled trials.	0
233	Evaluation and Management of Patients with Diabetes and Heart Failure: A Korean Diabetes Association and Korean Society of Heart Failure Consensus Statement. **2023**, 47, 10-26	0
232	Medical therapy. **2023**, 353-361	0
231	Management of Type 2 Diabetic Kidney Disease in 2022: A Narrative Review for Specialists and Primary Care. **2023**, 10, 205435812211505	1
230	The Kidney Failure Risk Equation: Evaluation of Novel Input Variables including eGFR Estimated Using the CKD-EPI 2021 Equation in 59 Cohorts. **2023**, Publish Ahead of Print,	1
229	Clinical and Pharmacotherapeutic Profile of Patients with Type 2 Diabetes Mellitus Admitted to a Hospital Emergency Department. **2023**, 11, 256	0
228	Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors: Benefits Versus Risk. **2023**,	0
227	Eligibility for sotagliflozin in a real-world heart failure population based on the SOLOIST-WHF trial enrolment criteria: Data from the swedish heart failure registry.	0
226	Advances in contemporary medical management to treat patients with heart failure. Publish Ahead of Print,	0
225	Clinical applications of machine learning in heart failure. **2023**, 217-233	0

224	Evaluation and Management of Patients With Diabetes and Heart Failure: A Korean Diabetes Association and Korean Society of Heart Failure Consensus Statement. **2023**, 5, 1	2
223	Sweet and Simple as Syrup: A Review and Guidance for Use of Novel Antihyperglycemic Agents for Post-Transplant Diabetes Mellitus and Type II Diabetes Mellitus After Kidney Transplantation.	0
222	Efficacy of cardiometabolic drugs in reduction of epicardial adipose tissue: a systematic review and meta-analysis. **2023**, 22,	0
221	Prevalence of admission hyponatremia in diabetic patients treated with and without an SGLT2-inhibitor.	0
220	Metabolomic profiling in kidney cells treated with a sodium glucose-cotransporter 2 inhibitor. **2023**, 13,	0
219	AASLD practice guidance on the clinical assessment and management of nonalcoholic fatty liver disease. Publish Ahead of Print,	5
218	II. Details: Therapeutic Agents for Chronic Heart Failure; 2. SGLT2 Inhibitor. **2022**, 111, 228-234	0
217	Beyond Blood Glucose and Blood Pressure Control in Type 2 Diabetes: Alternative Management Strategies to Prevent the Development and Progression of CKD. **2023**, 14, 215013192311535	0
216	Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: pathophysiology and implications for cardiovascular disease. **2023**, 137-173	0
215	Effects of finerenone in people with chronic kidney disease and type 2 diabetes are independent of HbA1c at baseline, HbA1c variability, diabetes duration and insulin use at baseline.	0
214	Emerging Therapy for Diabetic Cardiomyopathy: From Molecular Mechanism to Clinical Practice. **2023**, 11, 662	0
213	Effects of new hypoglycemic drugs on cardiac remodeling: a systematic review and network meta-analysis.	0
212	Remission with an Intervention. **2023**, 52, 65-88	0
211	The Effects of SGLT2 Inhibitors on Liver Cirrhosis Patients with Refractory Ascites: A Literature Review. **2023**, 12, 2253	0
210	Redefying the therapeutic strategies against cardiorenal morbidity and mortality: Patient phenotypes. 15, 76-83	0
209	Cost-effectiveness of dapagliflozin and empagliflozin for treatment of heart failure with reduced ejection fraction. **2023**, 376, 83-89	0
208	Effects of dapagliflozin on hospitalisations in people with type 2 diabetes: post-hoc analyses of the DECLARE-TIMI 58 trial. **2023**, 11, 233-241	0
207	Research progress on the effects of novel hypoglycemic drugs in diabetes combined with myocardial ischemia/reperfusion injury. **2023**, 86, 101884	0

206	The growing clinical effect of SGLT2 inhibitors. **2023**, 11, 218-219	0
205	Narrative Review of Glycemic Management in People With Diabetes on Peritoneal Dialysis. **2023**, 8, 700-714	0
204	Évolution de la stratégie thérapeutique hors insuline dans le diabète de type 2. **2023**,	0
203	Comparison of the effects of sitagliptin and dapagliflozin on time in range in Japanese patients with type 2 diabetes stratified by body mass index: A sub-analysis of the DIVERSITY-CVR study.	0
202	Cerebrovascular, Cognitive and Cardiac Benefits of SGLT2 Inhibitors Therapy in Patients with Atrial Fibrillation and Type 2 Diabetes Mellitus: Results from a Global Federated Health Network Analysis. **2023**, 12, 2814	0
201	Usage des gliflozines dans la maladie rénale chronique. **2023**,	0
200	Diabetes care among individuals with and without schizophrenia in three Canadian provinces: A retrospective cohort study. **2023**, 82, 19-25	0
199	Current Treatment Options, Including Diet, Exercise, and Medications. **2023**, 27, 397-412	0
198	Newer Glucose-Lowering Therapies in Older Adults with Type 2 Diabetes. **2023**, 52, 355-375	0
197	Advances in Chronic Kidney Disease in Africa. **2023**, 13, 4924	0
196	Impact of dapagliflozin on cardiac function following anterior myocardial infarction in non-diabetic patients âDACAMI (a randomized controlled clinical trial). **2023**, 379, 9-14	0
195	Recent developments in adjunct therapies for type 1 diabetes. **2022**, 31, 1311-1320	0
194	Empagliflozin ameliorates cardiac dysfunction in heart failure mice via regulating mitochondrial dynamics. **2023**, 942, 175531	0
193	Predictors, Disparities, and Facility-Level Variation: SGLT2 Inhibitor Prescription Among US Veterans With CKD. **2023**,	0
192	The Renal Effects of SGLT2 Inhibitors. 76-83	0
191	Clinical pharmacology of SGLT-2 inhibitors in heart failure. **2023**, 16, 149-160	0
190	Cardiovascular outcomes trial data from EMPA-REG OUTCOME , CAROLINA and CARMELINA : Assessment of a novel staging system for type 2 diabetes. **2023**, 25, 1372-1384	0
189	The effects of Sodium-glucose cotransporter 2 inhibitors on adipose tissue in patients with type 2 diabetes: A meta-analysis of randomized controlled trials. 14,	0

188	Understanding patient cost-sharing thresholds for diabetes treatment attributes via a discrete choice experiment. **2023**, 29, 139-150	0
187	Real-world impact of empagliflozin on total cost of care in adults with type 2 diabetes: Results from an outcomes-based agreement. **2023**, 29, 152-160	0
186	Partial Identification of Personalized Treatment Response with Trial-reported Analyses of Binary Subgroups. **2023**, 34, 319-324	0
185	Clinical effectiveness of second-line antihyperglycemic drugs on major adverse cardiovascular events: An emulation of a target trial. 14,	0
184	Metabolic Control, Diabetic Complications and Drug Therapy in a Cohort of Patients with Type 1 and Type 2 Diabetes in Secondary and Tertiary Care between 2004 and 2019. **2023**, 20, 2631	0
183	Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors and CKD: Are You a #Flozinator?. **2023**, 5, 100608	0
182	Efficacy and safety of the SGLT2 inhibitor empagliflozin versus placebo and the DPP-4 inhibitor linagliptin versus placebo in young people with type 2 diabetes (DINAMO): a multicentre, randomised, double-blind, parallel group, phase 3 trial. **2023**, 11, 169-181	1
181	Luseogliflozin and caloric intake restriction increase superoxide dismutase 2 expression, promote antioxidative effects, and attenuate aortic endothelial dysfunction in diet-induced obese mice. **2023**, 14, 548-559	0
180	Cardiovascular Manifestations in Rheumatoid Arthritis. Publish Ahead of Print,	0
179	Empagliflozin in Adults with Chronic Kidney Disease (CKD): Current Evidence and Place in Therapy. Volume 19, 133-142	0
178	Dapagliflozin attenuates myocardial remodeling in hypertension by activating the circadian rhythm signaling pathway. **2023**, 46, 117-130	0
177	Prevalence of type 2 diabetes complications and its association with diet knowledge and skills and self-care barriers in Tabriz, Iran: A cross-sectional study. **2023**, 6,	0
176	Influence of angiotensin receptor-neprilysin inhibition on the efficacy of Empagliflozin on cardiac structure and function in patients with chronic heart failure and a reduced ejection fraction: The Empire HF trial. **2023**, 26, 100264	0
175	Vascular ageing: moving from bench towards bedside.	1
174	Diabetic Kidney Disease in Post-Transplant Diabetes Mellitus: Causes, Treatment and Outcomes. **2023**, 11, 470	0
173	Empagliflozin suppresses mitochondrial reactive oxygen species generation and mitigates the inducibility of atrial fibrillation in diabetic rats. 10,	0
172	Empagliflozin suppressed cardiac fibrogenesis through sodium-hydrogen exchanger inhibition and modulation of the calcium homeostasis. **2023**, 22,	0
171	Comparing Effectiveness and Safety of SGLT2 Inhibitors vs DPP-4 Inhibitors in Patients With Type 2 Diabetes and Varying Baseline HbA1c Levels. **2023**, 183, 242	0

170	The Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitor Empagliflozin Reverses Hyperglycemia-Induced Monocyte and Endothelial Dysfunction Primarily through Glucose Transport-Independent but Redox-Dependent Mechanisms. **2023**, 12, 1356	0
169	Comparative efficacy of sodium-glucose co-transporter-2 inhibitors, glucagon-like peptide-1 receptor agonists and non-steroidal mineralocorticoid receptor antagonists in chronic kidney disease and type 2 diabetes: A systematic review and network meta-analysis.	0
168	Achievement of the ESC recommendations for secondary prevention of cardiovascular risk factors in high-risk patients with type 2 diabetes: A real-world national cohort analysis. **2023**, 377, 104-111	0
167	Ketone Bodies and Cardiovascular Disease: An Alternate Fuel Source to the Rescue. **2023**, 24, 3534	0
166	Association between Left Ventricular Hypertrophy and Neuroimaging Markers of Cerebral Small Vessel Disease in Patients with ischemic stroke: CNRS-III study.	0
165	Effects of empagliflozin on left ventricular diastolic function in addition to usual care in individuals with type 2 diabetes mellitusâ€esults from the randomized, double-blind, placebo-controlled EmDia trial.	0
164	Fracture risks associated with sodium-glucose cotransporter-2 inhibitors in type 2 diabetes patients across eGFR and albuminuria categories: A population-based study in Hong Kong. **2023**, 197, 110576	0
163	Renoprotective effects of empagliflozin are linked to activation of the tubuloglomerular feedback mechanism and blunting of the complement system. **2023**, 324, C951-C962	0
162	Type 2 Diabetes Mellitus: Beyond the Beta Cell. 36-46	0
161	Acute Biomechanical Effects of Empagliflozin on Living Isolated Human Heart Failure Myocardium.	0
160	Obesity-associated cardiometabolic complications in polycystic ovary syndrome: The potential role of sodium-glucose cotransporter-2 inhibitors. 14,	0
159	Risk of New-onset Stroke in Patients with Type 2 Diabetes with Chronic Kidney Disease on Sodium-glucose Co-transporter-2 Inhibitor Users.	0
158	A Web-based Application for Risk Stratification and Optimization in Patients with Cardiovascular Disease (STOP-CVD): Pilot Study (Preprint).	0
157	The SGLT2i-mediated regulation of cardiovascular and safety outcomes among patients with chronic kidney disease: A systematic review and meta-analysis of randomized controlled trials.	0
156	SGLT2 Inhibitors: The Next Blockbuster Multifaceted Drug?. **2023**, 59, 388	1
155	Metabolic Impact of Frailty Changes Diabetes Trajectory. **2023**, 13, 295	2
154	Mechanisms of SGLT2 Inhibitors in the Treatment of Myocardial Ischemia-Reperfusion Injury in Animal Models. **2023**, 13, 2232-2240	0
153	Sodium-Glucose Cotransporter 2 Inhibitors Among Heart Failure With Mildly Reduced and Preserved Ejection Fraction. 106002802311540	0

152	The risk of all-cause death with dapagliflozin versus placebo: a systematic review and meta-analysis of phase III randomized controlled trials. **2023**, 22, 133-140	0
151	Empagliflozin-Pretreated Mesenchymal Stem Cell-Derived Small Extracellular Vesicles Attenuated Heart Injury. **2023**, 2023, 1-17	0
150	Association of SGLT-2 inhibitors with bacterial urinary tract infection in type 2 diabetes.	0
149	Long-term increase in fasting blood glucose is associated with increased risk of sudden cardiac arrest. **2023**, 22,	0
148	Lower risks of sodium glucose cotransporter 2 (SGLT2) inhibitors compared to dipeptidyl peptidase-4 (DPP4) inhibitors for new-onset hip fracture risks in patients with type-2 diabetes: A propensity score-matched study with competing risk analysis.	0
147	Renal and Cardiovascular Metabolic Impact Caused by Ketogenesis of the SGLT2 Inhibitors. **2023**, 24, 4144	0
146	Effects of luseogliflozin treatment on hyperglycemia-induced muscle atrophy in rats. **2023**,	0
145	Mapping the metabolic reprogramming induced by sodium-glucose cotransporter 2 inhibition. **2023**, 8,	0
144	Therapieoptionen bei diabetischer Nephropathie.	0
143	Emerging Role of Sodiumâ□Glucose Co-Transporter 2 Inhibitors for the Treatment of Chronic Kidney Disease. Volume 16, 43-57	0
142	Deep-learning-based prognostic modeling for incident heart failure in patients with diabetes using electronic health records: A retrospective cohort study. **2023**, 18, e0281878	0
141	The Evolution of Diabetes Treatment Through the Ages: From Starvation Diets to Insulin, Incretins, SGLT2-Inhibitors and Beyond.	0
140	Meta-Analysis of Cardiovascular Risk Factors in Offspring of Preeclampsia Pregnancies. **2023**, 13, 812	0
139	Analysis of the Value of SGLT2i Combined with GLP-1RAs in Cardiovascular Benefit of Elderly T2DM Patients. **2023**, 13, 2736-2743	0
138	Clinical Study of Metabolic Parameters, Leptin and the SGLT2 Inhibitor Empagliflozin among Patients with Obesity and Type 2 Diabetes. **2023**, 24, 4405	0
137	The effect of SGLT2 inhibitors, GLP1 agonists, and their sequential combination on cardiometabolic parameters: A randomized, prospective, intervention study. **2023**, 37, 108436	1
136	Kidney glycolysis serves as a mammalian phosphate sensor that maintains phosphate homeostasis. **2023**, 133,	0
135	Incremental prognostic value of positron emission tomography-derived myocardial flow reserve in patients with and without diabetes mellitus.	0

134	Nonalcoholic Fatty Liver Disease and Cardiovascular Disease: Causation or Association. Publish Ahead of Print,	0
133	Impact of Contextual-Level Social Determinants of Health on Newer Antidiabetic Drug Adoption in Patients with Type 2 Diabetes. **2023**, 20, 4036	0
132	Effects of dietary sodium and protein intake on glomerular filtration rate in subjects with type 2 diabetes treated with sodium glucose cotransporter 2 inhibitors.	0
131	Call to action: Understanding the differences in the use of SGLT-2 inhibitors and GLP-1 receptor agonists. **2023**, 13, 100477	0
130	Sudden cardiac death prevention in the era of novel heart failure medications. **2023**, 27, 100281	0
129	Effect of Intensive Glycemic Control on Myocardial Infarction Outcome in Patients with Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis. **2023**, 2023, 1-11	0
128	Use of optimal medical therapy in patients with diabetes and atherosclerotic cardiovascular disease: Insights from a prospective longitudinal cohort study.	1
127	Nephroprotective Effects of Dapagliflozin in Patients with Type 2 Diabetes. **2023**, 62, 681-688	0
126	SGLT2 Inhibitors: Effect on Myocardial Infarction and Stroke in Type 2 Diabetes.	0
125	Sex and gender differences in myocarditis and dilated cardiomyopathy: An update. 10,	0
124	SGLT2 inhibition in heart failure with reduced or preserved ejection fraction: Finding the right patients to treat. **2023**, 293, 550-558	0
123	Effect of sodiumâglucose transporter 2 inhibitor empagliflozin on proteinuria and kidney function progression in patients with non-diabetic glomerulonephritis: a pilot superiority randomized controlled trial.	0
122	Euglycemic Diabetic Ketoacidosis Associated With SGLT2 Inhibitor Therapy: A Case Report. **2023**, 34, 27-32	0
121	Diabetic cardiomyopathy: The role of microRNAs and long non-coding RNAs. 14,	0
120	Significant publications in diabetes pharmacotherapy and technology in 2020.	0
119	Significant publications in diabetes pharmacotherapy and technology in 2020. **2023**, 18, 131-142	0
118	New Insight in Cardiorenal Syndrome: From Biomarkers to Therapy. **2023**, 24, 5089	0
117	Is It Time to Relitigate SGLT2 Inhibitor Dose for Heart Failure?. **2023**,	0

116	Kidney and Cardiovascular Effects of Canagliflozin According to Age and Sex: A Post Hoc Analysis of the CREDENCE Randomized Clinical Trial. **2023**,	0
115	Effect of Sacubitril/Valsartan vs Valsartan on Left Atrial Volume in Patients With Preâ Heart Failure With Preserved Ejection Fraction. **2023**, 8, 366	0
114	Data-driven classification of health status of older adults with diabetes: The diabetes and aging study.	0
113	Hyperglycemic exacerbation of myocardial infarction through SGLT1 - a glucose paradox.	0
112	Paradigm sift of the medical care in diabetes. **2023**, 19, 32-41	0
111	Indikationen von Antidiabetika jenseits der Glukosekontrolle. **2023**, 165, 42-49	0
110	Feasibility Study to Assess Canagliflozin Distribution and Sodium-Glucose Co-Transporter 2 Occupancy Using [18 F]Canagliflozin in Patients with Type 2 Diabetes.	0
109	Neutral effects of SGLT2 inhibitors in acute coronary syndromes, peripheral arterial occlusive disease, or ischemic stroke: a meta-analysis of randomized controlled trials. **2023**, 22,	0
108	Dramatic disease regression in a case of HFrEF with end-stage renal failure treated with sacubitril/valsartan and SGLT2i.	0
107	Effect of Ramipril on Cardiac Autonomic Neuropathy in Patients With Type II Diabetes Mellitus. **2023**,	0
106	Modeling unmeasured baseline information in observational time-to-event data subject to delayed study entry. 096228022311633	0
105	CVOT Summit 2022 Report: new cardiovascular, kidney, and glycemic outcomes. **2023**, 22,	0
104	Rationale and design of the Biventricular Evaluation of Gliflozins effects In chroNic Heart Failure: BEGIN-HF study.	0
103	Sodium-Glucose Cotransporter-2 (SGLT-2) Inhibitors Use among Heart Failure Patients and the Role of Pharmacists in Early Initiation of Therapy. **2023**, 11, 58	0
102	SGLT2 Inhibitorâ Dapagliflozin Attenuates Diabetes-Induced Renal Injury by Regulating Inflammation through a CYP4A/20-HETE Signaling Mechanism. **2023**, 15, 965	0
101	Efficacy and safety of bexagliflozin in patients with type 2 diabetes mellitus: A systematic review and meta-analysis.	0
100	Effects of Semaglutide and Empagliflozin on Inflammatory Markers in Patients with Type 2 Diabetes. **2023**, 24, 5714	0
99	Discontinuation and reinitiation of SGLT-2 inhibitors and GLP-1R agonists in patients with type 2 diabetes: a nationwide study from 2013 to 2021. **2023**, 100617	0

98	Efficacy of antihyperglycemic therapies on cardiovascular and heart failure outcomes: an updated meta-analysis and meta-regression analysis of 35 randomized cardiovascular outcome trials. **2023**, 22,	0
97	The Safety Profile of Sodium-Glucose Cotransporter-2 Inhibitors and Glucagon-like Peptide 1 Receptor Agonists in the Standard of Care Treatment of Type 2 Diabetes Mellitus. **2023**, 13, 839	0
96	Copeptin adaptive response to SGLT2 inhibitors in patients with type 2 diabetes mellitus: The GliRACo study. 17,	0
95	SGLT2i alleviates epicardial adipose tissue inflammation by modulating ketone bodyâglyceraldehyde-3-phosphate dehydrogenase malonylation pathway. **2023**, 24, 232-243	0
94	Recent Trials on the Cardioprotective Effects of New Generation Anti-diabetic and Lipid-Lowering Agents. **2023**, 117-167	0
93	Understanding the Mechanisms and Treatment of Heart Failure: Quantitative Systems Pharmacology Models with a Focus on SGLT2 Inhibitors and Sex-Specific Differences. **2023**, 15, 1002	0
92	A Role of Sodium-Glucose Co-Transporter 2 in Cardiorenal Anemia Iron Deficiency Syndrome. **2023**, 24, 5983	0
91	Update on Medical Management of Diabetes. **2023**,	0
90	Pathogenesis, Pathophysiology, and Treatment of Diabetic Nephropathy. **2018**, 252-265.e1	0
89	Empagliflozin increases kidney weight due to increased cell size in the proximal tubule S3 segment and the collecting duct. 14,	0
88	SGLT-2 Inhibitors in Heart Failure: A Review of Current Evidence. 5,	0
87	The Potential of SGLT-2 Inhibitors in the Treatment of Polycystic Ovary Syndrome: The Current Status and Future Perspectives. **2023**, 11, 998	0
86	Prescription appropriateness of anti-diabetes drugs in elderly patients hospitalized in a clinical setting: evidence from the REPOSI Register.	0
85	The SGLT2 inhibitor empagliflozin improves cardiac energy status via mitochondrial ATP production in diabetic mice. **2023**, 6,	0
84	Adherence to antidiabetic drug therapy and reduction of fatal events in elderly frail patients. **2023**, 22,	0
83	JAK2 unmutated erythrocytosis: 2023 Update on diagnosis and management.	0
82	Systematic review of sodium-glucose cotransporter 2 inhibitors: a hopeful prospect in tackling heart failure-related events.	0
81	Lower-limb peripheral arterial disease and amputations in people with diabetes: Risk factors, prognostic value and management. **2023**, 52, 104164	0

80	Emerging Diabetes Technologies: Continuous Glucose Monitors/Artificial Pancreases.	0
79	Der koronarkranke Diabetiker: moderne Therapieansï¿½ze und Behandlungspfade. **2023**, 12, 137-142	0
78	The health and budget impact of sodium-glucose co-transporter-2 inhibitors (SGLT2is) in The Netherlands. **2023**, 26, 547-553	0
77	Sodium glucose co-transporter 2 inhibition with empagliflozin on metabolic, cardiac and renal outcomes in recent cardiac transplant recipients (EMPA-HTx): protocol for a randomised controlled trial. **2023**, 13, e069641	0
76	Risk of Lactic Acidosis in Hospitalized Diabetic Patients Prescribed Biguanides in Japan: A Retrospective Total-Population Cohort Study. **2023**, 20, 5300	0
75	Cardiorenal outcomes, kidney function, and other safety outcomes with ertugliflozin in older adults with type 2 diabetes (VERTIS CV): secondary analyses from a randomised, double-blind trial. **2023**, 4, e143-e154	0
74	Efficacy and Safety of Empagliflozine and Semaglutide (Once Weekly) in T2DM Patients in Shtip. **2023**, 44, 71-77	0
73	Management of Heart Failure with Reduced Ejection Fraction Globally and in Lebanon: Where Do SGLT-2is Stand?. **2023**, 13, 138-169	0
72	The Role of Sodium-Glucose Cotransporter-2 Inhibitors in Heart Failure Management: The Continuing Challenge of Clinical Outcome Endpoints in Heart Failure Trials. **2023**, 15, 1092	0
71	Safety of SGLT2 Inhibitors in Three Chronic Diseases. **2023**, 64, 246-251	0
70	Subclinical systolic dysfunction detected by 2D speckle tracking echocardiography in adults with diabetes mellitus: systematic review and meta-analysis of 6668 individuals with diabetes mellitus and 7218 controls.	0
69	Treatment Strategies of Improving Quality of Care in Patients With Heart Failure. 53,	0
68	Glucagon-like peptide-1 receptor agonists: role in the prevention and treatment of diabetes-related cardiovascular complications. **2023**, 365-396	0
67	Cardiac energy metabolism in heart failure. **2023**, 175-198	0
66	Diabetes: evolution of multifactorial vascular risk reduction. **2023**, 311-335	0
65	Sodium-glucose Co-transporter-2 inhibitors: a new era of cardioprotection and renoprotection. **2023**, 337-363	0
64	The independent association of myocardial extracellular volume and myocardial blood flow with cardiac diastolic function in patients with type 2 diabetes: a prospective cross-sectional cohort study. **2023**, 22,	0
63	Prescription Trends for the Antidiabetic Agents Used to Treat Type 2 Diabetes Mellitus in Japan from 2012â2020: a Time-Series Analysis. **2023**, 46, 592-598	0

62	Management of diabetic kidney disease: where do we stand?: A narrative review. **2023**, 102, e33366	0
61	Meta-analysis of factors associated with antidiabetic drug prescribing for type 2 diabetes mellitus.	0
60	How SGLT2 inhibitors interact with metformin? A molecular dynamics study. 1-10	0
59	Persistence on Novel Cardioprotective Antihyperglycemic Therapies in the United States. **2023**,	0
58	Embedding guidelines into clinical practice. **2023**, 40, 28	0
57	Swiss recommendations of the Society for Endocrinology and Diabetes (SGED/SSED) for the treatment of type 2 diabetes mellitus (2023). **2023**, 153, 40060	0
56	Diabetes Professional Care conference 2022: key updates. **2023**, 40, 39-41	0
55	SGLT2 inhibition, glucose transport and peritoneal dialysis: Finding the sweet spot. **2023**, 43, 115-118	0
54	How to position sodium-glucose co-transporter 2 inhibitors in the management of diabetes in acromegaly patients.	0
53	Metformin adherence and the risk of cardiovascular disease: a population-based cohort study. **2023** , 14, 204062232311631	0
52	Evolving Diagnostic and Management Advances in Coronary Heart Disease. **2023**, 13, 951	0
51	Sodium Glucose Cotransporter 2 (SGLT2) Inhibitor Ameliorate Metabolic Disorder and Obesity Induced Cardiomyocyte Injury and Mitochondrial Remodeling. **2023**, 24, 6842	0
50	Effects of semaglutide and empagliflozin on oxygenation, vascular autoregulation, and central thickness of the retina in people with type 2 diabetes: A prespecified secondary analysis of a randomised clinical trial. **2023**, 37, 108472	0
49	Risk of ICU Admission and Related Mortality in Patients With Sodium-Glucose Cotransporter 2 Inhibitors and Dipeptidyl Peptidase-4 Inhibitors: A Territory-Wide Retrospective Cohort Study. Publish Ahead of Print,	0
48	Aortic stenosis: a review on acquired pathogenesis and ominous combination with diabetes mellitus. **2023**, 75,	0
47	Prevention of Cardiovascular Events in Patients With Chronic Kidney Disease. 106002802311657	0
46	Sodium-Glucose Cotransporter 2 Inhibitors: A Scoping Review of the Positive Implications on Cardiovascular and Renal Health and Dynamics for Clinical Practice. **2023**,	0
45	Cardiovascular and Renal Outcomes with SGLT-2 inhibitors and DPP-4 inhibitors Combination Therapy: A Meta-analysis of Randomized Cardiovascular Outcome Trials. **2023**,	0

44	Diabetic vascular diseases: molecular mechanisms and therapeutic strategies. **2023**, 8,	0
43	Ketones and the cardiovascular system.	0
42	Elevated Soluble Suppressor of Tumorigenicity 2 Predict Hospital Admissions Due to Major Adverse Cardiovascular Events (MACE). **2023**, 12, 2790	0
41	Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitor Therapy for the Primary and Secondary Prevention of Heart Failure in Patients With and Without Type 2 Diabetes Mellitus: A Systematic Review. **2023**,	0
40	Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors: Harms or Unexpected Benefits?. **2023**, 59, 742	0
39	Impact of diabetes duration on left ventricular mass regression with empagliflozin.	0
38	Pleiotropic Effects of Sodium-Glucose Cotransporter-2 Inhibitors in Cardiovascular Disease and Chronic Kidney Disease. **2023**, 12, 2824	0
37	Retrospective analysis of SGLT2 inhibitors in heart failure with preserved ejection fraction.	0
36	Cardioprotective Effect of Empagliflozin and Circulating Ketone Bodies During Acute Myocardial Infarction. **2023**, 16,	0
35	Acute effects of empagliflozin on open-loop baroreflex function and urine glucose excretion in Goto-Kakizaki diabetic rats. **2023**, 73,	0
34	Use of Animal Models for Investigating Cardioprotective Roles of SGLT2 Inhibitors.	0
33	The Effects of Cardioprotective Antidiabetic Therapy on Microbiota in Patients with Type 2 Diabetes MellitusâĂ Systematic Review. **2023**, 24, 7184	0
32	Use of Computation Ecosystems to Analyze the Kidney-Heart Crosstalk. **2023**, 132, 1084-1100	0
31	Speckle tracking echocardiography in early disease stages: a therapy modifier?. **2023**, 24, e55-e66	0
30	Cardiovascular Calcification Heterogeneity in Chronic Kidney Disease. **2023**, 132, 993-1012	0
29	Metabolic Syndrome and Cardiac Remodeling Due to Mitochondrial Oxidative Stress Involving Gliflozins and Sirtuins.	0
28	CLINICAL EFFECTIVENESS OF EMPAGLIFLOZIN IN PATIENTS WITH HEART FAILURE. **2023**, 76, 645-650	0
27	Prevention of Coronary Atherosclerosis. **2023**, 39-57	0

26	Perspectives In Weight Control In Diabetes â Sglt2 Inhibitors And Glp-1â Glucagon Dual Agonism. **2023**, 110669	0
25	Cardiac and Kidney Benefits of Empagliflozin in Heart Failure Across the Spectrum of Kidney Function: Insights from the EMPEROR-Preserved Trial.	0
24	Anti-Diabetic Therapy and Heart Failure: Recent Advances in Clinical Evidence and Molecular Mechanism. **2023**, 13, 1024	0
23	Management of Heart Failure in Patients With Diabetes Mellitus in the UAE: A Call to Action. **2023**, 28, 107424842311622	0
22	Treatment of type 2 diabetes patients with heart conditions. 1-11	0
21	Emerging sodium-glucose cotransporter-2 inhibitor therapies for managing heart failure in patients with chronic kidney disease. 1-11	0
20	Sodium-Glucose Co-Transporter Type 2 Inhibitors and Heart Failure: A Review of the State of the Art. **2023**, 5, 68-77	0
19	Pharmacological management of youth with type 2 diabetes and diabetic kidney disease: a comprehensive review of current treatments and future directions. 1-12	0
18	Sodium-glucose co-transporter-2 inhibitor use and JAK2 unmutated erythrocytosis in 100 consecutive cases.	0
17	Dapagliflozin induced hypernatremia via osmotic diuresis: a case report.	0
16	SGLT 2 inhibitors: Searching for the best in class. **2023**,	0
15	Combination of canagliflozin and puerarin alleviates the lipotoxicity to diabetic kidney in mice. **2023**, 27, 221-230	0
14	The interplay between bone and heart health as reflected in medication effects: A narrative review. **2023**, 19, 174550572311655	0
13	Adoption of sodium-glucose cotransporter-2 inhibitors among prescribers caring for nursing home residents.	0
12	Reduced incidence of cardiovascular disease in patients with type 2 diabetes through the integrated improvement of diabetes care by comparing two prospective observational cohorts in real-world clinical practice (JDDM 72). **2023**, 110674	0
11	Current understanding on pathogenesis and effective treatment of glycogen storage disease type Ib with empagliflozin: new insights coming from diabetes for its potential implications in other metabolic disorders. 14,	0
10	Precision medicine in type 2 diabetes: A systematic review of treatment effect heterogeneity for GLP1-receptor agonists and SGLT2-inhibitors.	0
9	Recent advances in the treatment of patients with obesity and chronic kidney disease. **2023**, 55,	0

8	Geriatrische Aspekte bei Diabetes mellitus (Update 2023). **2023**, 135, 307-318	0
7	Hospital diabetes management (Update 2023). **2023**, 135, 242-255	0
6	Injektionstherapie (GLP1-Rezeptor Agonisten und Insulin) bei Typ´2 Diabetes mellitus (Update 2023). **2023**, 135, 45-52	0
5	Treatment of type´2 diabetes.	0
4	Diabetes mellitus, koronare Herzkrankheit und Herzinsuffizienz (Update 2023). **2023**, 135, 201-206	0
3	Empagliflozin ameliorates diabetic cardiomyopathy via regulated branched-chain amino acid metabolism and mTOR/p-ULK1 signaling pathway-mediated autophagy. **2023**, 15,	0
2	COMBINSI (COMBat to INSufficient Insulin therapy) â□A Portuguese project in type 2 diabetes. **2023**, 17, 102776	0
1	Impact of polyethylene glycol loxenatide on cardiovascular outcomes in patients with type 2 diabetes: study protocol for a multicentre, randomised, double-blind, placebo-controlled trial (BALANCE-3). **2023**, 13, e069080	0